PN-ABC-269

EGYPT DRUG STUDY

CHILD SURVIVAL PHARMACEUTICALS

ANE/TR/HPN

October, 1987

Resources for Child Health Project

REACH

John Snow, Inc.
1100 Wilson Boulevard, 9th Floor
Arlington, VA
22209 USA
Telex: 272896 JSIW UR
Telephone: (703) 528-7474

EGYPT DRUG STUDY

CHILD SURVIVAL PHARMACEUTICALS

Dr. Amira Badr
Principal Investigator

The Resources for Child Health Project
1100 Wilson Boulevard
Ninth Floor
Arlington, VA 22209

AID Contract No: DPE-5927-C-00-5068-00

C O N T E N T S

CHAPTER	NAME	PAGE
I .	SUMMARY	1
II.	GENERAL DESCRIPTION OF THE EGYPTIAN PUBLIC & PRIVATE PHARMACEUTICAL SECTOR.	10
III.	REGISTRATION MECHANSIM AND POLICY CONSIDERATIONS.	50
IV.	FINANCE.	63
V.	EPIDEMIOLOGIC NEEDS OF CHILD SURVIVAL PHARMACEUTICALS.	86
VI.	PROVISION ACTIVITIES OF CHILD SURVIVAL PHARMACEUTICALS.	96
VII.	DISTRIBUTION OF CHILD SURVIVAL PHARMACEUTICALS.	205
VIII.	PRESCRIPTION BEHAVIOUR.	218
IX.	CONSUMPTION PATTERNS OF ANTIDIARRHEALS.	237
X.	RECOMMENDATIONS.	251

(I) SUMMARY

A. OBJECTIVES.
B. METHODOLOGY.
C. KEY FINDINGS.

(I) A - OBJECTIVES.

Egypt drug study is a documentary report describing the most important aspects of the Egyptian pharmaceutical sector, its licensing system and its provision system with regard to pharmaceuticals in general and to child survival pharamaceuticals (C.S.Fs) in particular.
The study also investigates prescription behaviour of doctors with regard to the most prevailing illnesses of childhood.

(I) B - METHODOLOGY.

The methods that were adopted in the study included :

* Analysis of relevant documents such as official reports, publications, decrees, files, financial statements and budgets.

* Compilation, classification and processing of consumption and production data.

* Interviews of top management officials of M.O.H. and the pharamceutical industry.

* A field study, designed to investigate prescription behaviour of doctors with regard to the most prevailing illnesses of children in Egypt, which included in addition to child-preventable diseases (Diphtheria, Tetanus, Pertussis, Measles, Polio), Malaria, T.B, Diarrhea and acute respiratory infections.

(I) C - KEY FINDINGS.

i. Population / Mortality & Morbidity

1. The targeted age group (0 - 6) years amounted to 9.6 million individuals in 1985/1986, constituting 19.2 % of total population.

2. Mortality rate of this age group decreased remarkably during the last six years (from 3 % to 2 %). This is one of the major reasons of the increased population growth rate from 2.7 % to 2.9 % in the same period. Total mortality rate decreased only by 0.06 % during the same period (from 1 % to 0.94 %).

3. Digestive system and respiratory system diseases were responsible for 79 % of total annual deaths in the targeted age group in 1980.

4. Reported morbidity rate figures of infectious diseases of our age group have decreased in all diseases except tetanus.

5. Measles, Pneumonia and diarrhea morbidity figures do not reflect the actual situation as these diseases are very poorly reported.

ii. Pharmaceuticals

1. The Egyptian pharmaceutical licensing authority consists of three institutions, namely :

   a. Pharmacy Department, M.O.H.
   b. Egyptian drug organization.
   c. National Oraganiztion of Drug Control and Research.

2. The Egyptian pharmaceutical provision system comprises :

   a. Fifteen manufacturing enterprises, eight of which are public sector enterprises.
   b. Forteen importing enterprises, one of which is a public sector enterprise.
   c. Eight wholesaling enterprises, one of which is a public sector enterprise.
   d. 7597 retail pharmacies, 22 of which are public sector pharmacies.

3. Local production of pharmaceuticals covered 80.8 % of the national annual needs in 1985/1986 in value terms.

ii. Pharmaceuticals (Cont.) ...

4. Pharmaceuticals are consumed mainly by the private sector, governmental consumption represented only 12 % of the national annual requirements in 1985/1986 in value terms.

   Table (I-1) shows the breakdown of national annual requirements in 1985/1986 by the providing and the consuming sectors in terms of value, volume and number of items.

5. Pharamaceuticals in Egypt are subsidized in two ways, either by the allocation of low-priced foreign currancy for importation, (used for infant milk formula and insulin) or the allocation of funds as a subsidy to imported products to stabilize their prices.
   The first way amounted to 45 million dollars and the second to 15 million Egyptian Pounds in 1986/1987.

6. Drugs are registered not only for epidemiologic needs, but also for the following :
   a. Supporting research and development of the pharmaceutical industry.
   b. Raise funds for further investments.
   c. Cross subsidy of low-priced drugs.
   d. Physicians' influence.

iii. Child Survival Pharmaceuticals

1. 245 items were identified as the most commonly prescribed child survival pharmaceuticals in Egypt (C.S.Ps).

2. National annual needs of C.S.Ps in 1985/1986 amounted to 123.4 million L.E. constituting 30 % of the total national needs of pharmaceuticals.
   Table (I-2) shows the national annual needs of C.S.Ps in 1985/1986 broken down by providing and consuming sectors in terms of value, volume and number of items.

3. Historical development of C.S.Ps consumption in the last five years shows that :
   3/1 Local production increased more than importation.
   3/2 Private consumption increased more than governmental consumption.

4. Governmental consumption of C.S.Ps constitutes 14.2 % of total governmental budget allocated for pharmaceuticals and at the same time constituting only 0.07 % of total national budget in 1985/1986.

TABLE (I-1) : NATIONAL ANNUAL NEEDS OF PHARMACEUTICALS IN 1985/1986.

TERMS & UNITS	NATIONAL ANNUAL REQUIREMENT	% PROVIDED BY		% CONSUMED BY	
		PRODUCTION	IMPORTATION	GOVERNMENT	PRIVATE SEC
VALUE MILLION L.E.	781.4	80.8 %	19.2 %	12.0 %	88.0 %
VOLUME MILLION PACKS	804.1	90.5 %	9.5 %	12.2 %	87.8 %
NO. OF ITEMS ITEMS	2317	74.0 %	26.0 %	20.7 %	99.0 %

* : 15 % of the items are utilized by both the government and the private sector.

TABLE (I-2) : NATIONAL ANNUAL NEEDS OF CSPs IN 1985/1986.

TERMS & UNITS	NATIONAL NEEDS OF CSPs	% PROVIDED BY		% CONSUMED BY	
		PRODUCTION	IMPORTATION	GOVERNMENT	PRIVATE SEC
VALUE MILLION L.E.	123.4	96.0 %	4.0 %	10.0 %	90.0 %
VOLUME MILLION PACKS	217.0	98.0 %	2.0 %	13.0 %	87.0 %
NO. OF ITEMS ITEMS	245	90.0 %	10.0 %	12.7 %	98.0 %

* : 10 % of the products are utilized by both the government and the private sector.

iii. Child Survival Pharmaceuticals (Cont.) ...

5. C.S.Ps are classified in 26 subgroups :

5/1 Antibiotic subgroup is the most prominent subgroup constituting 23 % of the total market of C.S.Ps in volume terms. This large consumption does not reflect a justified need as shown later by the field study findings of prescription behaviour.

5/2 Antidiarrheal drugs which are classified in eight subgroups (antimotility, antiemetic, anti-spasmodic, Antiamoebics antidiarrheal, restoratives/parentral, restoratives/oral and lactose-free milk) showed an increased consumption pattern except oral/restoratives (O.R.S) which showed a minor decrease in the last year.

5/3 Consumption of vaccines (20 % of C.S.P market) increased dramatically in the last five years. When this was compared with the population-estimated requirments vaccines consumption showed an over-utilization pattern in all vaccines except in tetanus. This over-utilization reflects waste and booster dosing.
Table (I-3) shows this comparison.

5/4 Consumption of pulmonics which includes three subgroups (cough-sedatives, expectorants and bronchodilators) constituted 12.5 % of the C.S.P market in volume terms. All subgroups showed an increased pattern, bronchodilators was the most increasing subgroup in the last five years.

5/5 Antimalarials was the only subgroup showing a decreased consumption pattern. Malaria is nearly eradicated from Egypt and pediatricians seldomly encounter a malaria case in years.

5/6 Contraceptives (5.7 % of the total C.S.P market), showed a modest increase in the last year, after a four-year stable pattern.

6. Although C.S.P prices has a wide range (from 0.1 L.E to 25 L.E), still 45 % of the items are sold for less than one L.E. which is consdired as an accessable price to the majority of population.
These low-priced items leaded to losses as most of them are negative-margined items.
26 % of the C.S.P items are negative-margined items, leading to 9.98 million L.E. annual losses in 1985/1986 (mainly by public sector firms).

iii. Child Survival Pharmaceuticals (Cont.) ...

Five items caused 47 % of this loss, namely :

1. Enteroquin syrup (16.2% of the annual loss)
2. Streptomycin vial (15.0% of the annual loss)
3. Penicillin-G-Sodium vial (9.0% of the annual loss)
4. Penicillin-Procaine vial (4.0% of the annual loss)
5. Sterptomycin / Chloramphenicol syrup (3.0% of the annual loss)

7. C.S.Ps are distributed via three distribution networks, private, public, and birth control networks. Average distribution costs in the private network is 8 % of total sales.

8. There is no recognition of C.S.P as such in health programs. Some groups of C.S.P such as contraceptives and vaccines are recognized individually in some health plans.

9. NO standard therapy lists are available.

10. An essential drug list is under preparation which includes most of the C.S.Ps. The list is to be used as a tool for price-stability decisions and raw materials importation priority programs.

iv. Prescription Behaviour

1. There is an over-prescribing pattern specially for antibiotic preparations in almost all investigated diseases. The average number of items per prescription is higher than the ideal (except Tetanus and Pertusis).

2. No difference has been noticed in the prescribing behaviour of public and private institutions.

3. O.R.S. is not used as a treatment in its own, but as a supplementary treatment.

TABLE (I-3) POPULATION VACCINES REQUIREMENTS VS. ACTUAL CONSUMPTION (1985/1986)

VACCINES	PERCENTAGE OF ACTUAL CONSUMPTION BY REQUIREMENTS
1. B.C.G.	241 %
2. D.P.T.	135 %
3. MEASLES VACCINE.	241 %
4. POLIO VACCINE.	582 %
5. TETANUS TOXOID.	13 %

* N.B. All tables without mentioned references are based on Egyptian Drug Organization sources.

(II) GENERAL DESCRIPTION OF THE EGYPTIAN PUBLIC AND PRIVATE PHARMACEUTICAL SECTOR.

A - General organization, functions.

B - Size of formulary.

C - Production, firms, value, volume, types, C.S.P.

D - Importations, firms, value, volume, types, C.S.P.

(II) A - GENERAL ORGANIZATION AND FUNCTIONS :

1 - DEFINITIONS :

** Pharmaceutical Product :

Any chemical entity, from plant, animal or mineral origin, either natural or synthetic used for treatment, prophylaxis or diagnosis of human diseases.

** Pharmaceutical Sector :

It encompasses all institutions responsible for the provision of safe and effective pharmaceutical products to all citizens. It comprises the following main functions or activities :-

1. R & D activities.
2. Provision activities (production, importation, marketing and distribution).
3. Evaluation, selection and licensing.
4. Control and monitoring activities (products, premises and post-market-surviellance).

2 - ORGANIZATIONAL DEVELOPMENT OF THE EGYPTIAN PHARMACEUTICAL SECTOR :

The Egyptian Pharmaceutical Sector underwent three stages of organizational development during its evolution which started in the year 1933.

*** STAGE ONE (1933 - 1960) :**

It is best defined as 'The Individual and Private Company Stage'.
In 1933 the first pharmaceutical firm was founded (Hegazi Company), then during the following 27 years, individual-family enterprises prevailed with some limited private share-holding companies.

The Pharmaceutical Sector by the mid of 1960 was composed of :-

* R & D Activities.

Very limited, almost negligible in some of the private share-holding companies.

* Provision Activities, Production.

Production was undertaken by :

- One state-owned lab for biological production of sera an vaccines.
- Three share-holding private companies (Misr - Memphis C.I.D.).
- Sixteen middle-sized private labs employing 20 - 15 workers.
- Twenty two small-sized individually owned labs producin pharmacopoeal preparations and employing less than 2 workers.

Total annual production in 1960 amounted to 4.3 million Egyptia Pounds which formed 30 % of the Total Annual Consumption.
The number of the locally produced products in the market wa approximately 200 products.

* Provision Activities, Importation.

Importation was undertaken by 63 private agents and drug stores.
Total importation value amounted to 14.3 million Egyptian Pound and the number of imported products in the market wa approximately 1800 products.

* Provision Activity, Distribution and Marketing.

Wholesale distribution was undertaken either by the producers, sales departments or by the importing agency or drug store.
Retail distribution was undertaken by private pharmacies and drug stores.
Promotion was undertaken by scientific offices of the mair international companies. Those offices were autonomous, or subordinated to an importing agency or a drug store.

* Evaluation, Selection and Licensing.

This activity was undertaken by the Department of Pharmacy, Ministry of Public Health. This department was considered the formal licensing authority in Egypt and performed all the different evaluation procedures for all pharmaceutical products.

* Control and Monitoring.

The Department of Pharmacy labs, as a licensing authority performed all the control activities on quality and conformance of pharmaceutical products in the market, together with inspection activities of the retail outlets (pharmacies).
There was very limited control and inspection on the premises of production and no post-market surveilliance of any sort.

N.B. In late fifties, (1957) a supreme organization for drugs subordinated to the Health Minister, was founded to formulate strategies and policies for drug importation and production. Its impact was limited until the year 1961 when the pharmaceutical sector was nationalized.

fig. (II-1) shows the organization and functions of the pharmaceutical sector by the mid of 1961.



Fig (II-1)

Organization and functions of the Pharmaceutical Sector by the mid of

——— subordination
═══ supervision

* STAGE TWO (1960 - 1975) :

It is best defined as the 'State or Public Domination Stage'. Most of the pharmaceutical sector's activities were performed either by state-owned or state-controlled enterprises and agencies.
The pharmaceutical sector by the end of 1975 was composed of :-

* R & D Activities.

These activities were undertaken by :

1. R & D departments of the eight public sector enterprises.
2. Pharmaceutical Research and Control Center, an entity subordinated to the General Organization of Pharmaceuticals, Chemicals and Medical Appliances "GOPCA", a state-owned organization.
   The center performed pharmaceutical researches together with pre-marketing control activities.

* Provision Activities, Production.

These activities were undertaken by :

1. A state-owned organization producing biological products "VACSERA", subordinated to the Ministry of Health.
2. Eight public sector formulation enterprises, subordinated to "GOPCA", one of which produced bulk chemicals together with formulation activities.
3. Three semi-owned private enterprises (by semi-owned is meant Egyptian - Foreign ownership).

The Total Annual Production value in 1975 amounted to 74.3 million Egyptian Pounds, which formed 84 % of total consumption. The number of locally produced drugs in the market was 1526 products.

* Provision Activities, Importation.

This activity was undertaken soley by "GOPCA" (after the nationalization of all agencies and drug stores in 1961).
The Total annual importation value in 1975 amounted to 14.1 million Egyptian Pounds. The number of imported products in the market was 671 products.

* Provision Activities, Distribution and Marketing.

Wholesale distribution was undertaken by :-

1. A public-sector enterprise 'Misria' (1965) subordinated to "GOPCA" and was responsible for the distribution of 100 % of the imported products and nearly 50 % of the locally produced products, through its main stores and branches.

2. Sales departments of the producers were responsible for the distribution of about 50 % of their production through their own main stores or their limited branch stores.

Retail distribution was undertaken mainly by private pharmacies and a limited number of public and co-operative pharmacies.

Marketing and promotion were undertaken by scientific offices under the general supervision of "GOPCA".

* Evaluation, Selection and Licensing.

Two organizations shared these activities :

1. GOPCA, which was responsible for selection, medical and clinical evaluation of pharmaceutical products.
2. The Pharmacy Department, which was responsible for pharmaceutical and chemical evaluation of pharmaceutical products and the administration of the licensing procedures.

* Control & Monitoring.

Two organizations shared these activities :

1. The Pharmaceutical Research and Control Center which was responsible for the pre-marketing quality assurance of pharmaceutical products. Its control activities encompased the conformance of pharmaceutical chemicals, pharmaceutical packaging materials and finished products.
   The center constituted an intermidiate control level between the producer's quality assurance departments and the pharmacy department.
2. The Pharmacy department, was responsible for quality and safety conformance testing of pharmaceutical products drawn from the market (i.e) post-marketing control.
   The department was also responsible for inspection of production premises, a modest activity due to modest formal specifications and prerequisites required for these premises.

No post-marketing surviellance of side effects was done.
Fig (II-2) shows the organization of the pharmaceutical sector by the end of 1975.



Fig. (II-2) Organization and Function of the Pharmaceutical Sector by the end of 1975.

———— Subordination

*** STAGE THREE (1975 - TO DATE) - THE PRESENT ORGANIZATION :**

It is best defined as the 'Re-privatization Stage'.
During this period, private participation in all provision activities was encouraged and the organization of the pharmaceutical sector underwent a state of transition, ending by the approval and erection of more than sixteen private and joint-venture enterprises and a new public sector organization.

Now, the mid of 1987, the pharmaceutical sector is composed of :-

*** R & D Activities.**

These activities are undertaken by :
1. R & D Departments of Producers.
2. National Organization for Drug Control and Research Center "NODCAR", a new organization formed by a merge between the former pharmaceutical research and control center and the pharmaceutical laboratories of the Pharmacy Department.
   The new organization performs, in addition to its pre-marketing control and research activities, the pharmaceutical and chemical evaluation of new drugs before licensing. The organization is directly subordinated to the Ministry of Health.

*** Provision Activities, Production.**

Production activities are undertaken by :-
1. The Egyptian Organization for biological products "VACSERA".
2. Fifteen pharmaceutical formulation firms (+ seven under construction) of which eight are public sector firms, subordinated to the Egypian Drug Organization (a governmental organization replacing GOPCA which was cancelled by the end of 1975).
   The other seven firms are private ventures :
   - three private Egyptian ventures
   - one private foreign venture
   - three private semi-owned (Egyptian-foreign) ventures.

The local annual production in 1985/1986 amounted to 631.3 million Egyptian Pounds which formed 80.8 % of the total consumption. The number of locally produced products is 1711 products.

*** Provision Activities, Importation.**

Thes activities are undertaken by :-
1. One public sector firm, "Misria".
2. Thirteen private importers.

Total importation amounted in 1985/1986 to 154.2 million Egyptian Pounds and the number of imported products amounted to 606 products.

* Provision Activities, Distribution and Marketing.

Wholesale distribution is undertaken by :

1. One public sector firm, "Misria" through its main stores and branches.
2. Private distributing small firms, mainly for privately imported pharmaceuticals.
3. Sales departments of producers.

Retail distribution is undertaken by :

1. Parivate pharmacies (7530 pharmacies).
2. Public pharmacies of Misria firm (22 pharmacies).
3. Co-operative pharmacies (45 pharmacies).

Marketing and promotion is still performed by the scientific offices.

* Control and Monitoring.

- Pre-marketing control is still performed by NODCAR.
- Post-marketing control is still performed by the Pharmacy Department together with the inspection of pharmacies and production premises. The latter has been developed lately after the issuance of G.M.P. prerequisites by M.O.H. in 1980.

No formal post-marketing survielliance procedures exist, but rather modest informal endevours by the drug information center at NODCAR and the Egyptian Drug Organization's information center called "EDIC".

Fig (II-3) shows the present organization structure and function of the pharmaceutical sector by mid 1987.



Fig. (II-3) Present Organization & Functions of the Pharmaceutical Sector by mid 1987.

——— Subordination
▬▬▬ Supervision

(II) B - SIZE OF FORMULARY :

1. Registered Items.

In 1985/86 more than 4000 pharmaceutical items were registered in Egypt of which only 2317 items are in the market, (the rest are either new products to be launched or out-dated products). These 2317 items represent 1643 chemical entities, combinations and forms.

Nearly 75 % of the 2317 available items are locally produced which represent 72 % of chemical entities, combinations and forms. Table (II-1) shows the 2317 available items, classified into 42 pharmacological groups (Egyptian Drug Organization classification system) and its respective number of chemical entity, combination and form.

It can be seen that eight groups comprise 57 % of the items. Antibiotics and dermatologicals have the highest number of items, (257,202) respectively,then they are followed by analgesics and antirheumatics (165), endocinics(154), tranquilizers (152), ophthalmics (143), cardiacs (138), and pulmonics (110).

TABLE (II-1) LIST OF AVAILABLE ITEMS IN THE EGYPTIAN MARKET BY 1985/198

PHARMACOLOGICAL GROUP			FORMULARY SIZE	
SER.	SC. CODE	GROUP NAME	ITEMS (BRAND-NAMES & GENERICS)	CHEMICAL ENTITIES, COMBINATIONS & FORMS.
1	01	ANAESTHETICS.	22	16
2	02	ANALGESICS, ANTIRHUEMATICS & ANTIPYRETCIS.	165	100
3	03	ANALEPTICS.	21	19
4	04	ANTHELMENTICS.	23	21
5	05	ANTIAMAEBICS & ENTEROSTATICS.	47	40
6	06	ANTIBIOTICS.	257	93
7	07	ANTIMALARIALS.	5	4
8	08	ANTICOAGULENTS.	9	6
9	10	ANTIHISTAMINICS.	41	32
10	11	CARDIACS & VASCULARETICS.	139	107
11	12	CATHARETICS.	30	23
12	13	CHEMOBIOTICS.	3	2
13	14	ANTITUBERCULOUS & ANTILEPROTICS.	12	8
14	16	SULPHONAMIDES & TRIMETHOPRIMS.	26	14
15	19	CYTOTOXICS.	41	28
16	20	DERMATOLOGICS.	202	171
17	21	ANORECTALS.	19	19
18	22	DIAGNOSTICS.	21	18
19	23	ENDOCRINICS.	154	104
20	24	GASTROINTESTINALS.	67	55
21	25	HEPATOBILINOGENICS.	22	15

TABLE (II-1) LIST OF AVAILABLE ITEMS IN THE EGYPTIAN MARKET BY 1985/1986.

(Cont.) ...

PHARMACOLOGICAL GROUP			FORMULARY SIZE	
SER.	SC. CODE	GROUP NAME	ITEMS (BRAND-NAMES & GENERICS)	CHEMICAL ENTITIES, COMBINATIONS & FORMS.
22	26	HAEMOSTATICS.	17	11
23	27	IMMUNOLOGICALS.	39	30
24	28	MESCILLINEOUS.	29	29
25	29	OPHTHALMICS.	143	110
26	30	ORODENTALS.	14	14
27	31	OTO-RHINO-LARYNGETICS.	31	18
28	32	OXYTOXICS.	11	8
29	33	PULMONICS.	110	94
30	34	SINGLE VITAMINS.	29	18
31	35	COMBINED VITAMINS.	59	52
32	36	MINERALS.	52	49
33	37	VITAMINS & MINERALS.	18	13
34	38	LIPOTROPICS.	12	12
35	39	PROTEINS.	4	3
36	41	RESTORATIVES.	43	24
37	42	SEDATIVES & HYPNOTICS.	34	25
38	43	TRANQUILIZERS & S.K.M. RELAXANTS.	152	96
39	44	SPASMOLYTICS.	82	60
40	45	UROLOGICS.	59	32
41	46	VAGINETICS.	31	28
42	47	MILK.	22	22
TOTAL			2317	1643

2. Child Survival Pharmaceutical Items "C.S.P.'s".

* C.S.P. items are those products which are commonly used for the treatment of the following diseases in children under the age of six :-

    1. Diarrhae, acute, chronic and toxic.
    2. Acute respiratory infections.
    3. Tuberculosis.
    4. Malaria.
    5. Measles.
    6. Pertussus.
    7. Tetanus.
    8. Diphtheria.
    9. Poliomyelitis.
    10. Contraception.

* C.S.P. items in the Egyptian market amounted to 245 items by 1985/86, which were equivalent to 157 chemical entities, combinations and forms.
  Nearly 93 % of those items were locally produced.
  Table (II-2) shows a list of C.S.P. items classified in pharmacological groups, (19 groups).

* It can be seen that the highest itemed group is the antibiotics group (76 items), followed by pulmonics (30 items), antiamaebics and enterostatics (26 items), endocinics (25 items) and restoratives (20 items).

TABLE (II-2) : C.S.P. ITEMS CLASSIFIED IN PHARMACOLOGICAL GROUPS (1985/1986)

CODE	PHARMACOLOGICAL GROUP	NUMBER OF ITEMS	NUMBER OF CHEMICAL ENTIT, COMB. & FORM
02	ANALGESICS, ANTIRHUEMATICS & ANTIPPURETICS.	9	6
05	ANTIAMAEBICS & ENTEROSTATICS.	26	19
06	ANTIBIOTICS.	76	33
07	ANTIMALARIALS.	3	2
10	ANTIHISTAMINICS.	7	5
13	CHEMOBIOTICS.	2	1
14	ANTITUBERCULOUS & ANTILEPROTICS.	4	3
16	SULPHONAMIDES & TRIMETHOPRIMS.	6	3
23	ENDOCRINICS.	25	16
27	IMMUNOLOGICALS.	12	10
28	MESCILLINEOUS.	1	1
33	PULMONICS.	30	26
35	COMBINED VITAMINS.	12	12
41	RESTORATIVES.	20	8
42	SEDATIVES & HYPNOTICS.	4	4
44	SPASMOLYTICS.	5	4
47	MILK.	3	3
T O T A L		245	157

(II) C - PRODUCTION :

1. Manufacturers.

Since mid 1987, fifteen formulation enterprises producing pharmaceutical products have been working in Egypt together with a state-owned organization for biological production of vaccines and sera.

All of the fifteen enterprises are large-scale producers, employing from 250 to 3600 workers and producing most of the known pharmaceutical forms (sterile forms, solid forms, liquid forms, ...etc).

Ownership of enterprises is as follows :
- 8 are public-sector enterprises (state-owned).
- 1 is public-private joint-venture.
- 6 are private-sector enterprises of which:
  - 2 are Egyptian private enterprises
  - 3 are Egyptian-foreign private enterprises
  - 1 is a foreign private enterprise.

Table (II-3) shows basic information of the Egyptian pharmaceutical manufacturers icluding names, addresses, establishment year, capital and number of workers.

TABLE (II-3) : EGYPTIAN PHARMACEUTICAL MANUFACTURERS BASIC INFORMATION.

SER.	NAME	ADDRESS	YEAR OF ESTABLISHMENT	NO. OF WORKERS	CAPITAL IN MILL.LE
** PUBLIC ENTERPRISES					
01	ALEXANDRIA CO. FOR PHARMACEUTICAL & CHEMICAL INDUSTRIES.	GAMILA BOHRID ST., AWAYAD, ALEXANDRIA.	1962	761	6.4
02	ARAB DRUG COMPANY (ADCO).	5 MASSANEA ST., EL-AMIRIA, CAIRO.	1963	1370	5.0
03	CHEMICAL INDUSTRIES DEVEL-OPMENT (C.I.D.).	EL-HARAM ST., CAIRO.	1947	3582	20.0
04	EL-NASR PHARMACEUTICAL & CHEMICAL INDUSTRIES.	ABOU ZA'ABAL, EL-BALAD, CAIRO.	1963	2163	14.0
05	EL-NILE CO. FOR PHARMACEUTICAL & CHEMICAL INDUSTRIES.	SAWAH ST., EL-AMIRIA, CAIRO.	1962	3382	13.16
06	KAHIRA PHARMACEUTICAL & CHEMICAL INDUSTRIES.	ABD EL-HAMID EL-DEEB ST., VICTORIA SQ. SHOUBRA, CAIRO.	1962	2115	8.4
07	MEMPHIS CHEMCIAL CO.	30 WABOUR EL-MAYA ST., ZATOUN, CAIRO.	1940	1822	10.0
08	MISR CO. FOR PHARMACEUTICAL INDUSTRIES.	92 MATARIA ST., CAIRO.	1940	2132	9.99

TABLE (II-3) : EGYPTIAN PHARMACEUTICAL MANUFACTURERS BASIC INFORMATION.

(Cont.) ....

SER.	NAME	ADDRESS	YEAR OF ESTABLISHMENT	NO. OF WORKERS	CAPITA IN MILL.L
** PUBLIC/PRIVATE ENTERPRISES					
09	EGYPTIAN PHARMACEUTICAL INTERNATIONAL CO. (EPICO).	TENTH OF RAMADAN CITY.	1984	716	15.0
** PRIVATE (EGYPTIAN) ENTERPRISES					
10	ADVANCED BIOCHEMICAL INDUSTRIES PHARMA-CEUTICAL CO. (ABI)	EL-SALAM CITY, CAIRO.	1985	385	16.0
11	ISLAMIC PHARMACEUTICAL CO. (FARCO) INDUSTRIES.	EL-AMRRYA, ALEXANDRIA.	1987	360	4.0
** PRIVATE (EGYPTIAN-FOREIGN) ENTERPRISES					
12	HOECHST ORIENT PHARMACEUTICAL CO.	EL-MASSANEA ST., EL-AMIRIA, CAIRO.	1962	765	5.0
13	PFIZER EGYPT S.A.A.	EL -THAWRA ST., CAIRO-SEUZ ROAD, CAIRO.	1961	488	1.55
14	SWISSPHARMA S.A.A. PHARMACEUTICAL INDUSTRIES.	EL SAWAH ST., EL-AMIRIA, CAIRO.	1962	488	2.81
** PRIVATE (FOREIGN) ENTERPRISES					
15	SQUIBB EGYPT.	17 STUDIO EL-AHRAM ST., PYRAMIDS ROAD, GIZA, CAIRO.	1979	250	$5.75

SOURCES :

1. DRUG OF EGYPT, EGYPTIAN DRUG ORGANIZATION, 1985.
2. INDEX OF PHARMACEUTICAL MANUFACTURERS, BASIC DATA SERIES, NO.(3), EDIC.

2. Annual Production Figures.

a. Total Annual Production and C.S.P.'s Production Values.

Total annual production value amounted to 631.3 million Egyptian Pounds in 1985/86 (evaluated by public prices) covering 80.8 % of total consumption.

Annual production value of C.S.P items amounted to 118.2 million Egyptian Pounds in the same year, (i.e), 8.7 % of total production value.

Table (II-4) shows the historical development of the total annual production value since 1952 and percentage coverage of total consumption.

Table (II-5) shows the total annual production value in 1985/1986 broken down by manufacturer, while table (II-6) shows total annual production value in 1985/1986 and C.S.P's production value broken down by pharmacological group.

TABLE (II-4) : THE HISTORICAL DEVELOPMENT OF TOTAL ANNUAL PRODUCTION VALUE AND THE PERCENTAGE OF CONSUMPTION COVERAGE.

(IN MILLION EGYPTIAN POUNDS).

YEAR	TOTAL ANNUAL PRODUCTION VALUE	PERCENTAGE OF CONSUMPTION COVERAGE
1952	0.5	10.4 %
1960	4.3	30.7 %
1965	26.6	85.5 %
70/71	45.2	82.04 %
1975	74.3	84.08 %
80/81	243.0	82.94 %
85/86	631.3	80.80 %

TABLE (II-5) : TOTAL PRODUCTION VALUE BROKEN DOWN BY MANUFACTURER IN 1985/86.

(IN MILLION EGYPTIAN POUNDS)

CODE	MANUFACTURER	TOTAL PRODUCTION VALUE	MARKET SHARE
513	VACSERA	4.4	0.7 %
501	ADCO	30.6	4.9 %
502	ALEXANDRIA	39.8	6.3 %
503	C.I.D.	80.7	12.8 %
504	EL NASR	9.4	1.5 %
505	EL NILE	79.2	12.5 %
507	KAHIRA	68.4	10.8 %
508	MEMPHIS	45.2	7.2 %
509	MISR	54.3	8.6 %
510	PFIZER - EGYPT	38.1	6.0 %
506	HOECHST	42.1	6.7 %
511	SWISSPHARMA	70.8	11.2 %
512	SQUIBB EGYPT	38.5	6.1 %
515	EIPECO	24.1	3.8 %
516	A.B.I.	5.7	0.9 %
T O T A L		631.3	100.0 %

TABLE (II-6) : TOTAL ANNUAL PRODUCTION VALUE BROKEN DOWN BY PHARMACOLOGICAL GROUP IN 1985/1986.

(IN MILLION EGYPTIAN POUNDS).

CODE	PHARMACOLOGICAL GROUP	PRODUCTION VALUE	C.S.P. VALUE
01	ANAESTTHETICS.	321	---
02	ANALGESICS, ANTIRHUEMATICS & ANTIPPURETICS.	78855	2629
03	ANALEPTICS.	2921	---
04	ANTHELMEUTICS.	7390	---
05	ANTIAMAEBICS & ENTEROSTATICS.	17733	11076
06	ANTIBIOTICS.	120323	42988
07	ANTIMALARIALS.	1120	153
08	ANTICOAGULENTS.	653	---
10	ANTIHISTAMINICS.	13468	2782
11	CARDIACS & VASCULARETICS.	20342	---
12	CATHARETICS.	5011	---
13	CHEMOBIOTICS.	10575	1223
14	ANTITUBERCULOUS & ANTILEPROTICS.	1971	628
16	SULPHONAMIDES & TRIMETHOPRIMS.	3401	2626
19	CYTOTOXICS.	0	---
20	DERMATOLOGICS.	36108	---
21	ANORECTALS.	2685	---
22	DIAGNOSTICS.	3	---
23	ENDOCRINICS.	28592	5664
24	GASTROINTESTINALS.	19313	---
25	HEPATOBILINOGENICS.	1989	---
26	HAEMOSTATICS.	1120	---
27	IMMUNOLOGICALS.	5020	4261
28	MESCILLINEOUS.	5061	14
29	OPHTHALMICS.	35077	---

TABLE (II-6) : TOTAL ANNUAL PRODUCTION VALUE BROKEN DOWN BY PHARMACOLOGICAL GROUP IN 1985/1986.

(IN MILLION EGYPTIAN POUNDS).

(Cont.) ...

CODE	PHARMACOLOGICAL GROUP	PRODUCTION VALUE	C.S.P. VALUE
30	ORODENTALS.	3856	---
31	OTO-RHINO-LARYNGETICS.	9000	---
32	OXYTOXICS.	1140	---
33	PULMONICS.	46042	21174
34	SINGLE VITAMINS.	10972	---
35	COMBINED VITAMINS.	205801	12222
36	MINERALS.	3742	---
37	VITAMINS & MINERALS.	4924	---
38	LIPOTROPICS.	4675	---
39	PROTEINS.	0	---
41	RESTORATIVES.	10743	7213
42	SEDATIVES & HYPNOTICS.	4171	1159
43	TRANQUILIZERS & S.K.M. RELAXANTS	14137	---
44	SPASMOLYTICS.	19129	2402
45	UROLOGICS.	14914	--
46	VAGINETICS.	3087	---
47	MILK.	0	---
T O T A L		631,385	118,214

b. Total Annual Production and C.S.P.'s Production volumes.

Total annual production volume in 1985/86 amounted to 727.2 million packs of different pharmaceutical forms covering 90.5 % of total consumption.

Annual production volumes of C.S.P's amounted to 214.5 million packs in the same year, (i.e), 29.5 % of total production volume.

Table (II-7) shows the total annual production volumes of different pharmaceutical forms.

Table (II-8) shows the total annual production volumes of 1985/86 broken down by pharmacological group.

TABLE (II-7) : TOTAL PRODUCTION VOLUMES OF DIFFERENT FORMS IN 1985/1986.

PHARMACEUTICAL FORM	UNIT	TOTAL PRODUCTION VOLUME (IN MILLION UNITS)
1. Sterile forms (ampoule, vial, vacolitre, carpule, ...etc.).	one amp/ vial	494.0
2. Solid forms (type-a) (tablets,capsules, vaginal tablets).	one tablet capsule	11668.0
3. Solid forms (type-b) (powders, granules).	one box/ sachet	16.0
4. Semi-solid forms (type-a) (ointments, creams, pastes).	one tube	56.1
5. Semi-solid forms (type-b) (suppositories ovules, pessaries).	one ovule supp.	98.8
6. Liquid forms (syrup, drop, suspension, ... etc.)	one bottle	210.0

TABLE (II-8) : TOTAL PRODUCTION VOLUMES AND C.S.P. PRODUCTION VOLUME IN 1985/86 BROKEN DOWN BY PHARMACOLOGICAL GROUP.

(IN 1000 PACKS).

CODE	PHARMACOLOGICAL GROUP	TOTAL PRODUCTION VOLUME	C.S.P. VOLUME
01	ANAESTTHETICS.	718	-----
02	ANALGESICS, ANTIRHUEMATICS & ANTIPPURETICS.	143427	5823
03	ANALEPTICS.	2849	-----
04	ANTHELMENTICS.	5702	----
05	ANTIAMAEBICS & ENTEROSTATICS.	17083	12195
06	ANTIBIOTICS.	107466	49751
07	ANTIMALARIALS.	1209	98
08	ANTICOAGULENTS.	199	----
10	ANTIHISTAMINICS.	13173	2882
11	CARDIACS & VASCULARETICS.	15511	----
12	CATHARETICS.	5091	----
13	CHEMOBIOTICS.	7266	2110
14	ANTITUBERCULOUS & ANTILEPROTICS.	1142	298
16	SULPHONAMIDES & TRIMETHOPRIMS.	3752	2436
19	CYTOTOXICS.	80	----
20	DERMATOLOGICS.	31810	----
21	ANORECTALS.	2413	----
22	DIAGNOSTICS.	30	----
23	ENDOCRINICS.	28585	14831
24	GASTROINTESTINALS.	17505	----
25	HEPATOBILINOGENICS.	1016	----
26	HAEMOSTATICS.	819	----
27	IMMUNOLOGICALS.	56288	44958
28	MESCILLINEOUS.	5373	41
29	OPHTHALMICS.	31689	----

TABLE (II-8) : TOTAL PRODUCTION VOLUMES AND C.S.P. PRODUCTION VOLUME IN 1985/86 BROKEN DOWN BY PHARMACOLOGICAL GROUP.
(IN 1000 PACKS).

(Cont.) ...

CODE	PHARMACOLOGICAL GROUP	TOTAL PRODUCTION VOLUME	C.S.P. VOLUME
30	ORODENTALS.	3258	----
31	OTO-RHINO-LARYNGETICS.	8630	----
32	OXYTOXICS.	1107	----
33	PULMONICS.	45161	26911
34	SINGLE VITAMINS.	9597	----
35	COMBINED VITAMINS.	42045	16426
36	MINERALS.	2618	----
37	VITAMINS & MINERALS.	16905	----
38	LIPOTROPICS.	3568	----
39	PROTEINS.	0	----
41	RESTORATIVES.	34101	29096
42	SEDATIVES & HYPNOTICS.	3039	2608
43	TRANQUILIZERS & S.K.M. RELAXANTS	12019	----
44	SPASMOLYTICS.	28767	4062
45	UROLOGICS.	13215	----
46	VAGINETICS.	2997	----
47	MILK.	0	----
T O T A L		727,233	214,526

c. Annual Production Types.

In 1985/86, 1711 items locally produced were in the Egyptian market, covering all pharmacological groups (except Infant Milk formulae and proteins).

C.S.P.'s items locally produced amounted to 221 items, (i.e), 13 % of total produced items.

Table (II-9) shows total number of produced items and C.S.P. items broken down by pharmacological group while table (II-10) shows total number broken down by manufacturer.

TABLE (II-9) TOTAL NUMBER OF PRODUCED ITEMS AND C.S.P. ITEMS BROKEN DOWN BY PHARMACOLOGICAL GROUP. (1985/86).

CODE	PHARMACOLOGICAL GROUP	TOTAL PRODUCED ITEMS	C.S.P. ITEMS
01	ANAETHETICS.	7	
02	ANALGESIC, ANTIRUEMATICS & ANTIPYRETICS.	154	9
03	ANALEPTICS.	17	
04	ANTHELMENTICS.	20	
05	ANTIAMAEBICS & ENTEROSTATICS.	41	25
06	ANTIBIOTICS.	242	74
07	ANTIMALARIALS.	4	3
08	ANTICOAGULENTS.	5	
10	ANTIHISTAMINICS.	35	7
11	CARDIACS & VASCULARETICS.	88	
12	CATHARETICS.	28	
13	CHEMOBIOTICS.	2	2
14	ANTITUBERCULOUS & ANTILEPROTICS.	9	4
16	SULPHONAMIDES & TRIMETHOPRIMS.	26	6
19	CYTOTOXICS.	3	
20	DERMATOLOGICS.	145	
21	ANORECTALS.	16	
22	DIAGNOSTICS.	1	
23	ENDOCRINICS.	98	12
24	GASTROINTESTINALS.	49	
25	HEPATOBILINOGENICS.	11	
26	HAEMOSTATICS.	9	
27	IMMUNOLOGICALS.	25	11
28	MESCILLINEOUS.	16	1
29	OPHTHALMICS.	61	

TABLE (II-9) TOTAL NUMBER OF PRODUCED ITEMS AND C.S.P. ITEMS BROKEN DOWN BY PHARMACOLOGICAL GROUP. (1985/86).

(CONT.) ...

CODE	PHARMACOLOGICAL GROUP	TOTAL PRODUCED ITEMS	C.S.P. ITEMS
30	ORODENTALS.	13	
31	OTO-RHINO-LARYNGETICS.	27	
32	OXYTOXICS.	5	
33	PULMONICS.	94	28
34	SINGLE VITAMINS.	26	
35	COMBINED VITAMINS.	56	12
36	MINERALS.	18	
37	VITAMINS & MINERALS.	50	
38	LIPOTROPICS.	12	
39	PROTEINS.	0	
41	RESTORATIVES.	40	18
42	SEDATIVES & HYPNOTICS.	22	4
43	TRANQUILIZERS & S.K.M. RELAXANTS.	91	
44	SPASMOLYTICS.	71	5
45	UROLOGICS.	53	
46	VAGINETICS.	21	
47	MILK.	0	0
T O T A L :		1711	221

TABLE (II-10) : TOTAL NUMBER OF LOCALLY PRODUCED ITEMS AND C.S.P. ITEMS BROKEN DOWN BY MANUFACTURER - 1985/1986.

MANUFACTURER	TOTAL PRODUCTION ITEMS	C.S.P. ITEMS
1. EGYPTIAN ORGANIZATION FOR BIOLOGICAL PRODUCTS (VACSERA)	25	11
2. ADCO	96	9
3. ALEXANDRIA	129	10
4. C.I.D.	233	42
5. EL-NASR	50	9
6. EL-NILE	210	26
7. KAHIRA	236	19
8. MEMPHIS	158	16
9. MISR	180	36
10. HOECHST ORIENT	62	5
11. PFIZER EGYPT	41	5
12. SWISS PHARMA	103	8
13. SQUIBB EGYPT	51	9
14. EPICO	90	9
15. A.B.I.	47	7
16. FARCO	INTRODUCED IN JUN. 87	JUN. 87
T O T A L	1711	221

II (D) - IMPORTATION

1. Importers.

- Egypt imports pharmaceuticals from all the international, research-based pharmaceutical companies.
- There is one public-sector importing company, Egyptian drug company for importation (Misria) which is responsible for more than 85 % of total importation value.
- There are 13 other private importing firms.
- Table (II-11) shows basic information on importers.

2. Annual Importation Figures.

a. Total Annual Importation, C.S.P. Importation Values.

- Total annual importation value amounted to 150.1 million Egyptain pounds in 1985/86 (evaluated by public prices) covering 19.2 % of total consumption.
- Annual importation value of C.S.P.'s amounted to 5.2 million pounds in the same year.
- Table (II-12) shows the historical development of total annual importation value since 1952 and percentage coverage of total consumption.
- Table (II-13) shows total annual importation value and C.S.P.'s importation value broken down by pharmacological group in 1985/1986.

b. Total Annual Importation and C.S.P. importation Volumes.

- Total annual importation volume amounted to 76.1 million packs in 1985/86.
- C.S.P. annual importation volume amounted to 2.7 million packs in the same year.
- Table (II-14) shows total annual importation volumes and C.S.P.'s volume in 1985/86 broken down by pharmacological group.

c. Total Annual Importation Types.

- By mid 1987 (606) items were imported in the Egyptian market, while C.S.P. imported items amounted to (24) items in the same year.
- Table (II-15) shows the total number of imported items and C.S.P. items broken down by pharmacological group.

TABLE (II-11) : MAIN EGYPTIAN PHARMACEUTICAL IMPORTERS (BASIC INFORMATION)

SER.	NAME	ADDRESS
1	EGYPTIAN COMPANY FOR DRUG IMPORTATION (MISRYIA).	18 ADLY ST., CAIRO.
2	CHEMIPHARM.	25 AHMED ORABI ST., GUIZA
3	AMOUN.	150 EL-HEGAZ ST., HELIOPOLIS, CAIRO
4	SOFICOPHARM.	37 TALAAT HARB ST. CAIRO
5	EGYPTIAN PROMOTER CENTER (EPC).	44 SHERIF ST., CAIRO
6	AL-KAMAL IMPORT OFFICE.	3 YEHIA TAWFIC ST., ZAMALEK, CAIRO.
7	ORGANON.	3 GHORNATA ST., HELIOPOLIS, CAIRO
8	ALPHACHEM.	5 AHMED SALMAN PASHA ST., HELIOPOLIS, CAIRO.
9	MATAGER EL-NILE.	44 SHERIF ST., CAIRO.
10	ICI.	43 GAMEAT EL-DOWAL ER-ARABIA ST., MOHANDESSIN, DOKKI, GUIZA.

TABLE (II-12) : HISTORICAL DEVELOPMENT OF TOTAL ANNUAL IMPORTATION VALUE.

YEAR	TOTAL ANNUAL IMPORTATION VALUE	% COVERAGE OF TOTAL CONSUMPTION
1952	4.3	89.60 %
1960	9.7	69.30 %
1970	4.5	14.50 %
1970/71	9.9	17.96 %
1975	14.1	15.95 %
1980/81	50.0	17.06 %
1985/86	150.1	19.20 %

TABLE (II-13) : TOTAL ANNUAL IMPORTATION VALUE BROKEN DOWN BY PHARMACOLOGICAL GROUP. (1985/86).

CODE	PHARMACOLOGICAL GROUP	TOTAL IMPORTATION VALUE	C.S.P. VALUE
01	ANAESTTHETICS.	1408	-
02	ANALGESICS, ANTIRHUEMATICS & ANTIPPURETICS.	5335	0
03	ANALEPTICS.	252	-
04	ANTHELMENTICS.	1352	-
05	ANTIAMAEBICS & ENTEROSTATICS.	270	145
06	ANTIBIOTICS.	11748	516
07	ANTIMALARIALS.	0	0
08	ANTICOAGULENTS.	571	0
10	ANTIHISTAMINICS.	353	0
11	CARDIACS & VASCULARETICS.	9752	-
12	CATHARETICS.	641	-
13	CHEMOBIOTICS.	800	0
14	ANTITUBERCULOUS & ANTILEPROTICS.	151	0
16	SULPHONAMIDES & TRIMETHOPRIMS.	0	0
19	CYTOTOXICS.	2007	-
20	DERMATOLOGICS.	6162	-
21	ANORECTALS.	16	-
22	DIAGNOSTICS.	645	-
23	ENDOCRINICS.	12963	1700
24	GASTROINTESTINALS.	7297	-
25	HEPATOBILINOGENICS.	5142	-
26	HAEMOSTATICS.	1262	-
27	IMMUNOLOGICALS.	398 *	78
28	MESCILLINEOUS.	2572	0
29	OPHTHALMICS.	8819	-

* Imported vacc. via UNICEF ws considered locally produced as it is titrated, packed and controlled by VACSERA.

TABLE (II-13) : TOTAL ANNUAL IMPORTATION VALUE BROKEN DOWN BY PHARMACOLOGICAL GROUP. (1985/86).

(Cont.) ...

CODE	PHARMACOLOGICAL GROUP	TOTAL IMPORTATION VALUE	C.S.P. VALUE
30	ORODENTALS.	22	-
31	OTO-RHINO-LARYNGETICS.	5738	-
32	OXYTOXICS.	447	-
33	PULMONICS.	6804	472
34	SINGLE VITAMINS.	82	-
35	COMBINED VITAMINS.	2554	0
36	MINERALS.	1030	-
37	VITAMINS & MINERALS.	1838	-
38	LIPOTROPICS.	0	-
39	PROTEINS.	272	-
41	RESTORATIVES.	1205	366
42	SEDATIVES & HYPNOTICS.	588	0
43	TRANQUILIZERS & S.K.M. RELAXANTS	11682	-
44	SPASMOLYTICS.	1907	0
45	UROLOGICS.	5694	-
46	VAGINETICS.	883	-
47	MILK.	21471	1925
T O T A L		150,133	

TABLE (II-14) : TOTAL IMPORTATION VOLUMES AND C.S.P. IMPORTATION VOLUME IN 1985/86 BROKEN DOWN BY PHARMACOLOGICAL GROUP.
(IN 1000 PACKS).

CODE	PHARMACOLOGICAL GROUP	TOTAL IMPORTATION VOLUME	C.S.P. VOLUME
01	ANAESTHETICS.	1195	-
02	ANALGESICS, ANTIRHUEMATICS & ANTIPPURETICS.	909	0
03	ANALEPTICS.	77	-
04	ANTHELMENTICS.	747	-
05	ANTIAMAEBICS & ENTEROSTATICS.	134	100
06	ANTIBIOTICS.	4501	60
07	ANTIMALARIALS.	9	0
08	ANTICOAGULENTS.	1607	-
10	ANTIHISTAMINICS.	241	0
11	CARDIACS & VASCULARETICS.	8606	-
12	CATHARETICS.	1650	-
13	CHEMOBIOTICS.	52	0
14	ANTITUBERCULOUS & ANTILEPROTICS.	60	0
16	SULPHONAMIDES & TRIMETHOPRIMS.	0	0
19	CYTOTOXICS.	271	-
20	DERMATOLOGICS.	19177	-
21	ANORECTALS.	121	-
22	DIAGNOSTICS.	218	-
23	ENDOCRINICS.	5765	582
24	GASTROINTESTINALS.	1940	-
25	HEPATOBILINOGENICS.	648	-
26	HAEMOSTATICS.	102	-
27	IMMUNOLOGICALS.	159	30
28	MESCILLINEOUS.	1377	0
29	OPHTHALMICS.	2456	-

TABLE (II-14) : TOTAL IMPORTATION VOLUMES AND C.S.P. IMPORTATION VOLUME IN 1985/86 BROKEN DOWN BY PHARMACOLOGICAL GROUP.
(IN 1000 PACKS).

(Cont.) ...

CODE	PHARMACOLOGICAL GROUP	TOTAL IMPORTATION VOLUME	C.S.P. VOLUME
30	ORODENTALS.	0	-
31	OTO-RHINO-LARYNGETICS.	104	-
32	OXYTOXICS.	106	-
33	PULMONICS.	2750	220
34	SINGLE VITAMINS.	116	-
35	COMBINED VITAMINS.	467	0
36	MINERALS.	197	-
37	VITAMINS & MINERALS.	2109	-
38	LIPOTROPICS.	0	-
39	PROTEINS.	72	-
41	RESTORATIVES.	654	22
42	SEDATIVES & HYPNOTICS.	323	0
43	TRANQUILIZERS & S.K.M. RELAXANTS	2885	-
44	SPASMOLYTICS.	173	0
45	UROLOGICS.	256	-
46	VAGINETICS.	70	-
47	MILK.	14597	1700
T O T A L		76,901	2,714

TABLE (II-15) : TOTAL NUMBER OF IMPORTED ITEMS AND C.S.P. ITEMS BROKEN DOWN BY PHARMACOLOGICAL GROUP. (1987)

CODE	PHARMACOLOGICAL GROUP	TOTAL NUMBER OF IMPORTED ITEMS	TOTAL NUMBER OF C.S.P.
01	ANAESTTHETICS.	15	-
02	ANALGESICS, ANTIRHUEMATICS & ANTIPPURETICS.	11	0
03	ANALEPTICS.	4	-
04	ANTHELMENTICS.	3	-
05	ANTIAMAEBICS & ENTEROSTATICS.	6	1
06	ANTIBIOTICS.	15	2
07	ANTIMALARIALS.	1	-
08	ANTICOAGULENTS.	4	-
10	ANTIHISTAMINICS.	6	0
11	CARDIACS & VASCULARETICS.	51	-
12	CATHARETICS.	2	-
13	CHEMOBIOTICS.	1	0
14	ANTITUBERCULOUS & ANTILEPROTICS.	3	0
16	SULPHONAMIDES & TRIMETHOPRIMS..	0	0
19	CYTOTOXICS.	38	-
20	DERMATOLOGICS.	57	-
21	ANORECTALS.	3	1
22	DIAGNOSTICS.	20	-
23	ENDOCRINICS.	56	13
24	GASTROINTESTINALS.	18	-
25	HEPATOBILINOGENICS.	11	-
26	HAEMOSTATICS.	8	-
27	IMMUNOLOGICALS.	14	1 *a
28	MESCILLINEOUS.	13	0
29	OPHTHALMICS.	82	-

*a : Vaccines D.P.T & D.T. are imported in bulk & are repacked locally and therefore are considered as locally produced.

TABLE (II-15) : TOTAL NUMBER OF ITEMS AND C.S.P. ITEMS BROKEN DOWNBY PHARMACOLOGICAL GROUP.
(1987)

(Cont.) ...

CODE	PHARMACOLOGICAL GROUP	TOTAL NUMBER OF IMPORTED ITEMS	TOTAL NUMBER OF C.S.P.
30	ORODENTALS.	1	-
31	OTO-RHINO-LARYNGETICS.	4	-
32	OXYTOXICS.	6	-
33	PULMONICS.	16	2
34	SINGLE VITAMINS.	3	-
35	COMBINED VITAMINS.	3	-
36	MINERALS.	2	-
37	VITAMINS & MINERALS.	0	-
38	LIPOTROPICS.	0	-
39	PROTEINS.	4	-
41	RESTORATIVES.	3	2
42	SEDATIVES & HYPNOTICS.	12	0
43	TRANQUILIZERS & S.K.M. RELAXANTS	61	-
44	SPASMOLYTICS.	11	0
45	UROLOGICS.	6	-
46	VAGINETICS.	10	-
47	MILK.	22	3
T O T A L		606	24

(III) REGISTRATION MECHANISM AND POLICY CONSIDERATIONS OF PHARMACEUTICALS IN EGYPT.

A - REGISTRATION, ORGANIZATION AND PROCEDURES.

B - EVALUATION AND SELECTION CRITERIA.

C - POLICY CONSIDERATIONS.

(III) A - Registeration, Organization and Procedures.

1. Organization.

* Registration of pharmaceuticals started in Egypt by the mid 1930's.
* Now three different institutions share the registration process and constitute the Egyptian licensing authority. The three institutions subordinate to the Health Minister. They are as follows :

1. Egyptian Drug Organization "EDO".

   performs medical/clinical evaluation and selection according to prevailing policies.

2. National Organization for Drug Control and Research "NODCAR".

   performs chemical/bacteriological/pharmaceutical evaluation and stability testing of the selected pharmaceuticals.

3. Pharmacy Department (Central Administration of Pharmacy Department) "CAPD".

   performs final evaluation and the administration of the registration process till the issuance of the registration grant.

* Fig.(III-1) shows the detailed organization of the departments and committees of the three institutions engaged in the registration process.



Fig. (III-1) : Departments and committees engaged in the registration process of pharmaceuticals in Egypt.

2. Procedures.

* The registration process was legalized by Law No. 127 for 1955 and was ammended by the following laws :

  Law No. 360 for 1956
  Law No. 253 for 1958
  Law No. 714 for 1982
  Law No. 14 for 1984.

* All the following articles must be registered by the Health Ministry before marketing :

  1. Pharmaceuticals for human use.
  2. Pharmaceuticals for vetrinary use.
  3. Food additions for vetrinary use.
  4. Sera and vaccines.
  5. Cosmetics.
  6. Domestic insecticides.

* The following steps constitute the official current procedure to be followed for registration of (pharmaceuticals for human use).

<u>Step 1.</u>

The applicant submits a package of three files to (CAPD), comprising :

a. Main file.
b. Subsidiary file.
c. Scientific file.

The applicant may be :

a. A licensed pharmaceutical company locally producing pharmaceuticals.
b. A licensed local scientific office.
c. A licensed agency office.

The files contain :

<u>a. Main File</u> includes the following documents :

1. A covering letter with a duty stamp of P.T. 20 directed to the undersecretary of state of (CAPD).
2. A L.E. 20 medical stamp.
3. Application for registeration form (Form No. 17 available at "CAPD") with a duty stamp of P.T. 55. The application should be typed.

a. Main File (Cont.) ...

4. Five copies of the product complete formulae with a duty stamp on each copy with P.T. 20.
5. A legalized free sale certificate.
6. A legalized Agency Agreement (for imported pharmaceuticals).
7. Five copies of the complete method of analysis. If any of the ingredients is not pharmacopeal, the company's specifications and methods of analyses should be added.
8. Seven free medical samples of the product in its original package presentation, signed by the pharmacist who had prepared it and bearing the manufacturing date, expirey date and the same batch number as the enclosed certificate of analysis.
9. Certificate of analysis of the enclosed samples bearing the same batch number, manufacturing date and expirey date of the samples.
10. Twenty inner leaflets (inserts) and twenty outer cardboard carton boxes, with a duty stamp of P.T. 20 on each.
11. Expected prices which may include :
    a. FOB price.
    b. C & F price.
    c. Ex-Factory price.
    d. Public price at the country of origin.
    e. Expected public price in Egypt.
12. Stability data, bearing the same batch number, manufacturing date and expirey date of the samples.
13. In case of antibiotic prepartions, a certificate of analysis of the raw matrials should be included.
14. Complete "EDIF Sheet" of scientific data. The sheets are available at the Egyptian drug information center (EDIC) at (EDO). The sheets should be typed.

b. Subsidiary File.

It includes a copy of all the documents of the Main file except duty stamps and medical stamps.

c. Scientific File.

It includes the following documents.
1. Pharmacological/pharmacokinetic studies.
2. Toxicological studies.
3. LD_{50}.
4. Therapeutic Potential index.
5. Stability data (detailed).
6. Dissolution and disintegration rates and method (for solid forms).
7. All published clinical trials and clinical evaluation studies.

Step 2.

CAPD revises the documents of the three files and if they are found satisfactory, it sends the subsidiary and scientific files to EDO for medical/clinical evaluation and selection.

Step 3.

Upon receite of the files, EDO refers the subsidiary file to EDIC, where the EDIF sheet document is revised, completed and supplemented with the following information :

1. All WHO, FDA, DHSS notifications and recommendations.
2. Informtion about similar or substitute products available in the market.

Both files are submitted to the High Scientific Committee of Drugs of EDO, for selection and evaluation. The committee can decide for or against the registration, using the available information of th files, or it might need to perfom local specialized clinical studies before reaching a decision. If so, the committee will refer the files to one of its subordinating specialized scientific committees (9 committees) where the product is locally, clinically santinized and returned once more, with the specialized committee's advice, to the High Scientific committee for the final decision.
The High Scientific committee's approval decisior is not a grant for registration, but rather a pre-requisite, it is a grant to proceed or not to proceed in the registration process.
The committee's disapproval decisions can be appealed for by the applicant if he so desires.

Step 4.

EDO will in turn send the subsidiary and scientific files of the product, together with the High Scientific committee's decision to CAPD. If the product was approved, CAPD will send the samples and documented method of assay to NODCAR for chemical/bacteriological/pharmaceutical evaluation and conformance testing. If the product was not approved, it will return its three files to the applicant.

Step 5.

NODCAR then notifies CAPD with the results of its detailed evaluation processes in a formal report.

Step 5 (Cont.) ...

All reports and studies of evaluation, together with the scientific file are collected and presented to the Technical Committee for Drug Registration at CAPD for final evaluation and final decision which is signed by the Health Minister. This committee is the legal entity responsible for issuing registration grants or licenses.
Fig. (III-2) shows a diagram of the procedure.



Fig. (III-2) : Diagram of the Egyptian Registration Procedure.

2.1 Locally-produced by Egyptian Technology. (Cont.) ...

e. If the product is similar to a sole (only one) locally produced product by Egyptian technology.

f. If the product is of vital therapeutic value and is similar to locally produced product (either by Egyptian or foreign technology) and is repeatedly out of stock due to production bottle-necks.

2.2 Locally-produced Products by Foreign Technology.

a. If the product is a breakthrough and has no similars in the market.
b. If the product is a new development of the currently available products with less side-effects or more potency and has no similars in the market.
c. If the product is similar to a currently imported product (either in finished form or bulk to be repacked locally).
d. It <u>must not</u> has current locally produced drug by Egyptian technology.
e. If the product is similar to a sole (just one) locally produced product by foreign technology.

(III) B - EVALUATION AND SELECTION CRITERIA.

Evaluation and selection of pharmaceuticals are performed by the High Scientific Committee of EDO according to the following criteria which were issued by EDO's board of directors and approved by the Health Minister (Decision No. of 198).

If medical/clinical evaluation studies, performed on the product by the High Scientific committee and/or one of its subordinated specialized committees, are found statisfactory and no warnings or limiations are received from national and international drug control authorities, the product is considered scientifically viable and it will be granted an approval to proceed on with its registration procedures if it satisfies one or more of the following criteria :

1. Selection Criteria of Imported Products.

a. If the product is a breakthrough with a new mode of action and of vital therapeutic potency (eg. Tagamet) and has no similars in the market.
b. If the product is a new development of the currently available products with less side effects or more potency, and has no similars in the market.
c. If the product is similar to a currently imported product in the market but with lower expected public price, on condition that its manufacturing company is of the same international status.
(assigned and approved by the High Scientific Committee).
d. If the product is similar to a currently locally produced product which is suffering from technical shortcomings and is repeatedly withdrawn from the market due to these technical difficulties.

2. Selection Criteria for Locally-Produced Products.

2.1 Locally-produced by Egyptian technology.

a. If the product is a breakthrough and has no similars in the market.
b. If the product is a new development of the currently available products with less side effects or more potency and has no similars in the market.
c. If the product is similar to a currently imported product (either in finished form or bulk to be repacked locally).
d. If the product is similar to a currently locally produced product by foreign technology (produced under license).

(III) C - POLICY CONSIDERATIONS.

No formal policy documents were defined related to provision of pharmaceuticals. Policy considerations are rather embodied implicitly in different plans, budgets, decrees and meeting proceedings of B.O.D's and different official committees. Nevertheless, they are trends rather than policies.
After performing a series of interviews with top officials of the pharmaceutical sector, policy considerations or trends can be described in the following categories :

a. R & D Policy Considerations.

1. Organizational development aiming at more intimate connections between productive powers and Academia is encouraged.

2. R & D is to be focused on developing complete (technological packages) rather than fragmented findings.

3. R & D is to be focused on technological packages for the production of pharmaceutical raw mataerials using local starting or intermediate materials or imported ones.

4. Foreign technology acquisition is to be freezed for the material whose Egyptian technological package is reached and is under evaluation and licensed to a productive facility.

5. Productive facilities are encouraged to fund research projects of Academia acording to a pre-defined standard contract.

6. Pilot plants erection to support the development stages of research projects are given a high priority in investment and international co-operation plans.

b. Investment Policy Considerations.

1. Investment in formulation facilities is freezed. It is only justified if acompanied by production of pharmaceutical raw materials.

2. High priority is given for projects for the production of :
   a. Imported pharmaceutical raw materials.
   b. Medical appliances.
   c. Intermediate, medical commodities (eg) X-ray films, catgut, ...etc.
   d. Pharmaceutical production machinary.
   e. Imported pharmaceutical packaging materials.

b. Investment Policy Considerations. (Cont.)...

3. Foreign capital investment participation is generally tolerated, but it is preferable to be less than 50 % in joint-venture projects with a public sector company.

4. It is prefered to allocate part of the project's outputs to foreign markets, to generate the project needs of foreign currancy.

c. Production, Importation and Distribution Policy Considerations.

1. An essential drug list is being prepared and is to be issued officially by the end of 1987 by EDO. Drugs on the list are given priority in provision of their raw materials and will be supplied in sufficient quantities all over the year. Their prices are going to be freezed and supported by subsidation programs.

2. Production, by using 100 % Egyptian technology is encouraged and given priority in registeration and tarification.

3. Production, by using 100 % foreign technolgy, is tolerated in the form of license-Royalty agreements as long as it satisfies the conditions of the standard license agreement contract issued by EDO.
In this contract, royalty is fixed as a maximum of 5 % of the net sales for a maximum period of 5 years.
Contracts must be approved by EDO's B.O.D.

4. Licensed products can be imported in bulk form and repacked locally prior to its production for a limited period (maximum period is one year). This is done to investigate the product market potential and to orient and prepare for the launching of the produced product.

5. Quality assurance programs are highly regarded and supported.

6. Grants and soft short-term loans to fund importation are encouraged.

7. Price-stability agreements for two or more years are encouraged and their products are given priority in importation plans.

8. Stock level of six months for imported products and three months for locally produced products should be maintained at the producers and whole-sale distributers.

c. Production, Importation and Distribution Policy Considerations. (Cont.) ...

9. Private importation is to be kept at a minimum and directed towards the highly therapeutic vital products

10. Increase in public sector distribution outlets at all levels including the retail level.

11. Encourage private sector participation in whole-sale distribution.

12. No C.S.P. policy considerations could be identified.

d. Tarrification Policy Considerations.

1. Tarrification is regarded as the hotest area of the pharmaceutical domain in Egypt. There are not any defined policies. Trends, and tendencies are highly volatile.

2. The prevailing tendency, now, is for a price freeze and profitability deterioration, which is contrary to the prior tendency of 1986 which aimed at price increases to maintain current profitability levels.

3. New drug introductions with good profit margins, are slown down and kept at a minimum. These new introductions were used as a compensation for the old drugs incurring losses.

(IV) FINANACE

A. M.O.H. BUDGETS, HEALTH INSURANCE BUDGETS.

B. ANNUAL GOVERNMENT EXPENDITURE & SUBSIDATION MECHANISMS.

C. PRIVATE EXPENDITURE FOR ALL PHARMACEUTICALS.

D. ANNUAL BUDGET FOR ALL PHARMACEUTICALS & C.S.P. BY PHARMACOLOGICAL GROUP & BY INDIVIDUAL DURG.

(IV) A - M.O.H. BUDGETS & HEALTH INSURANCE BUDGETS.

1. M.O.H. BUDGETS.

- M.O.H. budget amounted to 402.5 million Egyptian pounds in 1985/86 for all its services (L.E. 8.28 per capita).
- This budget constituted 2.5 % of the total national budget.
- 20.3 % of this budget (L.E. 81.68 millions), was allocated to commodities and services, including drugs, medical supplies, maintenance, transportation, ...etc.
- During 1985/86, M.O.H. bought pharmaceuticals and vaccines for 57.4 million Egyptian pounds (i.e.) 14.2 % of M.O.H. budget was spent on pharmaceuticals.
- Table (IV-1) shows the histrorical development of M.O.H. budgets and its allocation to commodities and its expenditure on pharmaceuticals in particular.

TABLE (IV-1) : M.O.H. BUDGETS AND ALLOCATIONS FOR PHARMACEUTICALS.

YEAR	TOTAL M.O.H. BUDGET		ALLOCATIONS TO COMMODITIES & SERVICES		EXPENDITURE ON PHARMACEUTICALS	
	SUM IN MILLION L.E.	% OF TOTAL NATIONAL BUDGET	SUM IN MILLION L.E.	% OF TOTAL M.O.H. BUDGET	SUM IN MILLION L.E.	% OF TOT M.O.H. BUDGET
*(a) 1975	67.7	1.1 %	20.7	31.0 %	8.8	13.0
*(a) 1980	179.4	2.3 %	42.2	23.5 %	23.3	13.0
83/84	333.1	2.5 %	77.9	23.4 %	43.3	13.0
84/85	374.4	2.5 %	78.9	21.1 %	51.0	13.7
85/86	402.5	2.5 %	81.6	20.3 %	57.4	14.3

*(a) = Allocation to pharmaceuticals was subjectively calculated as 13 %.

Sources :

Golden Book, pp.185-186.
Misria Balance Statement for 1985/86, p.7.
VACSERA Sales Statement Report, p.3.

2. HEALTH INSURANCE BUDGETS.

1. In 1985/1986 health insurance services covered 3.388 million benificiaries. Total budget allocated to commodities and salaries amounted to 70.05 million L.E., from which 36.15 million L.E. was allocated to pharmaceuticals, (i.e) 51.6 %.

2. Table (IV-2) shows the historical development of Health Insurance Organization's allocations to pharmaceuticals and to commodities at large and the number of benificiaries.

TABLE (IV-2) : HISTORICAL DEVELOPMENT OF HEALTH INSURANCE ORGANIZATION ALLOCATIONS TO PHARMACEUTICALS.

YEAR	ALLOCATION TO COMMODITIES & SALARIES IN MILLION L.E.	ALLOCATION TO PHARAMCEUTICALS IN MILLION L.E.	NUMBER OF BENIFICIARIES IN THOUSANDS
81/82	33.97	19.47	2720
82/83	41.82	24.83	2950
83/84	50.04	28.00	3073
84/85	61.50	32.77	3225
85/86	70.05	36.16	3388

SOURCE : Health Insurance Organization.

(IV) B ANNUAL GOVERNMENT EXPENDITURE AND SUBSIDIZATION MECHANISMS.

Government expenditure on pharamaceuticals comprises two main kinds :

1. Pharmaceuticals dispensed through different public health units free of charge.
2. Pharamceuticals dispensed and reimbursed through the health insurance system where the beneficiaries share in a minor way in the cost of pharmaceuticals.

In 1985/86 this expenditure amounted to 93.5 million Egyptian pounds. Table (IV-3) shows government expenditure in the last five years.

Subsidization mechanisms for pharmaceuticals are directed to maintain prices of imported drugs and infant milk formulae. This subsidy consists of two kirds :

1. An indirect subsidy suppling the public-sector importation company (Misria) with low-priced foreign currency share which is allocated for the importation of infant milk formulae and insulin.
2. A direct subsidy, which acts as a fund to balance the losses endured by Misria due to low-stable public prices of its imported pharmaceuticals.

Table (IV-4) shows the value of these two kinds of subsidies for the last four years and the expected one of 87/88.

(IV) C - PRIVATE EXPENDITURE FOR ALL PHARMACEUTICALS.

Private expenditure amounted to 688 million Egyptian pounds in 1985/86, scoring an annual increase of 9.5 % than the year before.

Table (IV-5) shows the histrorical development of private expenditure over the last five years. Annual rate of increase ranged from 9.5 % to 36 %.

TABLE (IV-3) : GOVERNMENT EXPENDITURE IN THE YEARS 1981-1986.
(in L.E. Million)

YEAR	GOVERNMENT TOTAL EXPENDITURE
1981/82	25.7
1982/83	45.8
1983/84	69.3
1984/85	83.6
1985/86	93.5

SOURCES :
1. Egyptian Drug Organization, Annual Financial Report 1985,86.
2. Golden Book.
3. Health Insurance Organization.

TABLE (IV-4) : SUBSIDIES FOR PHARMACEUTICALS IN 1983-1988.
(in L.E. Million & $ Million)

YEAR	LOW-PRICED FOREGIN CURRENCY (VALUE IN $)	DIRECT SUBSIDY FUND (VALUE IN L.E.)
1983/84	30.0	6.0
1984/85	35.0	20.8
1985/86	40.0	21.0
1986/87	45.0	15.0
1987/88 (Expected)	45.0	15.0

SOURCE : Misria Budgets and Balance Sheets.

TABLE (IV-5) : PRIVATE EXPENDITURE FOR PHARMACEUTICALS BY THE CURRENT PUBLIC PRICE. (in L.E. Million).

YEAR	PRIVATE EXPENDITURE (IN L.E. MILLION)	RATE OF INCREASE
1981/82	394.2	36.0 %
1982/83	474.9	20.5 %
1983/84	534.0	12.4 %
1984/85	628.0	17.6 %
1985/86	688.0	9.5 %

SOURCE : Drugs of Egypt, p.197.
Private Imports Plan Report

(IV) D - ANNUAL BUDGET OF ALL PHARMACEUTICALS AND C.S.P.'S.

1. Annual Budget of all pharmaceuticals by pharmacological group.

Total annual budget for all pharmaceuticals amounted to L.E. 853 millions in 1986/87.

Table (IV-6) shows the annual budget broken down by pharmacological groups.

It can be seen that the antibiotics group constitutes 17 % of the total budget followed by analgesics and antirheumatics group which constitute 10.7 %, pulmonics group (6.8 %), combined vitamins group (6.1 %) and endocrinics (6.0 %) of the total budget.

Table (IV-7) shows historical development of annual budgets of all pharmaceuticals in the last fiv years.

2. Annual budget of C.S.P.'S By Pharmacological Group and Individual Drug.

The annual budget for C.S.P. in 1986/87 amounted to L.E. 155.6 millions. Table (IV-8) shows the budget broken down by pharmacological subgroups (26 subgroup).
Annex (IV-1) shows the budget broken down by individual drug.

TABLE (IV-6) : TOTAL ANNUAL BUDGET FOR ALL PHARMACEUTICALS BROKEN DOWN BY PHARMACOLOGICAL GROUP IN 1986/87.

(IN MILLION L.E.)

SER.	CODE	PHARMACOLOGICAL GROUP	TOTAL ANNUAL BUDGET	PERCENTAGE
1	01	ANAESTTHETICS.	2.0	0.23 %
2	02	ANALGESICS, ANTIRHUEMATICS & ANTIPPURETICS.	91.8	10.76 %
3	03	ANALEPTICS.	3.7	0.43 %
4	04	ANTHELMENTICS.	9.6	1.12 %
5	05	ANTIAMAEPICS & ENTEROSTATICS.	20.0	2.34 %
6	06	ANTIBIOTICS.	146.1	17.12 %
7	07	ANTIMALARIALS.	1.3	0.15 %
8	08	ANTICOAGULENTS.	1.4	0.16 %
9	10	ANTIHISTAMINICS.	14.8	1.73 %
10	11	CARDIACS & VASCULARETICS.	32.1	3.76 %
11	12	CATHARETICS.	5.9	0.69 %
12	13	CHEMOBIOTICS.	13.1	1.53 %
13	14	ANTITUBERCULOUS & ANTILEPROTICS.	2.5	0.29 %
14	16	SULPHONAMIDES & TRIMETHOPRIMS.	1.6	0.19 %
15	19	CYTOTOXICS.	2.3	0.27 %
16	20	DERMATOLOGICS.	44.7	5.24 %
17	21	ANORECTALS.	2.9	0.34 %
18	22	DIAGNOSTICS.	0.8	0.09 %
19	23	ENDOCRINICS.	51.2	6.0 %
20	24	GASTROINTESTINALS.	30.0	3.52 %
21	25	HEPATOBILINOGENICS.	7.6	0.89 %
22	26	HAEMOSTATICS.	2.7	0.32 %
23	27	IMMUNOLOGICALS.	4.8	0.56 %
24	28	MESCILLINEOUS.	9.5	1.11 %
25	29	OPHTHALMICS.	48.7	5.71 %

SOURCE : Annual Budget File, Planning Sector EDO.

TABLE (IV-6) : TOTAL ANNUAL BUDGET FOR ALL PHARMACEUTICALS BROKEN DOWN BY PHARMACEUTICAL GROUP.

(in Million L.E.)

(Cont.) ...

SER.	CODE	PHARMACOLOGICAL GROUP	ANNUAL TOTAL BUDGET	PERCENTAGE
26	30	ORODENTALS.	3.9	0.46 %
27	31	OTO-RHINO-LARYNGETICS.	16.2	1.99 %
28	32	OXYTOXICS.	1.8	0.21 %
29	33	PULMONICS.	58.5	6.85 %
30	34	SINGLE VITAMINS.	11.5	1.35 %
31	35	COMBINED VITAMINS.	52.5	6.15 %
32	36	MINERALS.	4.6	0.54 %
33	37	VITAMINS & MINERALS.	23.9	2.8 %
34	38	LIPOTROPICS.	4.3	0.5 %
35	39	PROTEINS.	0.4	0.04 %
36	41	RESTORATIVES.	10.4	1.21 %
37	42	SEDATIVES & HYPNOTICS.	5.0	0.59 %
38	43	TRANQUILIZERS & S.K.M. RELAXANTS	29.7	3.48 %
39	44	SPASMOLYTICS.	27.1	3.17 %
40	45	UROLOGICS.	22.9	2.68 %
41	46	VAGINETICS.	4.5	0.53 %
42	47	MILK.	24.7	2.89 %
		T O T A L	853.0	100.0 %

SOURCE : Annual Budget File, Planning Sector, EDO.

TABLE (IV-7) : HISTORICAL DEVELOPMENT OF TOTAL ANNUAL BUDGETS IN LAST FIVE YEARS. (in Million L.E.).

YEAR	TOTAL ANNUAL BUDGET FOR ALL PHARMACEUTICALS
1982/83	480
1983/84	572
1984/85	650
1985/86	745
1986/87	853

SOURCE : Annual Budget Files, Planning Sector, EDO.

TABLE (IV-8) : ANNUAL BUDGET FOR C.S.P.'s BROKEN DOWN BY PHARMACOLOGICA SUBGROUPS FOR THE YEAR 1986/87. (in L.E. Million).

SER.	CODE	PHARAMCOLGICAL SUBGROUP	ANNUAL BUDGET	PRODUCT NO.
01	0200	ANALEGESICS & ANTIPYRETICS.	3.497	9
02	0502	ANTIMOTILITY ANTIDIARRHEALS.	0.433	2
03	0505	ANTIAMAEBICS.	1.740	1
04	0508	ANTIEMETICS.	3.408	8
05	0509	ANTIDIARRHEALS.	9.698	15
06	0600	ANTIBIOTICS.	61.136	78
07	0700	ANTIMALARIALS.	0.308	3
08	1000	ANTIHISTAMINICS.	3.399	7
09	1300	CHEMOBIOTICS.	1.788	2
10	1400	ANTITUBERCULOSIS.	1.659	4
11	1600	SULPHONAMIDES & TRIMETHOPRIMS.	3.639	6
12	2310	CORTICOSTERIODS.	13.406	15
13	2320	CONTRACEPTIVES / ORAL.	2.885	5
14	2701	VACCINES.	4.000	7
15	2702	ANTISERA.	1.000	3
16	2703	GAMMA GLOBULINS.	0.500	2
17	2800	MESCILLINEOUS.	0.010	1
18	3301	EXPECTORANTS.	13.927	12
19	3302	COUGH-SEDATIVES.	3.483	7
20	3303	BRONCHODIALATORS.	4.764	11
21	3500	MULTIVITAMINS.	8.028	12
22	4100	RESTORATIVES / PARENTRAL.	8.28	17
23	4106	RESTORATIVES / ORAL.	----	3
24	4200	SEDATIVES & HYPNOTICS.	1.924	4
25	4400	SPASMOLYTICS.	3.018	5
26	4700	LACTOSE-FREE INFANT MILK.	1.525	3
		T O T A L	157.855	242

N.B. There are no available information about budget figures for local contraceptives (5 products).

ANNEX (IV - 1)

ANNUAL BUDGET FOR C.S.P. IN 1986/1987

BROKEN DOWN BY INDIVIDUAL DRUG.

SERIAL	COM.CODE	TRADE NAME	PACK	VALUE
1	003211	HYDROCORTISONE I.V 100ML	1AMP+VL	1296000.
2	012501	BABYPHINOL	BT 20 ML	252000.
3	023088	SOLUDACORTEN 250MG	BX1 AMP	85800.
4	023089	SOLU DACORTIN 25 MG	BX 3 AMP	48000.
5	023131	FORTICORTIN " MG	AMP 100	95000.
6	050289	SODIUM-BICARBONATE 8.4%	BX 1VL 500C	16000.
7	053000	DEPO-MEDROL 40MG/ML	BX DISP.VL2ML	669600.
8	267068	CELESTONE CHRONODASE	1 VIAL	90000.
9	267076	DIPROFOS INJ 2CC	BX 1 AMP	312000.
10	267077	NETSOMYCIN 150 MG 1.5ML	BX 1 AMP	552000.
11	267078	NETROMYCIN 50 MG 2ML	BX 1 AMP	102000.
12	338003	SIMILAC ISOMIL	TN 454 GM	1000000.
13	344018	BEBILAC FREE LACTOSE	TN 400 GM	175000.
14	349502	RHINOPRONT	BT 30 ML	220000
15	364006	DEXAMETHASONE	BX. 100 AMP.	195000.
16	376006	PROCEBEE	BX 400 CC	750000.
17	417520	IMODIUM SYRUP	BX 30 ML	145000.
18	455009	HUMAN ALBUMIN 20% 50ML	BX 1VIAL	500000.
19	465002	GAMMA GLOBULIN 16.5%	VL 2 ML	130000.
20	501037	ALLERGYL SYP	SYP 120 ML.	270000.
21	501181	ENTROQUINE COMP SUSP.	SUSP 100ML	1500000.
22	501191	EXPECTYL SYP	SYP 120ML	1320000.
23	501285	MEDIVIT SYP	SYP 100ML	1200000.
24	501351	PHARMALGIN DROPS	DROPS 15ML	1800000.
25	501358	PHENADONE SYP	SYP 100ML	1080000.
26	501413	RIVO SUPP	SUPP 5	233500.
27	501430	SOLVIN SYP	SYP 60 CC	675000.
28	501453	SOLVIN DROPS	DROPS 15 ML	150000.
29	502103	DASRINOL TAB	TAB 1000 ST	500000.
30	502112	FLAVYL SUSP	SUSP 120 ML	1740000.

SERIAL	COM.CODE	TRADE NAME	PACK	VALUE
31	502168	LARGACTIL DROPS	DROP 30 ML	30000.
32	502269	PECTOKAL SUSP	SUSP 100 ML	225000.
33	502271	PHENERGAN SYP	SYP 120 ML	260000.
34	502274	PECTOKAL N SUSP	SUSP 100 ML	468000.
35	502308	SALBOVENT SYP	SYP 120 ML	450000.
36	502329	SUPRISTOL SUSP.	SYP 60 ML	114000.
37	502336	SEPTAZOLE SUSP	SUSP 100 ML	1650000.
38	502381	VICIPEX SYP	SYP 120 ML	220000.
39	502385	VEGASKINE INFANTILE SUPP	SUPP 5	900000.
40	503008	ALUPENT 1 ML IM AMP	AMP 6	4000.
41	503012	AMOXYCID 125 MG	SYP 60 ML	420000.
42	503020	AMOXYCID 250 MG SUSP	SUSP 60 GM.	405000.
43	503078	BISOLVON SOLUTION 4 MG/2ML	SOL 40 ML	246000.
44	503079	BISOLVON ELIXIR 4 MG/5 ML	ELIX. 115 ML	1710000.
45	503085	BRICANYL SYP	SYP 120 ML	372000.
46	503101	CID WATER SOL	SOL 120 ML	252000.
47	503119	CIDOCETINE 125 MG SUPP	SUPP 6	11000.
48	503123	CIDOCETINE SUSP	SUSP 60 ML	600000.
49	503124	CIDOCETINE BISMUTH SUPP	SUPP 4	468000.
50	503125	CIDOCETINE S SUSP	SUSP 60 ML	240000.
51	503138	CIDOQUINE 250 MG TAB	TAB 20	7200.
52	503147	COLDAL SYP	SYP 120 ML	528000.
53	503174	DEXASCHEROSON 5 MG IM AMP	AMP 1	600000.
54	503186	DIPHNACID SUSP	SUSP 60 ML.	360000.
55	503195	ERYTHROCID SUSP	SUSP.60 ML.	360000.
56	503205	ENTOCID COMPOUND POWDER	POWD 15 EAC	768000.
57	503262	FRUITAL SYP	SYP 120 ML	1560000.
58	503334	ISOCID 50 MG TAB.	TAB 100	12000.
59	503415	MICROVLAR TAB	TAB 21 ST	840000.
60	503421	NEOCOLDAL SYP	SYP 120 ML	576000.

SERIAL	COM.CODE	TRADE NAME	PACK	VALUE
61	503448	NOVACID DROPS	DROPS 10 ML	70000.
62	503453	NOVACID INF SUPP	SUPP 6	96000.
63	503474	PALITREX 100 MG DROPS	DROPS 10 ML	135000.
64	503475	PALITREX 125 MG SYP	SYP 60 ML	360000.
65	503476	PALITREX 250 MG SYP	SYP 60 ML	693000.
66	503515	PENTREXYL 125 MG SUSP	SUSP 60 ML	720000.
67	503519	PENICILLIN G SOD 1000000 U VIAL	VIAL 1	1500000.
68	503521	PENICILLIN PROCAINE 400000 U	VIAL 1	48000.
69	503530	PENTREXYL 250 MG SUSP	SUSP 60 ML	1620000.
70	503531	PENTREXYL DROPS	DROPS 10 ML	270000.
71	503535	PLEMAZOL SYP	SYP 120 ML.	360000.
72	503537	PLEMAZOL DROPS	DROPS 20 ML	360000.
73	503587	PROMACID DROPS	DROPS 15 ML	50400.
74	503640	TRIOVLAR TAB	TAB 21	720000.
75	503662	STREPTOCETINE SUSP	SUSP 60 GM	720000.
76	503663	STREPTOMYCIN SULPHATE 1 GM VIAL	VIAL 1	400000.
77	503995	MOALGAT EL GAFAF	1 PACK	0.
78	503996	MOALGAT EL GAFAF	10 PACK	0.
79	503997	REHYDRAN	10 PACK	0.
80	503998	PRINOVLAR	TAB 21	225000.
81	503999	ANOVLAR-1	TAB 21	225000.
82	504036	DEXTROSE 5 % 500 ML AMP	PACK 1	1900000.
83	504038	DEXTROSE 10% SOLUTION	PACK 1	500000.
84	504041	DEXTROSE IN NORMAL SALINE	SOL 500 ML	432000.
85	504096	RINGER LACTATED SOLUTION	SOL 500ML	90000.
86	504100	NORMAL SALINE 500 ML AMP	AMP 1	1710000.
87	504141	SEPACK DEXTROSE 5% BAG.	BAG 32	2700.
88	504143	SEPACK DEXTROSE IN NORMAL SALINE	BAG 32	1000.
89	504146	SEPACK N. SALINE 500 ML BAG.	BAG 32	900.
90	504152	SULPHAGUANIDINE 500 MG TAB	TAB 200 ST	150000

SERIAL	COM.CODE	TRADE NAME	PACK	VALUE
91	505053	AMPICILLIN 125 MG SUSP	SUSP 60 ML	732000.
92	505054	AMPICILLIN FORT 250 MG DRY SUSP	SUSP 60 ML	1554000.
93	505131	CAMOQUIN TAB	TAB 100	1275.
94	505148	CHLORAL SYRUP	SYP 120 ML	32400.
95	505164	CLOXAPEN 250 MG DRY SUSP	SUSP 60 ML	300000.
96	505168	CORTIGEN B6 PEDIATRIC AMP	AMP 3	864000.
97	505212	DEXTROSE 5% SOLUTION	SOL 500 ML	1682000.
98	505236	DEXTROSE 5% IN NORM SALINE SOL	SOL 500 ML	290000.
99	505302	ECAFLEX C SYRUP	SYP 120 ML	198000.
100	505323	ENTEROGUANIL SUSP	SUSP 60 ML	210000.
101	505343	ENTRIM SUSP	SUSP 100 ML	288000.
102	505383	PERCURAL N SUSP	SUSP 60	120000.
103	505405	GRIEPO SUPP	SUPP 6	288000.
104	505468	ISILIN SYRUP	SYP 120 ML	720000.
105	505485	FLEROCORTID 100 MG AMP	AMP 1	45000.
106	505611	NORDETTE TAB	TAB 21X5 ST	875000.
107	505614	NEOCEF 250 MG DRY SYP	BOTT 60 GM	508200.
108	505640	NORMAL SALINE SOLUTION	SOL 500 ML	870000.
109	505666	OSFEN 400 MG SYP	SYP 60 ML	192000.
110	505686	ASMASONE DROPS	DROPS 10 ML	561000.
111	505709	PENICILLIN PROCAINE VIAL	VIAL 1	420000.
112	505812	RINGER.S LACTATED SOLUTION	SOL 500 ML	164000.
113	505837	SODIUM BICARBONATE 5%	SOL 500 ML	464000.
114	505876	STREPTOMYCIN VIAL	VIAL 1	630000.
115	505890	SULFAGUANIDINE	TAB 10	15000.
116	505952	VERACETIN SUSP	SUSP 60 ML	300000.
117	506010	AVIL SYP	SYP 100 ML	425000.
118	506011	BARALGIN INFANT SUPP	SUPP 5	39000.
119	506013	AVIFECT SYP 100 ML	SYP 100 ML	950000.
120	506017	AMPLOSIN 500 /ML SYP	SYP 60 ML	715000

SERIAL	COM.CODE	TRADE NAME	PACK	VALUE
121	506168	NOVALGIN INFANT SUPP	SUPP 5	720000.
122	507460	SPASMOPYRALGIN M INF SUPP	SUPP 5	168000.
123	507502	ERYTHROCIN GRAN 200MG/5ML	SUSP 60 ML	2970000.
124	507504	PENSTAF DRY MIX 62.5%	SUSP 60 ML	650.
125	507511	BROMOSYRUP	SYP 125 ML	462000.
126	507512	BRONCHISTAL SYP	SYP 120 ML	2200000.
127	507522	GARIOZOL SUSP	SUSP 120 ML	288000.
128	507524	SEDALINE SYP	SYP 125 ML	600000.
129	507525	PERIACTIN SYP	SYP 114 ML	487500.
130	507542	CHEMOTRIM SUSP	SUSP 100 ML	342000.
131	507549	LOMOTIL SYP	SYP 60 ML	288000.
132	507558	DICLOPEN DRY SYP	SYP 60 ML	456000.
133	507561	KEFLEX DRY SYP 250 MG	SYP 60 ML	1728000.
134	507562	KEFLEX DRY SYP 125 MG	SYP 60 ML	1200000.
135	507564	KEFLEX DRY DROPS 100 MG	DROPS 10 ML	63000.
136	507566	VI-DAYLIN SYP.	SYP 90 ML	540000.
137	507568	WALIRINE SYP	SYP 125 ML	840000.
138	507586	PIPTAL PED DROPS	DROPS 15 ML	214000.
139	507589	TUSSILAR DROPS	DROPS 15 ML	132000.
140	507591	NEOTOTAVINE DROPS	DROPS 15 ML	216000.
141	508007	SFANOL 2ML IN AMP	AMP 6	17500.
142	508072	GARAMYCIN 20 MG AMP	AMP 6	1920000.
143	508087	DEXTROSE 25% 20ML IM AMP	AMP 5X5	300000.
144	508541	DIAMYCIN DRY SUSP	SUSP 100ML	525000.
145	508559	NEOMYCIN DRY SUSP	SUSP 60ML	65000.
146	508609	BRONCHOLASE SYP	SYP 120 ML	250000.
147	508615	PIRAFENE 2 MG /5 ML SYP	SYP 120 ML	40500.
148	508618	PRIMPERAN SYP.	SYP 120 ML	1280000.
149	508619	DOLTRAMINE EXPECT SYP.	SYP 120 ML	950000.
150	508637	SUTTON SUSP	SUSP 100 ML	1050000.

SERIAL	COM.CODE	TRADE NAME	PACK	VALUE
151	508641	VAROLEX SYP	SYP 120 ML	540000.
152	508657	LYNAEROM SYRUP	BT 120 ML	510000.
153	508664	MEMCOCETIN SUSP	SUSP 60ML	100000.
154	508697	MULTIVAROL DROPS	DROPS 15 ML	50000.
155	508704	PRIMPERAN DROPS	DROPS 30 ML	280000.
156	508799	LYNAEROM SUPP	SUPP 10	156000.
157	509327	NEURAZINE DROPS	DROPS 10 ML	180000.
158	509329	ETHAMIVAN DROPS	DROPS 10ML	10300.
159	509330	PIMAFUCIN SUSP	SUSP 5 ML	58000.
160	509331	ERYTHRIN DROP	DROPS 30 ML	200000.
161	509333	FLEMOXIN DROPS	DROPS 15 ML	292500.
162	509334	POLYVIT DROPS	DROPS 10 ML	180000.
163	509337	SPASMOTAL DROPS	DROPS 10 ML	450000.
164	509391	INHIBEX TAB	TAB 60	37500.
165	509805	PECO C SYRUP	SYP 125 ML.	390000.
166	509817	FUDIZOL SUSP	SUSP 100 ML	312000.
167	509821	PROMANTINE SYRUP	SYP 125 ML.	81000.
168	509835	K CHLOR SOLUTION	SOL 100 ML	60000.
169	509843	SEDAMOL SUPP	SUPP 5	150000.
170	509847	PYRAPHOL INFANTILE SUPP	SUPP 6	70000.
171	509850	PARAMOL 125MG SUPP.	SUPP 5	135000.
172	509854	EUCAPHOL INF. SUPP	SUPP 6	91000.
173	509860	AMPICILLIN 250MG VIAL	VIAL 1	500000.
174	509884	STREPTOMYCIN 1 GM VIAL	VIAL 1	300000.
175	509885	DIACILLIN INJECTION	VIAL 1	150000.
176	509886	PENCILLIN G 1000000 U VIAL	VIAL 1	450000.
177	509908	AMPIPEN 250 MG VIAL	VIAL 1	225000.
178	509925	DISMOPHENICOL SUPP	SUPP 3	1320000.
179	509926	MIPHENICOL 125 MG SUPP	SUPP 6	67500.
180	509928	DICYCLIN 125 MG SUSP	SUSP 40 ML	27500.

SERIAL	COM.CODE	TRADE NAME	PACK	VALUE
181	509931	FLIMOXIN SUSP.125MG	SUSP 60 ML	175000.
182	509932	FLIMOXIN 250 MG SUSP	SUSP 60ML	337500.
183	509934	LIDAPRIM SUSP	SUSP 60 ML	195000.
184	509935	MIPHENICOL 125 MG SUSP	SUSP 60 ML	600000.
185	509936	STREPTOPHENICOL SUSP	SUSP 60 ML	1920000.
186	509937	AMPICILLIN 125 MG SYP	SYP 60 ML	600000.
187	509938	AMFIPEN 125 MG SYP	SYP 60 ML	180000.
188	509939	AMFIPEN 250 MG SYP	SYP 60 ML	1200000.
189	509940	AMPICILLIN 250MG SYP	SYP 60 ML	2000000.
190	509942	ERYTHRINE 200 MG SUSP	SUSP 60 ML	800000.
191	509945	MOXIPEN 125 MG SYP	SYP 60ML	350000.
192	509946	MOXIPEN 250MG SYP	SYP 60ML	562500.
193	509[illegible]	DIAKAN SUSP	SUSP 60 ML	920000.
194	510033	DIAPEC S SUSP	SUSP 120 ML	2250000.
195	510074	OSINEX SYRUP	SYRUP 120 ML.	2062500.
196	510107	SIGMAMYCIN 125 MG-ML SYP	SYP 90 ML	480000.
197	510131	TERRAMYCIN 125MG	SYP 60 ML	280000.
198	510173	VIBRAMYCIN SYP	SYP 30ML	186000.
199	511056	TAVEGYL 100 ML SYP	SYP 100ML	1837500.
200	511391	SPASMO CIBALGIN CH	SUPP 5 ST	2145000.
201	511408	RIMACTAZID C.T	TAB 80 ST	560700.
202	511413	RIMACTAN SYP	SYP 50 ML	1113000.
203	511660	RIMACTAZID C.T	TAB 8 ST	1050000.
204	511671	TRIAMINIC SYRUP	SYRUP 100ML.	1260000.
205	511673	TRIAMINIC DROPS	DROPS 15 ML.	420000.
206	511763	ZADITEN PEDIATRIC SYP	SYP 100 ML	768500.
207	512023	DEXACILLIN 125 MG SUSP	SUSP 60 ML	992[illegible]00.
208	512024	DEXACILLIN 250 MG SUSP	SUSP 60 ML	3078000.
209	512025	DEXACILLIN 10 ML DROPS	DROPS 10 ML	540000.
210	512052	KENACORT-A-I.M 40 MG VIAL	VIAL 1 ML	4578000

SERIAL	COM.CODE	TRADE NAME	PACK	VALUE
211	512071	MYCOSTATIN ORAL SUSP.	12 DOSE	2140200.
212	512101	THERAGRAN LIQ	LIQ 90ML	2250000.
213	512123	VELOSEF 125 MG SUSP	SUSP 60 ML	1260000.
214	512124	VELOSEF 250 MG SUSP	SUSP 60 ML	3420000.
215	512125	VELOSEF 250 MG VAIL	VAIL 1 ML	624000.
216	513001	DIPHTHERIA ANTITOXIN 4000U	1 AMP	0.
217	513002	DIPHTHERIA ANTITOXIN 20000U	1 AMP	0.
218	513003	GAMMA GLOBULIN 16%	1 AMP	5.504000
219	513004	TETANUS ANTITOXIN 1500U	5 AMP	0.
220	513005	TETANUS ANTITOXIN 30000U	5 AMP	0.
221	513006	B.C.G VACCINE	20 DOSE	0.
222	513007	DIPHTHERIA TOXOID	1 AMP	0.
223	513008	DIPHTHERIA & TETANUS VACCINE	1 AMP	0.
224	513009	DIPHTHERIA & TETANUS VACCINE	1 VIAL	0.
225	513010	TRIPLE VACCINE	3 AMP	0.
226	513011	MEASLES VACCINE	1 AMP	0.
227	513012	TETANUS TOXOID	1 AMP	0.
228	513013	TETANUS TOXOID	1 VIAL	0.
229	513014	POLIOMYELITIS VACCINE	20 DOSE	0.
230	515056	BECOZYM SYP	SYP 125 ML	900000.
231	515140	CODELCORTON T.B.A. VIAL	VIALS 3	202500.
232	515194	DECADRON VIAL	VIAL I	1350000.
233	515244	EPICOCILLIN 250MG DRY MIX	SYP 60 ML	1500000.
234	515246	EPICOCILLIN 125 MG DRY MIX	SYP 60 ML	750000.
235	515322	FLUMOX DRY MIX	SYP 60 ML	1920000.
236	515390	KAPECT SUSP	SUSP 120 ML	612000.
237	515392	KAPECT CO SUSP	SUSP 120 ML	1200000.
238	515670	SOLU-CORTEF 100 MG	VIAL 1	1462500.
239	516103	AMPICYN 125 MG DRY SYRUP	SYP 60 ML	600000.
240	516104	AMPICYN 250 MG DRY SYRUP	SYP 60 ML	1687500.

SERIAL	COM.CODE	TRADE NAME	PACK	VALUE
241	516145	AQUA BABY SYRUP	SYP 125 ML	800000.
242	516304	IBIAMOX 125 MG DRY SYRUP	SYP 60 ML	1350000.
243	516305	IBIAMOX 250 MG DRY SYRUP	SYP 60 ML	2762500.
244	516325	IBILEX 125 MG. DRY SYRUP.	SYP 60 ML	513000.
245	516326	IBILEX 250 MG DRY SYRUP	SYP 60 ML	1728000.
			TOTAL	157.855.02

(V) EPIDEMIOLOGIC NEED FOR C.S.P.'S

A. Population and vital statistics.

B. Current morbidity patterns.

C. Needs for C.S.P.'s.

(V) A - POPULATION AND VITAL STATISTICS

1. Population.

- Total population of Egypt amounted to 50.45 millions in 1986. Annual rate of growth is 2.9 %, which is the difference between a birth rate of 3.84 % and a death rate of 0.94 %.
- Population distribution by age group shows that age group (0 to 6) years constitute almost 19.2 % of the whole population, amounting to 9.68 millions. The Egyptian population is considered to be a young population as 59.3 % is under the age of 25 years (1986).
  Table (V-1) shows age distribution of the Egyptian population in 1986.
  Table (V-2 shows the net increase rate in the last six years.
- Geographical distribution of age group (0 to 6) years shows that 43.9 % are living in rural areas
  56.1 % are living in urban areas
  9.8 % are living in Cairo & Alexandria
- Women in the age of child bearing in Egypt amounted to 7.582 millions in 1986.

2. Vital Statistics.

- Total death rate in 1986 amounted to 0.94 %, while the death rate of the newly born was 1.21 %,
  the death rate of infants (from 0 to 1 years) = 4.41 %
  the death rate of children (from 1 to 5 years) = 0.56 %
  Table (V-3) shows these rates in the last 6 years.
- Diseases of early childhood was the fourth cause of death in Egypt (in 1979) amounting to 4.25 % of total deaths in the same year.
  Table (V-4) shows the causes of death in Egypt in 1979.
- In 1980, diseases of the digestive system and diseases of the respiratory system were the first two causes of death among infants under the age of one year, amounting to nearly 51 % and 26 % of total deaths of this age respectively. These two causes were also the first two causes of deaths among children (from 1 to 5 years), amounting nearly to 48.6 % and 35.9 % of total deaths of this age group respectively.
  Table (V-5) shows the causes of death in the age group (0 - 1) years in 1980 while table (V-6) shows the causes of death in the age group (1 - 5) years in 1980.
  Table (V-7) shows causes of death due to diseases relevent to the study ;in the age groups (0-1) years and (1-5) years.

TABLE (V - 1) : AGE DISTRIBUTION OF THE EGYPTIAN POPULATION (1986)

AGE GROUP	NUMBER IN MILLIONS	PERCENTAGE
< 6	9.686	19.2 %
6 to 13	7.517	14.9 %
13 to 64	31.784	63.0 %
> 64	1.463	2.9 %
TOTAL POPULATION	50.450	100.0 %

SOURCE : 1st results of 1986 census, April 1986,
Central Authority for Mobilization & Statistics

TABLE (V-2) : NET RATE OF INCREASE OF THE EGYPTIAN POPULATION (1981 - 1986)

YEAR	BIRTH RATE %	DEATH RATE %	NET RATE OF INCREASE %
1981	3.7	1.02	2.68
1982	3.73	1.04	2.69
1983	3.76	1.00	2.76
84-86	3.84	0.94	2.9

SOURCE : 1st results of 1986 census, APRIL 1986,
Central Authority for Mobilization & Statistics.

TABLE (V-3) : DEATH RATES

YEAR	DEATH RATE OF NEWLY BORN	DEATH RATE OF INFANTS (0 TO 1 YEARS)	DEATH RATE OF CHILDREN (1 TO>5 YEARS)
1981	1.22	7.00	1.03
1982	1.49	7.00	1.22
1983	1.29	6.57	0.88
1984	1.20	6.12	0.91
1985	1.51	5.57	0.76
1986	1.21	4.41	0.56

SOURCES :1) 81,82 Central Authority for Mobilization and Statistics.
2) 1st results, Health Governerates, Ministry of Health, Documentation Center.

TABLE (V-4) : CAUSES OF DEATH IN EGYPT (1979)

CAUSE OF DEATH	% : TOTAL DEATHS		
	MALE	FEMALE	TOTAL
1. DIGESTIVE SYSTEM DISEASES.	25.6	27.8	26.70
2. CIRCULATORY SYSTEM DISEASES.	19.1	18.0	18.55
3. RESPIRATORY SYSTEM DISEASES.	16.6	16.7	16.65
4. DISEASES OF EARLY CHILDHOOD.	4.3	4.2	4.25
5. ACCIDENTS, POISONING.	5.5	2.9	4.20
6. OTHER CAUSES.	28.9	30.4	29.65

SOURCE : Birth/Death Year Book, Central Authority for Mobilization and Statistics, 1979.

TABLE (V-5) : CAUSES OF DEATH IN EGYPT FOR THE AGE GROUP (0 TO 1) YEARS (1980)

CAUSES OF DEATH	NUMBER	PERCENTAGE
1. DISEASES OF THE DIGESTIVE SYSTEM.	60739	50.92 %
2. DISEASES OF THE RESPIRATORY SYSTEM.	31033	26.02 %
3. BIRTH TRAUMA & OTHER CONDITIONS ORIGINATING IN THE PERINTAL PERIOD.	13090	10.97 %
4. INFECTIONS & PARASETIC DISEASES.	4676	3.91 %
5. CONGENITAL ANOMALITIES.	3356	2.82 %
6. DISEASES OF THE CIRCULATORY SYSTEM.	2616	2.19 %
7. ILL DEFINED REASONS.	1108	0.93 %
8. DISEASES OF THE NERVOUS SYSTEM & SENSORY ORGANS.	970	0.81 %
9. NUTRITIONAL DEFFICIENCES & ANAEMIAS	637	0.54 %
10. ACCIDENTS & ADVERSE EFFECTS.	249	0.21 %
11. OTHER CAUSES.	816	0.68 %
ALL CAUSES	119290	100.00 %

SOURCE : World Health Statistics, Annual Report, 1986

TABLE (V-6) : CAUSES OF DEATH IN EGYPT FOR THE AGE GROUP (1 TO>5) YEARS (1980)

CAUSES OF DEATH	NUMBER	PERCENTAGE
1. DISEASES OF THE DIGESTIVE SYSTEM.	25498	48.63 %
2. DISEASES OF THE RESPIRATORY SYSTEM.	18803	35.86 %
3. ILL DEFINED REASONS.	1547	2.95 %
4. DISEASES OF THE CIRCULATORY SYSTEM.	3925	7.49 %
5. ACCIDENTS & ADVERSE EFFECTS.	620	1.18 %
6. INFECTIONS & PARASETIC DISEASES.	563	1.07 %
7. DISEASES OF THE NERVOUS SYSTEM & SENSORY ORGANS.	423	0.81 %
8. NUTRITIONAL DEFFICIENCES & ANAEMIAS	273	0.52 %
9. DISEASES OF GENITOURINARY SYSTEM.	238	0.45 %
10. CONGENITAL ANOMALITIES.	227	0.43 %
11. OTHER CAUSES.	320	0.61 %
ALL CAUSES	52437	100.00 %

SOURCE : World Health Statistics, Annual Report, 1986

TABLE (V-7) : CAUSES OF DEATH DUE TO DISEASES RELEVENT TO THE STUDY IN THE AGE GROUPS (0 TO 1) YEARS AND (1 TO>5) YEARS.

CAUSE OF DEATH	AGE GROUP (0 TO 1) YEARS		AGE GROUP (1 TO>5) YEARS	
	NUMBER	%	NUMBER	%
1. T.B. - RESPIRATORY.	14	0.01 %	21	0.04 %
2. T.B. - OTHER.	23	0.02 %	22	0.04 %
3. WOUPING COUGH.	9	0.007 %	5	0.01 %
4. TETANUS.	1706	1.43 %	86	0.16 %
5. MEASLES.	55	0.046 %	74	0.14 %
6. MALARIA.	0	0.00 %	0	0.00 %
7. ACUTE UPPER RESPIRATORY INFECTIONS.	170	0.14 %	90	0.17 %
8. ACUTE BRONCHITIS & BRONCHOLITIS.	15516	13.00 %	9442	18.00 %
9. PNEUMONIA.	7295	6.11 %	5308	10.10 %
10. CHRONIC BRONCHITIS, UNSPECIFIED EMPHYSEMA AND ASTHMA.	7680	6.43 %	3796	7.24 %
11. ALL CAUSES.	119290	100.00 %	52437	100.00 %

SOURCE : World Health Statistics, Annual Report, 1986.

(V) B - CURRENT MORBIDITY PATTERNS

From the rather modest available information of morbidity rates of diseases in Egypt, the following facts could be identified :-

Morbidity rates of communicable diseases specially those which should be reported to authorities can be found in different official health reports, with analytical information as to age and sex distributions.

The study drew on the expertise of Egyptian clinicians and preventive medicine experts as an alternative source of information for morbidity rates of A.R.I. diseases (2 infections per year) for the age group (0-6) years.

Table (V-B) shows the absolute number of cases and morbidity rates of the relevant diseases in the age group (0-6) years in 1984 and 1985.

TABLE (V-8) : ABSOLUTE NUMBER OF CASES & MORBIDITY RATES OF RELEVENT DISEASES IN THE AGE GROUP (0 TO 6) YEARS IN 1984 & 1985.

DISEASES	1984		1985	
	NUMBER OF CASES	MORBIDITY RATE 100.000	NUMBER OF CASES	MORBIDITY RATE 100
1. DIPHTHERIA.	581	6.4	457	4.9
2. POLIO.	346	3.8	103	1.1
3. MEASLES.	3663	40.43	3694	39.6
4. PERTUSSUS.	27	0.29	8	0.08
5. TETANUS.	6625	73.1	7068	75.8
6. T.B., PULMONARY.	141	1.55	69	0.74
7. T.B., OTHER.	34	0.37	45	0.48
8. MALARIA.	17	0.18	11	0.12
9. PNEUMONIA.	5991	66.12	5446	58.4
10. A.R.I. **	18000000	198600.	18600000	199300
11. DIARRHEA **	26000000	286900.	27000000	289400

SOURCES :

1. Ministry of Health, Statistical dep., Documentation Center.

** 2. Clinicians' & Preventive Medicine Experts' estimates.

(V) C - NEEDS FOR C.S.P.'S

By combining facts and figures of population, vital statistics and morbidity rates, we can summarize needs for C.S.P.'s as :-

1. Total population with potential needs for C.S.P.'s (1986) = 9.68 million child.

2. Total population with potential needs for contraception = 7.0 millions.

3. Potential needs for vaccination :
   a. Polio 7.0 million doses
   b. D.P.T. 8.0 million doses
   c. Measles 3.0 million doses
   d. T.B. 4.5 million doses
   e. Tetanus 14.0 million doses

4. Potential needs for treatments of :
   a. Diarrhea 27 million cases
   b. A.R.I. 19 million cases
   c. Measles 484,000 cases
   d. Tetanus 73,500 cases
   e. Diphtheria 4800 cases
   f. Polio 110 cases
   g. Malaria 12 cases
   h. T.B. Pulmonary 75 cases.

(VI) PROVISION ACTIVITIES

A. CONSUMPTION PATTERNS OF C.S.P. IN THE LAST FIVE YEARS.

B. LOCAL PRODUCTION / IMPORTS OF C.S.P.

C. PRICES / COSTS.

D. M.O.H. ALLOCATIONS & EXPENDITURES.

E. PROJECTED NEEDS OF C.S.P. FOR THE NEXT FIVE YEARS.

(VI) - A CONSUMPTION PATTERNS OF C.S.P.'S.

* C.S.P.'s (as defined in this study) comprise 26 subgroups of pharmaceuticals, detailed in table (VI-1).

  The 26 groups include 245 pharmaceutical product, representing 157 chemical entities, combinations and forms.

  Only 24 pharamceutical products are imported (i.e.) almost all the C.S.P.'s needs are satisfied by local production.

* Consumption figures in volume terms (number of packs) and in value terms (evaluated in public prices) were compiled for C.S.P.'s for the last five years.
  Table (VI-2), table (VI-3) show the compiled volume consumption, while table (VI-4) and table (VI-5) show the compiled value consumption.

  Consumption pattern for each subgroup was plotted, and the graphs showed :-

  - Nine subgroups had a linear increasing pattern, those are namely, (antiamaebics, antidiarrheals, antituberculous, sulphonamides, corticosteroids, bronchodilators, parentral restoratives, spasmolytics, and lactose free milk).

  - Ten subgroups had a linear increasing pattern which showed a decreasing tendency last year (1985/86). Those are namely, (analgesics and antimotility, antihistaminics, chemobiotics, multivitamins, oral restoratives and sedatives).

  - Six subgroups had a non-linear fluctuating pattern (antibiotics, antimalarials, contraceptives, vaccines, mescillenous, and gamma globulins).

  - Only one subgroup had a decreasing pattern (sera).

  Annex (VI-1) comprises the consumption pattern graphs of all subgroups.

Market share of each subgroup during the last five years was (calculated in volume abd value terms).

* It was found that in volume terms, antibiotics, vaccines and oral restoratives are the dominating subgroups, constituting (in 1985/86) (23 %), (20 %) and (10.6) % of the market respectively.

  Expectorants constituted (9.9 %), miltivitamins (7.5 %), antidiarrheals (4 %).

  The lowest subgroups were mescilleneous (0.02 %), gamma glubulins (0.03 %), antimalarials (0.05 %), antituberculous (0.14 %) and antimotility (0.16 %).

* It was also found that the market share of antibiotics, expectorants, sera and multivitamins is decreasing during the last five years, while the market share of oral restoratives, antidiarrheals, bronchodilators is increasing substantially.

  Table (VI-6) shows the pattern of consumption (market share) of C.S.P.'s in volume terms for the years 81/82 - 85/86.

TABLE (VI - 1) : A LISTING OF SUBGROUPS CODE AND NAME OF C.S.P.

SUBGROUP CODE	SUBGROUP NAME
200	ANALGESICS / ANTIPYRETICS
502	ANTIMOTILITY DRUGS
505	ANTIAMAEBICS
508	ANTIEMETICS
509	ANTIDIARRHEALS
600	ANTIBIOTICS
700	ANTIMALARIALS
1000	ANTIHISTAMINICS
1300	CHEMOBIOTICS
1400	ANTITUBERCULOUS
1600	SULPHA + TRIMETHOPRIMS
2310	CORTICOSTEROIDS
2320	CONTRACEPTIVES
2701	VACCINES
2701	SERA
2703	GAMMA GLOBULINS
2800	MESCILLINEOUS
3301	EXPECTORANTS / MYCOLYTICS
3302	COUGH SEDATIVES
3303	BRONCHODILATORS
3500	MULTIVITAMINS
4100	RESTORATIVES / PARENTRAL
4106	RESTORATIVES / ORAL
4200	SEDATIVES / HYPNOTICS
4300	TRANQUILLIZERS
4400	SPASMOLYTICS
4700	LACTOSE - FREE MILK

TABLE (VI) - 2

CONSUMPTION FIGURES IN VOLUME TERMS BROKEN DOWN BY INDIVIDUAL PHARMACEUTICAL

FOR YEARS (81/82 - 85/86)

CONSUMPTION FIGURES IN VOLUME TERMS BROKEN DOWN BY INDIVIDUAL PHARMACEUTICAL

FOR YEARS (81/82 - 85/86)

PACKS FOR C.S.P. S : 1000 PACKS

PAGE NO : 1

SUBGROUP : ANALGESICS / ANTIPYRETICS

IN QUNATITY TERMS

DSP CODE	COMMERCIAL CODE	TRADE NAME	PACK	QUANTITY 81/82	QUANTITY 82/83	QUANTITY 83/84	QUANTITY 84/85	QUANTITY 85/86
200	501351	PHARMALGIN DROPS	DROPS 15 ML.	677	763	721	1119	1120
200	501413	RIVO SUPP.	SUPP 5	0	38	139	253	526
200	502385	VEGASKINE INFANTILE SUPP.	SUPP 5	397	435	604	1110	1027
200	503448	NOVACID DROPS	DROPS 10 ML.	352	346	451	339	263
200	503453	NOVACID INF. SUPP.	SUPP 6	0	179	177	223	258
200	505405	GRIPPO SUPP.	SUPP 6	391	464	450	402	662
200	506168	NOVALGIN INFANT SUPP.	SUPP 5	499	1022	1338	1577	1457
200	509843	SEDAMOL SUPP	SUPP 5	0	57	148	212	254
200	509850	PARAMOL 125 MG SUPP.	SUPP 5	0	0	85	213	260
TOTALS				2316	3304	4222	5507	5827

Compiled by MIRGOTEGH. M. Gamaledin

CONSUMPTION FIGURES IN VOLUME TERMS BROKEN
DOWN BY INDIVIDUAL PHARMACEUTICAL

FOR YEARS (81/82 - 85/86)

PACKS FOR C.S.F.'S : 1000 PACKS

PAGE NO : 2

SUBGROUP : ANTIMOTILITY DRUGS

IN QUNATITY TERMS

CSP CODE	COMMERCIAL CODE	TRADE NAME	PACK	QUANTITY 81/82	QUANTITY 82/83	QUANTITY 83/84	QUANTITY 84/85	QUANTITY 85/86
502	417520	IMODIUM SYRUP IMPORT	BOT 30 ML	0	0	[illegible]	[illegible]	[illegible]
502	507549	LOMOTIL SYP	SYP 60 ML	242	227	214	[illegible]	245
TOTALS				242	227	214	509	245

Compiled by MISCOTECH, M. Genaledin

CONSUMPTION FIGURES IN VOLUME TERMS BROKEN DOWN BY INDIVIDUAL PHARMACEUTICAL

FOR YEARS (81/82 - 85/86)

PACKS FOR C.S.F.'S : 1000 PACKS

PAGE NO : 3

SUBGROUP : ANTIAMOEBICS

IN QUNATITY TERMS

CSF CODE	COMMERCIAL CODE	TRADE NAME	PACK	QUANTITY 81/82	QUANTITY 82/83	QUANTITY 83/84	QUANTITY 84/85	QUANTITY 85/86
505	502112	FLAGYL SUSP	SUSP 120 ML	177	263	457	573	1024
TOTALS				177	263	457	573	1024

Compiled by MIRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VOLUME TERMS BROKEN
DOWN BY INDIVIDUAL PHARMACEUTICAL

FOR YEARS (81/82 - 85/86) PACKS FOR C.S.F.'S : 1000 PACKS

PAGE NO : 4

SUBGROUP : ANTIEMETICS

CSP CODE	COMMERCIAL CODE	TRADE NAME	PACK	IN QUNATITY TERMS QUANTITY 81/82	QUANTITY 82/83	QUANTITY 83/84	QUANTITY 84/85	QUANTITY 85/86
508	502168	LARGACTIL DROPS	DROP 30 ML	0	0	0	0	7
508	503535	PLEMAZOL SYP	SYR 120 ML	0	0	0	0	42
508	503537	PLEMAZOL DROPS	DROPS 20 ML	0	0	0	0	50
508	503587	PROMACID DROPS	DROPS 15 ML	377	411	297	217	193
508	505168	CORTIGEN B6 PEDIATRIC AMP	AMP 3	638	930	1294	1709	1225
508	508618	PRIMPERAN SYP	SYP 120 ML	0	0	0	0	517
508	508704	PRIMPERAN DROPS	DROPS 30 ML	0	0	0	0	1
508	509327	NEURAZINE DROPS	DROPS 10 ML	185	321	229	293	219
TOTALS				1200	1662	1541	2265	2267

Compiled by MISSRIGEN, M. Genaleda

CONSUMPTION FIGURES IN VOLUME TERMS BROKEN DOWN BY INDIVIDUAL PHARMACEUTICAL

FOR YEARS (81/82 - 85/86)

PACKS FOR C.D.F. S : 1000 PACKS

PAGE NO : 5

SUBGROUP : ANTIDIARRHEALS

IN QUNATITY TERMS

CSF CODE	COMMERCIAL CODE	TRADE NAME	PACK	QUANTITY 81/82	QUANTITY 82/83	QUANTITY 83/84	QUANTITY 84/85	QUANTITY 85/86
509	501181	ENTROQUINE COMP SUSP	SUSP 100 ML	1093	1449	1260	2280	1626
509	502269	PECKTONAL SUSP	SUSP 100 ML	264	246	219	190	159
509	502274	PECKTONAL N SUSP	SUSP 100 ML	423	376	467	536	405
509	503205	ENTOCID COMPOUND POWDER	POWD 15 BAG	128	478	859	990	881
509	504152	SULPHAGUANIDINE 500 MG TAB	TAB 10 ST	0	0	0	0	100
509	505323	ENTEROGUANIL SUSP	SUSP 60 ML	392	238	479	537	357
509	505363	PERCURAL N SUSP	SUSP 60	93	27	229	430	376
509	505890	SULFAGUANIDINE STRIPS	PX 10 TAB	60	90	90	80	90
509	507522	GABIDZOL SUSP	SUSP 120 ML	173	201	163	284	259
509	508541	DIAMYCIN DRY SUSP	SUSP 100 ML	186	164	336	351	440
509	509817	FUDIZOL SUSP	SUSP 100 ML	198	92	171	240	499
509	509947	DIAKAN SUSP	SUSP 60 ML	113	206	231	478	759
509	510033	DIAFEC S SUSP	SUSP 90 ML	0	451	720	1168	1375
509	515390	KAFECT SUSP	SUSP 120 ML	0	0	0	0	450
509	515392	KAFECT CO SUSP	SUSP 120 ML	0	0	0	0	816
TOTALS				3123	4018	5028	7514	8662

Compiled by MUHUTEDH, M. Ganaledin

CONSUMPTION FIGURES IN VOLUME TERMS BROKEN
DOWN BY INDIVIDUAL PHARMACEUTICAL

FOR YEARS (81/82 - 85/86) PACKS FOR C.S.F. S : 1000 PACKS

PAGE NO : 6

SUBGROUP : ANTIBIOTICS

CSF CODE	COMMERCIAL CODE	TRADE NAME	PACK	IN QUNATITY TERMS QUANTITY 81/82	QUANTITY 82/83	QUANTITY 83/84	QUANTITY 84/85	QUANTITY 85/86
600	267077	NETROMYCIN 150 MG. 1.5 ML	BX1 AMP	0	0	0	0	36
600	267078	NETROMYCIN 50 MG. 2 ML.	BX1 AMP	0	0	0	0	24
600	503012	AMOXYCID 125 MG.	SYP 60 ML	0	0	0	0	156
600	503020	AMOXYCID 250 MG SUSP	SUSP 60 MG	0	0	0	0	150
600	503119	CIDOCETINE 125 MG SUPP	SUPP 6	111	164	119	170	166
600	503123	CIDOCETINE SUSP	SUSP 60 ML	620	782	620	851	825
600	503125	CIDOCETINE S SUSP	SUSP 60 ML	0	0	271	359	275
600	503186	DIFENACID SUSP	SUSP 60 ML	0	0	0	0	10
600	503195	ERYTHROCID SUSP	SUSP 60 ML	0	0	0	0	45
600	503474	FALITREX DROPS	BOTT 10 ML	25	21	60	25	82
600	503475	FALITREX 125 MG SYRUP	SYP 60 ML	82	120	107	159	129
600	503476	FALITREX 250 MG SYRUP	SYP 60 ML	0	0	0	93	146
600	503515	FENTREXYL 125 MG SUSP	SUSP 60 ML	527	531	232	360	1467
600	503519	FENICILLIN G SOD 1000000 U VIAL	VIAL 1	5558	9942	7772	5601	5785
600	503521	FENICILLIN PROCAINE 400000 U	VIAL 1	7071	8695	7617	6342	6768
600	503530	FENTREXYL 250 MG SUSP	SUSP 60 ML	518	513	713	803	937
600	503531	FENTREXYL DROPS	DROPS 10 ML.	241	359	47	247	227
600	503662	STREPTOCETINE SUSP	SUSP 60 ML	408	542	472	836	817
600	503663	STREPTOMYCIN SULPHATE 1 GM. VIAL	VIAL 1	7100	7400	6225	4720	3372
600	505053	AMPICILLIN 125 MG SUSP	SUSP 60 ML	276	39	265	311	341
600	505054	AMPICILLIN FORT 250 MG DRY SUSP	SUSP 60 ML	72	347	169	787	831
600	505164	CLOXAPEN 250 MG DRY SUSP	SUSP 60 ML	0	0	0	0	170
600	505614	NEOCEF 250 MG DRY SYR	BOTT 60 ML	0	0	0	149	151
600	505666	OSPEN 400 MG SYP	SYP 60 ML	0	21	55	20	35
600	505709	PENICILLIN PROCAINE VIAL	VIAL 1	3597	2619	1104	1776	1176
600	505876	STREPTOMYCIN VIAL	VIAL 1	4783	3392	1206	1321	1778
600	505952	VERACETIN SUSP	SUSP 60 ML	0	0	0	0	292
600	506017	AMBLOSIN 50 MG/ML SYP	SYP 60 ML	0	0	239	332	142
600	507502	ERYTHROCIN GRAN 200 MG / 5 ML	SUSP 60 ML	338	365	823	1127	1185
600	507504	PENSTAF DRY MIX 62.5%	SUSP 60 ML	59	26	37	55	42
600	507558	DICLOPEN DRY SYP	SYP 60 ML	0	47	42	61	0
600	507561	KEFLEX SYRUP 250 MG	SUSP 60 ML	0	0	0	0	270
600	507562	KEFLEX SYRUP 125 MG	SUSP 60 ML	154	211	339	760	552
600	507564	KEFLEX DRY DROPS	BOTT 19 ML	52	141	154	34	40
600	508072	GARAMYCIN 20 MG AMP	AMP 6	46	141	274	522	535
600	508559	NEOMYCIN DRY SUSP	SUSP 60 ML	48	60	39	44	59
600	508664	MEMOCETIN SUSP	SUSP 60 ML	0	71	156	117	110
600	509330	PIMAFUCIN SUSP	SUSP 5 ML.	23	19	18	35	50
600	509331	ERYTHRIN DROP	DROPS 30 ML	0	0	0	0	2
600	509333	FLIMOXIN DROPS	DROPS 15 ML.	0	0	0	0	10
600	509860	AMPICILLIN 250 MG VIAL	VIAL 1	0	0	535	785	[illegible]
600	509884	STREPTOMYCIN 1 GM VIAL	VIAL 1	2509	[illegible]	[illegible]	[illegible]	[illegible]

Compiled by [illegible], M. Gebeleyn

CONSUMPTION FIGURES IN VOLUME TERMS BROKEN DOWN BY INDIVIDUAL PHARMACEUTICAL

FOR YEARS (81/82 - 85/86)

PACKS FOR C.S.P.'S : 1000 PACKS

PAGE NO : 7

SUBGROUP : ANTIBIOTICS

CSP CODE	COMMERCIAL CODE	TRADE NAME	PACK	IN QUNATITY TERMS QUANTITY 81/82	QUANTITY 82/83	QUANTITY 83/84	QUANTITY 84/85	QUANTITY 85/86
600	509885	DIACILLIN INJECTION	VIAL 1	762	204	705	1368	1339
600	509886	PENICILLIN G SOD 1000000 U	VIAL 1	2777	2758	1802	1148	1203
600	509908	AMFIPEN 250 MG VIAL	VIAL 1	639	940	682	773	594
600	509926	MIPHENICOL 125 MG SUPP	SUPP 6	184	217	147	158	156
600	509929	MICYCLINE 125 MG SUSP	SUSP 60 ML	497	171	81	150	73
600	509931	FLIMOXIN SUSP. 125 MG	SUSP 60 ML	0	0	0	0	60
600	509932	FLIMOXIN 250 MG SUSP	SUSP 60 ML	0	0	0	0	80
600	509935	MIPHENICOL 125 MG SUSP	SUSP 60 ML	761	833	536	656	776
600	509936	STREPTOPHENICOL SUSP	SUSP 60 ML	642	788	1067	1095	917
600	509937	AMPICILLIN 125 MG SYP	SYP 60 ML	1213	1237	675	566	589
600	509938	AMFIPEN 125 MG SYP	SYP 60 ML	532	598	606	448	415
600	509939	AMFIPEN 250 MG SYP	SYP 60 ML	795	894	769	852	729
600	509940	AMPICILLIN 250 MG SYP	SYP 60 ML	0	0	426	525	1074
600	509942	ERYTHRINE 200 MG SUSP	SUSP 60 ML	0	0	0	103	348
600	509945	MOXIPEN 125 MG SYP	SYP 60 ML	0	0	0	0	120
600	509946	MOXIPEN 250 MG SYP	SYP 60 ML	0	0	0	0	130
600	510107	SIGMAMYCIN SYRUP	SUSP 60 ML	627	597	878	661	448
600	510131	TERRAMYCIN 125 MG	SYP 90 ML	402	420	528	316	295
600	510173	VIBRAMYCIN SYRUP	SUSP 60 ML	282	292	291	205	116
600	511413	RIMACTAN SYP	SYP 50 ML	49	107	145	206	220
600	512023	DEXACILLIN 125 MG SUSP	SUSP 60 ML	249	339	451	194	178
600	512024	DEXACILLIN 250 MG SUSP	SUSP 60 ML	321	280	456	257	456
600	512025	DEXACILLIN 10 ML DROPS	DROPS 10 ML.	11	142	180	169	157
600	512071	MYCOSTATIN ORAL SUSP.	12 DOSE	0	0	143	502	500
600	512123	VELOSEF 125 MG SUSP	SUSP 60 ML	198	115	181	141	301
600	512124	VELOSEF 250 MG SUSP	SUSP 60 ML	92	69	169	150	300
600	512125	VELOSEF 250 MG. VIAL	VIAL 1 ML	0	0	57	53	73
600	515322	FLUMOX DRY MIX	SYP 60 ML	0	0	0	0	300
600	516103	AMPICYN 125 MG DRY SYRUP	SYP 60 ML	0	0	0	0	0
600	516104	AMPICYN 250 MG BRY SYRUP	SYP 60 ML	0	0	0	0	0
600	516304	IBIAMOX 125 MG DRY SYRUP	SYP 60 ML	0	0	0	0	350
600	516305	IBIAMOX 250 MG DRY SYRUP	SYP 60 ML	0	0	0	0	500
600	516325	IBILEX 125 MG. DRY SYRUP	SYP 60 ML	0	0	0	0	10
600	516326	IBILEX 250 MG. DRY SYRUP	SYP 60 ML	0	0	0	0	10
TOTALS				44877	50418	45342	44957	49811

Compiled by MIRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VOLUME TERMS BROKEN
DOWN BY INDIVIDUAL PHARMACEUTICAL

FOR YEARS (81/82 - 85/86)

PACKS FOR C.S.P.'S : 1000 PACKS

PAGE NO : 8

SUBGROUP : ANTIMALARIALS

IN QUNATITY TERMS

CSP CODE	COMMERCIAL CODE	TRADE NAME	PACK	QUANTITY 81/82	QUANTITY 82/83	QUANTITY 83/84	QUANTITY 84/85	QUANTITY 85/86
700	502103	DAGRINOL TAB	TAB 100 ST	57	60	106	67	54
700	503138	CIDOQUINE 250 MG. TAB	TAB 20	56	25	23	23	39
700	505131	CAMOQUIN TAB	TAB 100	4	3	3	4	5
TOTALS				117	88	132	94	98

Compiled by MIRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VOLUME TERMS BROKEN DOWN BY INDIVIDUAL PHARMACEUTICAL

FOR YEARS (81/82 - 85/86)

PACKS FOR C.S.F. S : 1000 PACKS

PAGE NO : 9

SUBGROUP : ANTIHISTAMINICS

IN QUNATITY TERMS

CSF CODE	COMMERCIAL CODE	TRADE NAME	PACK	QUANTITY 81/82	QUANTITY 82/83	QUANTITY 83/84	QUANTITY 84/85	QUANTITY 85/86
1000	501037	ALLERGYL SYP	SYP 120 ML.	357	405	495	608	651
1000	502271	PHENERGAN SYP.	SYP 120 ML.	0	56	183	187	186
1000	506010	AVIL SYP	SYP 100 ML.	99	111	357	365	281
1000	507525	PERIACTIN SYP	SYP 114 ML	1079	1030	1190	831	717
1000	508615	PIRAFENE 2 MG/5 SYP	SYP 120 ML.	81	103	68	85	57
1000	509821	PROMANTINE SYRUP	SYP 125 ML	248	147	190	218	166
1000	511056	TAVEGYL 100 ML. SYP	SYP 120 ML.	334	305	487	796	824
TOTALS				2198	2157	2970	3090	2882

Compiled by MIRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VOLUME TERMS BROKEN DOWN BY INDIVIDUAL PHARMACEUTICAL

FOR YEARS (81/82 - 85/86)

PACKS FOR C.S.P.'S : 1000 PACKS

PAGE NO : 10

SUBGROUP : CHEMOBIOTICS

IN QUNATITY TERMS

CSP CODE	COMMERCIAL CODE	TRADE NAME	PACK	QUANTITY 81/82	QUANTITY 82/83	QUANTITY 83/84	QUANTITY 84/85	QUANTITY 85/86
1300	503124	CIDOCETINE BISMUTH SUPP	SUPP 4	479	370	518	816	625
1300	509925	BISMOPHENICOL SUPP.	SUPP 3	451	284	682	1444	1485
TOTALS				930	654	1200	2260	2110

Compiled by MIRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VOLUME TERMS BROKEN DOWN BY INDIVIDUAL PHARMACEUTICAL

FOR YEARS (81/82 - 85/86)

PACKS FOR C.S.F.'S : 1000 PACKS

PAGE NO : 1.

SUBGROUP : ANTITUBERCULOUS

IN QUANTITY TERMS

CSP CODE	COMMERCIAL CODE	TRADE NAME	PACK	QUANTITY 81/82	QUANTITY 82/83	QUANTITY 83/84	QUANTITY 84/85	QUANTITY 85/86
1400	503334	ISOCID 50 MG TAB	TAB 100	89	70	102	109	104
1400	509391	INHIBEX TAB	TAB 60	2	15	118	104	109
1400	511408	RIMACTAZID C.T.	TAB 80 ST	0	0	0	2	4
1400	511660	RIMACTAZID C.T.	TAB 8 ST	0	0	0	60	81
TOTALS				91	85	220	275	298

Compiled by MIRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VOLUME TERMS BROKEN
DOWN BY INDIVIDUAL PHARMACEUTICAL

FOR YEARS (81/82 - 85/86) PACKS FOR C.S.P. S : 1000 PACKS

PAGE NO : 12

SUBGROUP : SULPHA + TRIMETHOPRIM IN QUNATITY TERMS

CSP CODE	COMMERCIAL CODE	TRADE NAME	PACK	QUANTITY 81/82	QUANTITY 82/83	QUANTITY 83/84	QUANTITY 84/85	QUANTITY 85/86
1600	502329	SUPRISTOL SUSP	SYP 60 ML	0	0	0	0	103
1600	502336	SEPTAZOLE SUSP	SUSP 100 ML	395	365	621	743	891
1600	505343	ENTRIM SUSP	SUSP 100 ML	0	22	125	170	196
1600	507542	CHEMOTRIM SUSP	SUSP 100 ML	189	205	274	266	165
1600	508637	SUTRIM SUSP	SUSP 100 ML	371	509	436	750	997
1600	509934	LIDAPRIM SUSP	SUSP 60 ML	0	0	0	0	84
TOTALS				955	1101	1457	1929	2436

Compiled by MIRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VOLUME TERMS BROKEN DOWN BY INDIVIDUAL PHARMACEUTICAL

FOR YEARS (81/82 - 85/86) PACKS FOR C.S.P.'S : 1000 PACKS

PAGE NO : 13

SUBGROUP : CORTICOSTEROIDS IN QUNATITY TERMS

CSP CODE	COMMERCIAL CODE	TRADE NAME	PACK	QUANTITY 81/82	QUANTITY 82/83	QUANTITY 83/84	QUANTITY 84/85	QUANTITY 85/86
2310	3211	HYDROCORTISONE I.V. 100 ML.	1 AMP. + VL	0	100	100	120	240
2310	23088	SOLUDACORTEN 250 MG.	B X 1 AMP.	6	8	16	11	15
2310	23089	SOLU DACOTRIN 25 MG.	B X 3 AMP.	12	12	14	8	13
2310	23131	FORTECORTIN 8 MG. 2 CC	B X 1 AMP.	52	35	47	122	96
2310	53000	DEPO-MEDROL 40 MG./ML	B X DISP.VL 2ML	0	0	63	96	204
2310	267068	CELESTONE CHRONODASE	1 VIAL	0	0	0	6	8
2310	267076	DIFROFOS INJ. 2cc	B X 1 AMP	0	0	0	4	4
2310	364006	DEXAMETHASONE	B X AMP.	0	0	0	2	2
2310	501358	PHENADONE SYP	SYP 100 ML	955	944	1013	1091	842
2310	503174	DEXASCHEROSON 5 MG IM AMP	AMP 1	362	556	679	918	1005
2310	505485	FLEBOCORTID 100 MG AMP	AMP 1	8	10	6	17	63
2310	512052	KENACORT-A-I.M 40 MG VIAL	VIAL 1 ML	184	152	338	355	529
2310	515140	CODELCORTON T.B.A. VIAL	VIAL 3	0	0	0	0	1
2310	515194	DECADRON VIAL	VIAL 1	0	0	0	0	2
2310	515670	SOLU-CORTEF 100 MG	VIAL 1	0	0	0	0	1
TOTALS				1579	1817	2276	2750	3025

Compiled by MIRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VOLUME TERMS BROKEN DOWN BY INDIVIDUAL PHARMACEUTICAL

FOR YEARS (81/82 - 85/86)

PACKS FOR C.S.P.'S : 1000 PACKS

PAGE NO : 14

SUBGROUP : CONTRACEPTIVES

IN QUNATITY TERMS

CSP CODE	COMMERCIAL CODE	TRADE NAME	PACK	QUANTITY 81/82	QUANTITY 82/83	QUANTITY 83/84	QUANTITY 84/85	QUANTITY 85/86
2320	503415	MICROVLAR TAB	TAB 21	794	1169	2208	2405	2505
2320	503640	TRIVLAR TAB	TAB 21	0	0	0	0	248
2320	503998	PRIMOVLAR	TAB 21	3971	3104	2954	2737	4724
2320	503999	ANOVLAR-1	TAB 21	3040	4147	4000	2531	4023
2320	505611	NORDETTE	TAB 21 X 5 ST	300	300	400	400	500
2320	520001	LIPPES LOOP	1 LP.	0	0	0	0	58
2320	520002	COPPER T LOOP	1 LP.	0	0	0	0	152
2320	520003	CONDOMS	BX 100	0	0	0	0	140
2320	520004	NEOSAMPOON	20 T	0	0	0	0	102
2320	520005	NEOSAMPOON	20 T	0	0	0	0	336
TOTALS				8105	8720	9562	8273	12388

Compiled by MIRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VOLUME TERMS BROKEN
DOWN BY INDIVIDUAL PHARMACEUTICAL

FOR YEARS (81/82 - 85/86) PACKS FOR C.S.P.'S : 1000 PACKS

PAGE NO : 15

SUBGROUP : VACCINES IN QUNATITY TERMS

CSP CODE	COMMERCIAL CODE	TRADE NAME	PACK	QUANTITY 81/82	QUANTITY 82/83	QUANTITY 83/84	QUANTITY 84/85	QUANTITY 85/86
2701	513006	B.C.G. VACCINE	1 DOSE	846	0	1840	1860	3500
2701	513007	DIPHTHERIA TOXOID	1 AMP	60	60	68	100	500
2701	513009	DIPHTHERIA AND TETANUS VACCINE	1 VIAL	164	1862	1992	1362	2421
2701	513010	TRIPLE VACCINE	1 AMP	3195	4692	3236	5201	5899
2701	513011	MEASLES VACCINE	1 AMP	800	1000	1269	2000	3500
2701	513013	TETANUS TOXOID	1 VIAL	1100	1600	1500	3950	3000
2701	513014	POLIOMYELITIS VACCINE	1 DOSE	8845	34800	29353	29999	25350
TOTALS				15010	44014	39258	44472	44165

Compiled by MIRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VOLUME TERMS BROKEN
DOWN BY INDIVIDUAL PHARMACEUTICAL

FOR YEARS (81/82 - 85/86)

PACKS FOR C.S.P.'S : 1000 PACKS

PAGE NO : 16

SUBGROUP : SERA

IN QUNATITY TERMS

CSP CODE	COMMERCIAL CODE	TRADE NAME	PACK	QUANTITY 81/82	QUANTITY 82/83	QUANTITY 83/84	QUANTITY 84/85	QUANTITY 85/86
2702	513002	DIPHTHERIA ANTITOXIN 20,000 U	1 AMP	20	20	25	30	40
2702	513004	TETANUS ANTITOXIN 1.500 U	5 AMP	1363	2463	2029	1072	690
2702	513005	TETANUS ANTITOXIN 30,000 U	5 AMP	18	18	20	18	24
TOTALS				1401	2501	2074	1120	754

Compiled by MIRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VOLUME TERMS BROKEN
DOWN BY INDIVIDUAL PHARMACEUTICAL

FOR YEARS (81/82 - 85/86) PACKS FOR C.S.F.'S : 1000 PACKS

PAGE NO : 17

SUBGROUP : GAMMA GLOBULINS IN QUNATITY TERMS

CSP CODE	COMMERCIAL CODE	TRADE NAME	PACK	QUANTITY 81/82	QUANTITY 82/83	QUANTITY 83/84	QUANTITY 84/85	QUANTITY 85/86
2703	465002	GAMMA GLOBULIN 16.5 %	VL 2 ML.	20	20	20	30	30
2703	513003	GAMMA GLOBULIN 16%	1 AMP	15	3	17	32	35
TOTALS				35	23	37	62	65

Compiled by MIRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VOLUME TERMS BROKEN
DOWN BY INDIVIDUAL PHARMACEUTICAL

FOR YEARS (81/82 - 85/86) PACKS FOR C.S.F.'S : 1000 PACKS

PAGE NO : 18

SUBGROUP : MESCILLINEOUS IN QUNATITY TERMS

CSP CODE	COMMERCIAL CODE	TRADE NAME	PACK	QUANTITY 81/82	QUANTITY 82/83	QUANTITY 83/84	QUANTITY 84/85	QUANTITY 85/86
2800	509329	ETHAMIVAN DROPS	DROPS 10 ML.	52	42	39	38	41
TOTALS				52	42	39	38	41

Compiled by MIRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VOLUME TERMS BROKEN
DOWN BY INDIVIDUAL PHARMACEUTICAL

FOR YEARS (81/82 - 85/86) PACKS FOR C.S.P.'S : 1000 PACKS

PAGE NO : 19

SUBGROUP : EXPECTORANTS / MYCOLYTICS IN QUNATITY TERMS

CSP CODE	COMMERCIAL CODE	TRADE NAME	PACK	QUANTITY 81/82	QUANTITY 82/83	QUANTITY 83/84	QUANTITY 84/85	QUANTITY 85/86
3301	501191	EXPECTYL SYP	SYP 120 ML	1222	2858	1106	1958	1196
3301	501430	SOLVIN SYP	SYP 60 CC	42	355	602	208	67
3301	501453	SOLVIN DROPS	DROPS 15 ML	0	0	0	47	126
3301	503078	BISOLVON SOLUTION 4 MG / 2 ML	SOL 40 ML	0	0	61	132	166
3301	503079	BISOLVON ELIXIR 4 MG/ 5ML	ELIX. 115 ML	0	87	489	672	1077
3301	503147	COLDAL SYP	SYP 120 ML	1230	1185	1472	1970	1319
3301	503421	NEOCOLDAL SYP	SYP 120 ML	1494	1300	1294	1240	1652
3301	505468	ISILIN SYRUP	SYP 120 ML	2678	2459	1843	2050	1738
3301	506013	AVIPECT SYP 100 ML	SYP 100 ML	1586	2301	2809	3615	3352
3301	507512	BRONCHISTAL SYP	SYP 120 ML	3463	4152	3899	3879	3740
3301	507524	SEDALINE SYP	SYP 125 ML	1066	1293	1195	1197	996
3301	508609	BRONCHOLASE SYP	SYP 120 ML	5890	4837	5121	4909	6971
TOTALS				18671	20827	19882	21007	21500

Compiled by MIRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VOLUME TERMS BROKEN DOWN BY INDIVIDUAL PHARMACEUTICAL

FOR YEARS (81/82 - 85/86)

PACKS FOR C.S.P.'S : 1000 PACKS

PAGE NO : 20

SUBGROUP : COUGH SEDATIVES

CSP CODE	COMMERCIAL CODE	TRADE NAME	PACK	IN QUNATITY TERMS QUANTITY 81/82	QUANTITY 82/83	QUANTITY 83/84	QUANTITY 84/85	QUANTITY 85/86
3302	507511	BROMOSYRUP	SYP 125 ML	1064	596	890	993	893
3302	507589	TUSSILAR DROPS	DROPS 15 ML	195	236	177	204	169
3302	508657	LYNABROM SYP	SYP 120 ML	447	419	577	593	590
3302	508799	LYNABROM SUPP	SUPP 10	1271	1157	1196	996	224
3302	509847	PYRAFHOL INFATILE SUPP	SUPP 6	0	0	56	56	123
3302	509854	EUCAFHOL INF. SUPP	SUPP 10	0	0	0	34	34
3302	510074	OSINEX SYRUP	SYRUP 120 ML	0	0	679	790	1027
TOTALS				2977	2408	3575	3668	3060

Compiled by MIRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VOLUME TERMS BROKEN DOWN BY INDIVIDUAL PHARMACEUTICAL

FOR YEARS (81/82 - 85/86)

PACKS FOR C.S.P.'S : 1000 PACKS

PAGE NO : 21

SUBGROUP : BRONCHODILATORS

IN QUNATITY TERMS

CSP CODE	COMMERCIAL CODE	TRADE NAME	PACK	QUANTITY 81/82	QUANTITY 82/83	QUANTITY 83/84	QUANTITY 84/85	QUANTITY 85/86
3303	12501	BABY-RHINOL	BT 120 ML	0	100	100	120	120
3303	349502	RHINOPRONT SYRUP	BT 90 ML	0	0	100	110	100
3303	502308	SALBOVENT SYP	SYP 120 ML	0	92	195	316	425
3303	503008	ALUPENT 1 ML IM AMP	AMP 6	4	5	7	5	6
3303	503085	BRICANYL SYP	SYP 120 ML	0	0	94	155	257
3303	505686	ASMASONE DROPS	DROPS 10 ML	59	60	98	161	173
3303	508007	EFANOL 2 ML IM AMP	AMP 6	292	430	363	404	287
3303	508619	POLARAMINE EXPECT SYR.	SYP 120 ML	0	0	0	0	0
3303	511671	TRIAMINIC SYRUP	BT 100 ML	0	0	700	800	840
3303	511673	TRIAMINIC DROPS	BT 15 ML	0	0	200	220	290
3303	511763	ZADITEN PEDIATRIC SYP	SYP 100 ML	0	30	57	71	83
TOTALS				355	717	1904	2362	2571

Compiled by MIRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VOLUME TERMS BROKEN DOWN BY INDIVIDUAL PHARMACEUTICAL

FOR YEARS (81/82 - 85/86)

PACKS FOR C.S.F.'S : 1000 PACKS

PAGE NO : 22

SUBGROUP : MULTIVITAMINS

IN QUNATITY TERMS

CSF CODE	COMMERCIAL CODE	TRADE NAME	PACK	QUANTITY 81/82	QUANTITY 82/83	QUANTITY 83/84	QUANTITY 84/85	QUANTITY 85/86
3500	501285	MEDIVIT SYP	SYP 100 ML	3312	2128	2102	2004	1859
3500	502381	VICIBEX SYP	SYP 120 ML	813	890	686	391	310
3500	503262	FRUITAL SYP	SYP 120 ML	12	897	839	1059	1213
3500	505302	ECAPLEX C SYRUP	SYP 120 ML	594	579	647	668	549
3500	507566	VI-DAYLIN SYR.	SYP 90 ML	0	0	59	249	476
3500	507591	NEOTOTAVINE DROPS	DROPS 15 ML	310	578	341	232	228
3500	508641	VAROLEX SYP	SYP 120 ML	6287	7181	9294	5983	9160
3500	508697	MULTIVAROL DROPS	DROPS 15 ML	2744	3470	2718	1975	731
3500	509334	POLYVIT DROPS	DROPS 10 ML	101	192	220	233	240
3500	509805	BECO C SYRUP	SYP 125 ML	624	639	627	769	799
3500	512101	THERAGRAN LIQ	LIQ 90 ML	0	231	278	290	461
3500	515056	BECOZYM SYP	SYP 125 ML	0	0	0	0	360
TOTALS				14797	16785	17803	17852	16426

Compiled by MIRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VOLUME TERMS BROKEN DOWN BY INDIVIDUAL PHARMACEUTICAL

FOR YEARS (81/82 - 85/86)

PACKS FOR C.S.P.'S : 1000 PACKS

PAGE NO : 23

SUBGROUP : RESTORATIVES / PARENTRAL

IN QUNATITY TERMS

CSP CODE	COMMERCIAL CODE	TRADE NAME	PACK	QUANTITY 81/82	QUANTITY 82/83	QUANTITY 83/84	QUANTITY 84/85	QUANTITY 85/86
4100	50289	SODIUM-BICARBONATE 8.4 %	B X 1 VL 50 CC	0	3	5	8	8
4100	455009	HUMAN ALBUMIN 20 % 50 ML.	B X 1 VIAL	3	4	9	12	14
4100	504036	DEXTROSE 5% 500 ML AMP	PACK 1	562	1492	910	1117	1447
4100	504038	DEXTROSE 10 % SOLUTION	PACK 1	0	0	21	24	23
4100	504041	DEXTROSE IN NORMAL SALINE	SOL 500 ML	119	120	120	160	178
4100	504096	RINGERS LACTATED SOLUTION	SOL. 500 ML	0	0	100	100	132
4100	504100	NORMAL SALINE 500 ML AMP	AMP 1	293	338	587	572	946
4100	504141	SEPACK DEXTROSE 5% BAG	BAG 1	0	0	0	448	288
4100	504143	SEPACK DEXTROSE IN NORMAL SALINE	BAG 1	0	0	0	0	64
4100	504146	SEPACK N. SALINE 500 ML BAG	BAG 1	0	0	0	128	304
4100	505212	DEXTROSE 5% SOLUTION	SOL 500 ML	780	614	1139	997	1160
4100	505236	DEXTROSE 5% IN NORM SALINE SOL	SOL 500 ML	253	234	245	286	84
4100	505640	NORMAL SALINE SOLUTION	SOL 500 ML	558	449	712	519	478
4100	505812	RINGER LACTATED SOLUTION	SOL 500 ML	86	132	171	128	108
4100	505837	SODIUM BICARBONATE 5 %	SOL 500 ML	0	0	0	24	32
4100	508087	DEXTROSE 25 % 20 ML IM AMP	AMP 5 X 5	43	29	36	49	55
4100	509835	K CHLOR SOLUTION	SOL 100 ML	269	217	152	184	180
TOTALS				2966	3632	4207	4756	6101

Compiled by MIRCOTECH, M. Samaledin

CONSUMPTION FIGURES IN VOLUME TERMS BROKEN DOWN BY INDIVIDUAL PHARMACEUTICAL

FOR YEARS (81/82 - 85/86)

PACKS FOR C.S.F.'S : 1000 PACKS

PAGE NO : 24

SUBGROUP : RESTORATIVES / ORAL

IN QUNATITY TERMS

CSP CODE	COMMERCIAL CODE	TRADE NAME	PACK	QUANTITY 81/82	QUANTITY 82/83	QUANTITY 83/84	QUANTITY 84/85	QUANTITY 85/86
4106	503995	MOALGAT EL GAFAF 5.5 GM.	1 PACK	5089	3884	8881	26691	18017
4106	503996	MOALGAT EL GAFAF M.O.H. 5.5 MG.	1 PACK	0	0	0	2000	5000
4106	503997	REHYDRAN	10 PACKS	515	438	973	83	0
TOTALS				5604	4322	9854	28774	23017

Compiled by MIRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VOLUME TERMS BROKEN DOWN BY INDIVIDUAL PHARMACEUTICAL

FOR YEARS (81/82 - 85/86)

PACKS FOR C.S.P.'S : 1000 PACKS

PAGE NO : 25

SUBGROUP : SEDATIVES / HYPNOTICS

IN QUNATITY TERMS

CSP CODE	COMMERCIAL CODE	TRADE NAME	PACK	QUANTITY 81/82	QUANTITY 82/83	QUANTITY 83/84	QUANTITY 84/85	QUANTITY 85/86
4200	503101	CID WATER	SYP 100 ML	883	769	761	1085	320
4200	505148	CHLORAL SYRUP	SYP 120 ML	63	54	45	29	25
4200	507568	WALIRINE SYP	SYP 125 ML	1282	1519	2048	1833	1863
4200	516145	AQUA BABY SYRUP	SYP 125 ML	0	0	0	0	400
TOTALS				2228	2342	2854	2947	2608

Compiled by MIRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VOLUME TERMS BROKEN DOWN BY INDIVIDUAL PHARMACEUTICAL

FOR YEARS (81/82 - 85/86)

PACKS FOR C.S.P.'S : 1000 PACKS

PAGE NO : 26

SUBGROUP : SPASMOLYTICS

IN QUNATITY TERMS

CSP CODE	COMMERCIAL CODE	TRADE NAME	PACK	QUANTITY 81/82	QUANTITY 82/83	QUANTITY 83/84	QUANTITY 84/85	QUANTITY 85/86
4400	506011	BARALGIN INFANT SUPP	SUPP 5	165	144	88	100	81
4400	507460	SPASMOPYRALGIN M INF SUPP	SUPP 5	276	196	235	290	308
4400	507586	PIPTAL PED DROPS	DROPS 15 ML	92	195	495	121	295
4400	509337	SPASMOTAL DROPS	DROPS 10 ML	343	261	335	579	922
4400	511391	SPASMO CIBALGIN CH	SUPP 5 ST	1381	1385	2337	2799	2455
TOTALS				2257	2181	3490	3989	4062

Compiled by MIRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VOLUME TERMS BROKEN DOWN BY INDIVIDUAL PHARMACEUTICAL

FOR YEARS (81/82 - 85/86)

PACKS FOR C.S.P.'S : 1000 PACKS

PAGE NO : 27

SUBGROUP : LACTOSE - FREE MILK

IN QUNATITY TERMS

CSP CODE	COMMERCIAL CODE	TRADE NAME	PACK	QUANTITY 81/82	QUANTITY 82/83	QUANTITY 83/84	QUANTITY 84/85	QUANTITY 85/86
4700	338003	SIMILAC ISOMEL	TN 4554 GM.	240	420	1000	1000	1000
4700	344018	BEBELAC FREE LACTOSE	TN 400 GM.	0	0	0	0	100
4700	376006	PROSEBEE	TN 400 GM.	48	60	100	300	600
TOTALS				288	480	1100	1300	1700

Compiled by MIRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VOLUME TERMS BROKEN DOWN BY INDIVIDUAL PHARMACEUTICAL

FOR YEARS (81/82 - 85/86)

PACKS FOR C.S.P.'S : 1000 PACKS

PAGE NO : 28

SUBGROUP :

IN QUNATITY TERMS

CSP CODE	COMMERCIAL CODE	TRADE NAME	PACK	QUANTITY 81/82	QUANTITY 82/83	QUANTITY 83/84	QUANTITY 84/85	QUANTITY 85/86
GRAND TOTAL :				132551	174788	181758	212383	217240

TABLE (VI) - 3

TOTAL CONSUMPTION FIGURES IN
VOLUME TERMS BROKEN DOWN BY SUBGROUP

FOR YEARS (81/82 - 85/86)

TOTAL CONSUMPTION FIGURES IN VOLUME
TERMS BROKEN DOWN BY SUBGROUP

FOR YEARS (81/82- 85/86)

UNIT : IN 1000 PACKS

PAGE NO : 1

IN QUNATITY TERMS

CSP CODE	SUBGROUP NAME	QUANTITY 81/82	QUANTITY 82/83	QUANTITY 83/84	QUANTITY 84/85	QUANTITY 85/86
200	ANALGESICS / ANTIPYRETICS	2316	3304	4222	5507	5823
502	ANTIMOTILITY DRUGS	242	227	314	509	346
505	ANTIAMOEBICS	177	263	457	573	1024
508	ANTIEMETICS	1200	1662	1901	2405	2263
509	ANTIDIARRHEALS	3123	4018	5228	7514	8662
600	ANTIBIOTICS	44877	50418	45342	44957	49811
700	ANTIMALARIALS	117	88	132	94	98
1000	ANTIHISTAMINICS	2198	2157	2970	3090	2882
1300	CHEMOBIOTICS	930	654	1200	2260	2110
1400	ANTITUBERCULOUS	91	85	220	275	298
1600	SULPHA + TRIMETHOPRIM	955	1101	1457	1929	2436
2310	CORTICOSTEROIDS	1579	1817	2376	2750	3025
2320	CONTRACEPTIVES	8105	8720	9562	8273	12789
2701	VACCINES	15010	44014	39258	44472	44169
2702	SERA	1401	2501	2074	1120	754
2703	GAMMA GLOBULINS	35	23	37	62	65
2800	MESCILLINEOUS	52	42	39	38	41
3301	EXPECTORANTS / MYCOLYTICS	18671	20827	19882	21007	21500
3302	COUGH SEDATIVES	2977	2408	3575	3668	3060
3303	BRONCHODILATORS	355	717	1904	2362	2571
3500	MULTIVITAMINS	14797	16785	17903	17952	16426
4100	RESTORATIVES / PARENTRAL	2966	3632	4207	4756	6101
4106	RESTORATIVES / ORAL	5604	4322	9954	28774	27017
4200	SEDATIVES / HYPNOTICS	2228	2342	2854	2947	2608
4400	SPASMOLYTICS	2257	2181	3490	3989	4062
4700	LACTOSE - FREE MILK	288	480	1100	1300	1700
TOTAL :		132551	174788	181358	212383	217241

Compiled by MICROTECH, M. Gamaledin

TABLE (VI) - 4

CONSUMPTION FIGURES IN VALUE TERMS BROKEN DOWN BY INDIVIDUAL PHARAMCEUTICAL

FOR YEARS (81/82 - 85/86)

CONSUMPTION FIGURES IN VALUE TERMS BROKEN DOWN BY INDIVIDUAL PHARAMCEUTICAL

FOR YEARS (81/81 - 85/86)

UNIT : IN L.E. 1000

PAGE NO : 1

SUBGROUP : ANALGESICS / ANTIPYRETICS

CSP CODE	COMMERCIAL CODE	TRADE NAME	PACK	IN VALUE TERMS VALUE 81/82	VALUE 82/83	VALUE 83/84	VALUE 84/85	VALUE 85/86
200	501351	PHARMALGIN DROPS	DROPS 15 ML.	507.75	572.25	540.75	839.25	840.00
200	501413	RIVO SUPP.	SUPP 5	0.00	17.10	62.10	131.85	236.70
200	502385	VEGASKINE INFANTILE SUPP.	SUPP 5	119.10	130.50	181.20	333.00	306.90
200	503448	NOVACID DROPS	DROPS 10 ML.	123.20	121.10	157.85	139.30	92.05
200	503453	NOVACID INF. SUPP.	SUPP 6	0.00	71.60	69.20	89.20	103.20
200	505405	GRIPPO SUPP.	SUPP 6	117.30	139.20	147.00	120.60	198.60
200	506168	NOVALGIN INFANT SUPP.	SUPP 5	199.60	408.80	555.20	614.80	582.80
200	509843	SEDAMOL SUPP	SUPP 5	0.00	34.20	100.80	127.20	152.40
200	509650	PARAMOL 125 MG SUPP.	SUPP 5	0.00	0.00	40.05	95.85	117.00
TOTALS				1066.95	1494.75	1854.15	2491.05	2629.65

Compiled by MIRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VALUE TERMS BROKEN
DOWN BY INDIVIDUAL PHARAMCEUTICAL

FOR YEARS (81/81 - 85/86)

UNIT : IN L.E. 1000

PAGE NO : 2

SUBGROUP : ANTIMOTILITY DRUGS

IN VALUE TERMS

CSP CODE	COMMERCIAL CODE	TRADE NAME	PACK	VALUE 81/82	VALUE 82/83	VALUE 83/84	VALUE 84/85	VALUE 85/86
502	417520	IMODIUM SYRUP IMPORT	BOT 30 ML	0.00	0.00	0.00	290.00	145.00
502	507549	LOMOTIL SYP	SYP 60 ML	193.60	181.60	251.20	247.20	196.80
TOTALS				193.60	181.60	251.20	537.20	341.80

Compiled by MIRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VALUE TERMS BROKEN DOWN BY INDIVIDUAL PHARAMCEUTICAL

FOR YEARS (81/81 - 85/86)

UNIT : IN L.E. 1000

PAGE NO : 3

SUBGROUP : ANTIAMOEBICS

CSP CODE	COMMERCIAL CODE	TRADE NAME	PACK	IN VALUE TERMS VALUE 81/82	VALUE 82/83	VALUE 83/84	VALUE 84/85	VALUE 85/86
505	502112	FLAGYL SUSP	SUSP 120 ML	256.65	381.35	662.65	830.85	1484.80
TOTALS				256.65	381.35	662.65	830.85	1484.80

Compiled by MIRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VALUE TERMS BROKEN DOWN BY INDIVIDUAL PHARAMCEUTICAL

FOR YEARS (81/81 - 85/86)

UNIT : IN L.E. 1000

PAGE NO : 4

SUBGROUP : ANTIEMETICS

CSP CODE	COMMERCIAL CODE	TRADE NAME	PACK	IN VALUE TERMS VALUE 81/82	VALUE 82/83	VALUE 83/84	VALUE 84/85	VALUE 85/86
508	502168	LARGACTIL DROPS	DROP 30 ML	0.00	0.00	0.00	0.00	7.00
508	503535	PLEMAZOL SYP	SYR 120 ML	0.00	0.00	0.00	0.00	42.00
508	503537	PLEMAZOL DROPS	DROPS 20 ML	0.00	0.00	0.00	0.00	50.00
508	503587	PROMACID DROPS	DROPS 15 ML	226.20	246.60	172.20	127.80	62.40
508	505168	CORTIGEN B6 PEDIATRIC AMP	AMP 3	382.80	558.00	771.60	1145.40	755.00
508	508618	PRIMPERAN SYP	SYP 120 ML	0.00	0.00	0.00	0.00	827.20
508	508704	PRIMPERAN DROPS	DROPS 30 ML	0.00	0.00	0.00	0.00	0.00
508	509327	NEURAZINE DROPS	DROPS 10 ML	111.00	192.60	196.80	169.80	130.80
TOTALS				720.00	997.20	1140.60	1443.00	1914.40

Compiled by MIRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VALUE TERMS BROKEN
DUWN BY INDIVIDUAL FHARAMCEUTICAL

FOR YEARS (81/81 - 85/86)

UNIT : IN L.E. 1000

PAGE NO : 5

SUBGROUP : ANTIDIARRHEALS

IN VALUE TERMS

CSF CODE	COMMERCIAL CODE	TRADE NAME	PACK	VALUE 81/82	VALUE 82/83	VALUE 83/84	VALUE 84/85	VALUE 85/86
509	501181	ENTROQUINE COMP SUSP	SUSP 100 ML	546.50	724.50	630.00	1140.00	813.00
509	502269	PECKTOKAL SUSP	SUSP 100 ML	118.80	110.70	98.10	81.00	71.55
509	502274	PECKTOKAL N SUSP	SUSP 100 ML	274.95	244.40	300.55	348.40	263.90
509	503205	ENTOCID COMPOUND POWDER	POWD 15 BAG	102.40	382.40	687.20	792.00	704.80
509	504152	SULPHAGUANIDINE 500 MG TAB	TAB 10 ST	0.00	0.00	0.00	0.00	300.00
509	505323	ENTEROGUANIL SUSP	SUSP 60 ML	117.60	71.40	143.70	161.10	107.10
509	505383	PERCURAL N SUSP	SUSP 60	46.50	13.50	114.00	215.00	188.00
509	505890	SULFAGUANIDINE STRIPS	PX 10 TAB	9.00	13.50	13.50	12.00	13.50
509	507522	GABIOZOL SUSP	SUSP 120 ML	103.80	120.60	93.80	170.40	155.40
509	508541	DIAMYCIN DRY SUSP	SUSP 100 ML	195.30	172.20	363.30	368.55	462.00
509	509817	FUDIZOL SUSP	SUSP 100 ML	128.70	59.80	111.15	156.00	324.35
509	509947	DIAKAN SUSP	SUSP 60 ML	129.95	236.90	265.65	503.70	917.70
509	510033	DIAPEC S SUSP	SUSP 90 ML	0.00	563.75	900.00	1460.00	1743.75
509	515390	KAFECT SUSP	SUSP 120 ML	0.00	0.00	0.00	0.00	382.50
509	515392	KAFECT CD SUSP	SUSP 120 ML	0.00	0.00	0.00	0.00	1032.50
TOTALS				1773.50	2713.65	3725.35	5408.15	7480.05

Compiled by MIRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VALUE TERMS BROKEN DOWN BY INDIVIDUAL PHARAMCEUTICAL

FOR YEARS (81/81 - 85/86)

UNIT : IN L.E. 1000

PAGE NO : 6

SUBGROUP : ANTIBIOTICS

IN VALUE TERMS

CSP CODE	COMMERCIAL CODE	TRADE NAME	PACK	VALUE 81/82	VALUE 82/83	VALUE 83/84	VALUE 84/85	VALUE 85/86
600	267077	NETROMYCIN 150 MG. 1.5 ML	BX1 AMP	0.00	0.00	0.00	0.00	414.00
600	267078	NETROMYCIN 50 MG. 2 ML.	BX1 AMP	0.00	0.00	0.00	0.00	102.00
600	503012	AMOXYCID 125 MG.	SYP 60 ML	0.00	0.00	0.00	0.00	273.00
600	503020	AMOXYCID 250 MG SUSP	SUSP 60 MG	0.00	0.00	0.00	0.00	337.50
600	503119	CIDOCETINE 125 MG SUPP	SUPP 6	49.95	73.80	53.55	76.50	74.70
600	503123	CIDOCETINE SUSP	SUSP 60 ML	620.00	782.00	820.00	851.00	825.00
600	503125	CIDOCETINE S SUSP	SUSP 60 ML	0.00	0.00	394.00	359.00	295.00
600	503186	DIPENACID SUSP	SUSP 60 ML	0.00	0.00	0.00	0.00	30.00
600	503195	ERYTHROCID SUSP	SUSP 60 ML	0.00	0.00	0.00	0.00	130.00
600	503474	PALITREX DROPS	BOTT 10 ML	43.75	36.75	105.00	43.75	143.50
600	503475	PALITREX 125 MG SYRUP	SYP 60 ML	184.50	270.00	231.75	582.75	290.25
600	503476	PALITREX 250 MG SYRUP	SYP 60 ML	0.00	0.00	0.00	319.55	562.10
600	503515	PENTREXYL 125 MG SUSP	SUSP 60 ML	632.40	637.20	711.60	552.00	1755.60
600	503519	PENICILLIN G SOD 1000000 U VIAL	VIAL 1	1389.50	2460.50	1993.00	2400.25	1346.25
600	503521	PENICILLIIN PROCAINE 400000 U	VIAL 1	707.10	868.50	764.70	654.20	676.80
600	503530	PENTREXYL 250 MG SUSP	SUSP 60 ML	1165.50	1154.25	1604.25	1806.75	2022.75
600	503531	PENTREXYL DROPS	DROPS 10 ML.	216.90	349.20	42.30	186.30	200.7[illegible]
600	503662	STREPTOCETINE SUSP	SUSP 60 GM	489.60	651.60	807.60	1063.20	975.60
600	503663	STREPTOMYCIN SULPHATE 1 GM. VIAL	VIAL 1	1065.00	1110.00	978.75	708.00	12[illegible]5.95
600	505053	AMPICILLIN 125 MG SUSP	SUSP 60 ML	355.20	46.80	318.00	292.80	409.20
600	505054	AMPICILLIN FORT 250 MG DRY SUSP	SUSP 60 ML	133.20	641.95	1043.40	1459.65	1561.40
600	505164	CLOXAPEN 250 MG DRY SUSP	SUSP 60 ML	0.00	0.00	0.00	0.00	247.00
600	505614	NEDCEF 250 MG DRY SYR	BOTT 60 GM	0.00	0.00	0.00	569.80	631.40
600	505666	OSPEN 400 MG SYP	SYP 60 ML	0.00	42.00	110.00	40.00	70.00
600	505709	PENICILLIN PROCAINE VIAL	VIAL 1	359.70	261.80	210.10	197.60	145.60
600	505876	STREPTOMYCIN VIAL	VIAL 1	658.35	538.80	180.90	228.00	292.20
600	505952	VERACETIN SUSP	SUSP 60 ML	0.00	0.00	0.00	0.00	348.00
600	506017	AMBLOSIN 50 MG/ML SYP	SYP 60 ML	0.00	0.00	774.80	863.20	369.20
600	507502	ERYTHROCIN GRAN 200 MG / 5 ML	SUSP 60 ML	676.00	730.00	1646.00	2046.00	2770.00
600	507504	PENSTAF DRY MIX 62.5%	SUSP 60 ML	38.35	16.90	43.55	42.25	39.00
600	507558	DICLOPEN DRY SYP	SYP 60 ML	0.00	89.30	91.20	115.90	0.00
600	507561	KEFLEX SYRUP 250 MG	SUSP 60 ML	0.00	0.00	0.00	0.00	1296.00
600	507562	KEFLEX SYRUP 125 MG	SUSP 60 ML	308.00	488.00	596.00	1720.00	1104.00
600	507564	KEFLEX DRY DROPS	BOTT 19 ML	91.00	246.75	269.50	59.50	70.00
600	508072	GARAMYCIN 20 MG AMP	AMP 6	110.40	338.40	705.60	1276.80	2004.00
600	508559	NEOMYCIN DRY SUSP	SUSP 60 ML	31.20	39.00	45.50	41.60	61.10
600	508664	MEMCOCETIN SUSP	SUSP 60 ML	0.00	71.00	186.00	149.00	110.00
600	509330	PIMAFUCIN SUSP	SUSP 5 ML.	33.35	20.30	26.10	50.75	72.50
600	509331	ERYTHRIN DROP	DROPS 30 ML	0.00	0.00	0.00	0.00	4.00
600	509333	FLIMOXIN DROPS	DROPS 15 ML.	0.00	0.00	0.00	0.00	274.[illegible]
600	509860	AMPICILLIN 250 MG VIAL	VIAL 1	0.00	0.00	277.50	392.50	522.50
600	509884	STREPTOMYCIN 1 GM VIAL	VIAL 1	376.35	405.30	254.85	164.70	151.25

Compiled by MIRCROTECH, M. Ganaledin

CONSUMPTION FIGURES IN VALUE TERMS BROKEN DOWN BY INDIVIDUAL PHARAMCEUTICAL

FOR YEARS (81/81 - 85/86)

UNIT : IN L.E. 1000

PAGE NO : 7

SUBGROUP : ANTIBIOTICS

IN VALUE TERMS

CSF CODE	COMMERCIAL CODE	TRADE NAME	PACK	VALUE 81/82	VALUE 82/83	VALUE 83/84	VALUE 84/85	VALUE 85/86
600	509885	DIACILLIN INJECTION	VIAL 1	114.30	30.60	105.75	205.20	200.95
600	509886	PENICILLIN G SOD 1000000 U	VIAL 1	555.40	551.60	350.40	229.60	240.60
600	509908	AMFIPEN 250 MG VIAL	VIAL 1	287.55	423.00	306.90	149.85	226.80
600	509926	MIPHENICOL 125 MG SUPP	SUPP 6	82.80	97.65	66.15	71.10	70.20
600	509929	MICYCLINE 125 MG SUSP	SUSP 60 ML	273.35	94.05	44.55	82.50	40.15
600	509931	FLIMOXIN SUSP. 125 MG	SUSP 60 ML	0.00	0.00	0.00	0.00	105.00
600	509932	FLIMOXIN 250 MG SUSP	SUSP 60 ML	0.00	0.00	0.00	0.00	180.00
600	509935	MIPHENICOL 125 MG SUSP	SUSP 60 ML	761.00	833.00	536.00	656.00	776.00
600	509936	STREPTOPHENICOL SUSP	SUSP 60 ML	770.40	945.60	1280.40	1314.00	1100.40
600	509937	AMPICILLIN 125 MG SYP	SYP 60 ML	1455.60	1484.40	910.00	679.20	706.80
600	509938	AMFIPEN 125 MG SYP	SYP 60 ML	638.40	717.60	727.20	537.60	498.00
600	509939	AMFIPEN 250 MG SYP	SYP 60 ML	1590.00	1788.00	1538.00	1704.00	1458.00
600	509940	AMPICILLIN 250 MG SYP	SYP 60 ML	0.00	0.00	852.00	1050.00	2148.00
600	509942	ERYTHRINE 200 MG SUSP	SUSP 60 ML	0.00	0.00	0.00	206.00	696.00
600	509945	MOXIPEN 125 MG SYP	SYP 60 ML	0.00	0.00	0.00	0.00	210.00
600	509946	MOXIPEN 250 MG SYP	SYP 60 ML	0.00	0.00	0.00	0.00	292.50
600	510107	SIGMAMYCIN SYRUP	SUSP 60 ML	407.55	388.05	570.70	429.65	304.20
600	510131	TERRAMYCIN 125 MG	SYP 90 ML	562.80	588.00	739.20	442.40	413.00
600	510173	VIBRAMYCIN SYRUP	SUSP 60 ML	338.40	350.40	349.20	246.00	139.20
600	511413	RIMACTAN SYP	SYP 50 ML	129.85	283.55	384.25	545.90	609.50
600	512023	DEXACILLIN 125 MG SUSP	SUSP 60 ML	423.30	576.30	766.70	329.80	302.60
600	512024	DEXACILLIN 250 MG SUSP	SUSP 60 ML	914.85	798.00	1299.60	732.45	1299.60
600	512025	DEXACILLIN 10 ML DROPS	DROPS 10 ML.	14.85	191.70	243.00	228.15	211.95
600	512071	MYCOSTATIN ORAL SUSP.	12 DOSE	0.00	0.00	207.35	727.90	725.00
600	512123	VELOSEF 125 MG SUSP	SUSP 60 ML	594.00	345.00	543.00	423.00	903.00
600	512124	VELOSEF 250 MG SUSP	SUSP 60 ML	437.00	327.75	802.75	712.50	1425.00
600	512125	VELOSEF 250 MG. VIAL	VIAL 1 ML	0.00	0.00	111.15	103.35	142.35
600	515322	FLUMOX DRY MIX	SYP 60 ML	0.00	0.00	0.00	0.00	1200.00
600	516103	AMPICYN 125 MG DRY SYRUP	SYP 60 ML	0.00	0.00	0.00	0.00	0.00
600	516104	AMPICYN 250 MG DRY SYRUP	SYP 60 ML	0.00	0.00	0.00	0.00	0.00
600	516304	IBIAMOX 125 MG DRY SYRUP	SYP 60 ML	0.00	0.00	0.00	0.00	945.00
600	516305	IBIAMOX 250 MG DRY SYRUP	SYP 60 ML	0.00	0.00	0.00	0.00	1625.00
600	516325	IBILEX 125 MG. DRY SYRUP	SYP 60 ML	0.00	0.00	0.00	0.00	28.50
600	516326	IBILEX 250 MG. DRY SYRUP	SYP 60 ML	0.00	0.00	0.00	0.00	48.00
TOTALS				20086.70	23184.35	27929.75	31119.45	43504.25

Compiled by MIRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VALUE TERMS BROKEN
DOWN BY INDIVIDUAL PHARAMCEUTICAL

FOR YEARS (81/81 - 85/86)

UNIT : IN L.E. 1000

PAGE NO : 8

SUBGROUP : ANTIMALARIALS

IN VALUE TERMS

CSF CODE	COMMERCIAL CODE	TRADE NAME	PACK	VALUE 81/82	VALUE 82/83	VALUE 83/84	VALUE 84/85	VALUE 85/86
700	502103	DAGRINOL TAB	TAB 100 ST	142.50	150.00	265.00	167.50	135.00
700	503138	CIDOQUINE 250 MG. TAB	TAB 20	8.40	3.75	3.45	3.45	5.85
700	505131	CAMOQUIN TAB	TAB 100	10.20	7.65	7.65	10.20	12.75
TOTALS				161.10	161.40	276.10	181.15	153.60

Compiled by MIRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VALUE TERMS BROKEN
DOWN BY INDIVIDUAL PHARAMCEUTICAL

FOR YEARS (81/81 - 85/86)

UNIT : IN L.E. 1000

PAGE NO : 9

SUBGROUP : ANTIHISTAMINICS

CSP CODE	COMMERCIAL CODE	TRADE NAME	PACK	IN VALUE TERMS VALUE 81/82	VALUE 82/83	VALUE 83/84	VALUE 84/85	VALUE 85/86
1000	501037	ALLERGYL SYP	SYP 120 ML.	160.65	182.25	222.75	273.60	292.95
1000	502271	PHENERGAN SYP.	SYP 120 ML.	0.00	72.80	237.90	243.10	241.50
1000	506010	AVIL SYP	SYP 100 ML.	84.15	94.35	303.45	310.25	238.85
1000	507525	PERIACTIN SYP	SYP 114 ML	701.35	669.50	773.50	540.15	466.05
1000	508615	PIRAFENE 2 MG/5 SYP	SYP 120 ML.	36.45	46.35	30.60	38.25	25.65
1000	509821	PROMANTINE SYRUP	SYP 125 ML	111.60	66.15	85.50	98.10	74.70
1000	511056	TAVEGYL 100 ML. SYP	SYP 120 ML.	584.50	533.75	852.25	1393.00	1442.00
TOTALS				1678.70	1665.15	2505.95	2896.45	2782.00

Compiled by MIRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VALUE TERMS BROKEN DOWN BY INDIVIDUAL PHARAMCEUTICAL

FOR YEARS (81/81 - 85/86)

UNIT : IN L.E. 1000

PAGE NO : 10

SUBGROUP : CHEMOBIOTICS

CSF CODE	COMMERCIAL CODE	TRADE NAME	PACK	IN VALUE TERMS VALUE 81/82	VALUE 82/83	VALUE 83/84	VALUE 84/85	VALUE 85/86
1300	503124	CIDOCETINE BISMUTH SUPP	SUPP 4	311.35	240.50	336.70	530.40	406.25
1300	509925	BISMOPHENICOL SUPP.	SUPP 3	248.05	156.20	375.10	794.20	816.75
TOTALS				559.40	396.70	711.80	1324.60	1223.00

Compiled by MIRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VALUE TERMS BROKEN DOWN BY INDIVIDUAL PHARAMCEUTICAL

FOR YEARS (81/81 - 85/86)

UNIT : IN L.E. 1000

PAGE NO : 11

SUBGROUP : ANTITUBERCULOUS

IN VALUE TERMS

CSP CODE	COMMERCIAL CODE	TRADE NAME	PACK	VALUE 81/82	VALUE 82/83	VALUE 83/84	VALUE 84/85	VALUE 85/86
1400	503334	ISOCID 50 MG TAB	TAB 100	13.35	10.50	15.30	16.35	15.60
1400	509391	INHIBEX TAB	TAB 60	0.50	3.75	29.50	26.00	27.25
1400	511408	RIMACTAZID C.T.	TAB 80 ST	0.00	0.00	0.00	80.10	160.20
1400	511660	RIMACTAZID C.T.	TAB 8 ST	0.00	0.00	0.00	315.00	425.25
TOTALS				13.85	14.25	44.80	437.45	628.30

Compiled by MIRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VALUE TERMS BROKEN
DOWN BY INDIVIDUAL PHARAMCEUTICAL

FOR YEARS (81/81 - 85/86)

UNIT : IN L.E. 1000

PAGE NO : 12

SUBGROUP : SULPHA + TRIHETHOPRIM

IN VALUE TERMS

CSP CODE	COMMERCIAL CODE	TRADE NAME	PACK	VALUE 81/82	VALUE 82/83	VALUE 83/84	VALUE 84/85	VALUE 85/86
1600	502329	SUPRISTOL SUSP	SYP 60 ML	0.00	0.00	0.00	0.00	97.85
1600	502336	SEPTAZOLE SUSP	SUSP 100 ML	434.50	401.50	683.10	817.30	980.10
1600	505343	ENTRIM SUSP	SUSP 100 ML	0.00	26.40	151.20	294.00	235.20
1600	507542	CHEMOTRIM SUSP	SUSP 100 ML	179.55	194.75	260.30	252.70	156.75
1600	508637	SUTRIM SUSP	SUSP 100 ML	389.55	534.45	457.80	787.50	1044.95
1600	509934	LIDAPRIM SUSP	SUSP 60 ML	0.00	0.00	0.00	0.00	109.20
TOTALS				1003.60	1157.10	1552.40	2061.50	2625.95

Compiled by MIRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VALUE TERMS BROKEN DOWN BY INDIVIDUAL PHARAMCEUTICAL

FOR YEARS (81/81 - 85/86)

UNIT : IN L.E. 1000

PAGE NO : 13

SUBGROUP : CORTICOSTEROIDS

IN VALUE TERMS

CSP CODE	COMMERCIAL CODE	TRADE NAME	PACK	VALUE 81/82	VALUE 82/83	VALUE 83/84	VALUE 84/85	VALUE 85/86
2310	3211	HYDROCORTISONE I.V. 100 ML.	1 AMP. + VL	0.00	270.00	270.00	324.00	648.00
2310	23088	SOLUDACORTEN 250 MG.	B X 1 AMP.	42.90	57.20	114.40	78.65	107.25
2310	23089	SOLU DACOTRIN 25 MG.	B X 3 AMP.	48.00	48.00	56.00	32.00	52.00
2310	23131	FORTECORTIN 8 MG. 2 CC	B X 100 AMP.	49.40	33.25	44.65	115.90	91.20
2310	53000	DEPO-MEDROL 40 MG./ML	B X DISP.VL 2ML	0.00	0.00	195.30	297.60	632.40
2310	267068	CELESTONE CHRONODASE	1 VIAL	0.00	0.00	0.00	15.00	20.00
2310	267076	DIPROFOS INJ. 2cc	B X 1 AMP	0.00	0.00	0.00	20.80	20.80
2310	364006	DEXAMETHASONE	B X AMP.	0.00	0.00	0.00	130.00	130.00
2310	501358	PHENADONE SYP	SYP 100 ML	859.50	849.60	911.70	981.90	757.80
2310	503174	DEXASCHEROSON 5 MG IM AMP	AMP 1	217.20	333.60	407.40	550.80	603.00
2310	505485	FLEBOCORTID 100 MG AMP	AMP 1	6.40	8.00	4.80	13.60	50.40
2310	512052	KENACORT-A-I.M 40 MG VIAL	VIAL 1 ML	644.00	532.00	1183.00	1242.50	1851.50
2310	515140	CODELCORTON T.B.A. VIAL	VIAL 3	0.00	0.00	0.00	0.00	2.70
2310	515194	DECADRON VIAL	VIAL 1	0.00	0.00	0.00	0.00	4.50
2310	515670	SOLU-CORTEF 100 MG	VIAL 1	0.00	0.00	0.00	0.00	1.95
TOTALS				1867.4	2131.65	3187.25	3872.75	4973.15

Compiled by MIRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VALUE TERMS BROKEN DOWN BY INDIVIDUAL PHARAMCEUTICAL

FOR YEARS (81/81 - 85/86)

UNIT : IN L.E. 1000

PAGE NO : 14

SUBGROUP : CONTRACEPTIVES

IN VALUE TERMS

CSP CODE	COMMERCIAL CODE	TRADE NAME	PACK	VALUE 81/82	VALUE 82/83	VALUE 83/84	VALUE 84/85	VALUE 85/86
2320	503415	MICROVLAR TAB	TAB 21	277.90	409.15	772.80	841.75	876.75
2320	503640	TRIVLAR TAB	TAB 21	0.00	0.00	0.00	0.00	223.20
2320	503998	PRIMOVLAR	TAB 21	198.55	155.20	147.70	146.85	216.20
2320	503999	ANOVLAR-1	TAB 21	152.00	207.35	200.00	126.55	201.15
2320	505611	NORDETTE	TAB 21 X 5 ST	525.00	525.00	700.00	700.00	875.00
2320	520001	LIPPES LOOP	1 LP.	0.00	0.00	0.00	0.00	0.00
2320	520002	COPPER T LOOP	1 LP.	0.00	0.00	0.00	0.00	0.00
2320	520003	CONDOMS	BX 100	0.00	0.00	0.00	0.00	0.00
2320	520004	NEOSAMPOON	20 T	0.00	0.00	0.00	0.00	0.00
2320	520006	ORTHO DIAPHRAGM	1 DIAPH.	0.00	0.00	0.00	0.00	0.00
TOTALS				1153.45	1296.70	1820.50	1815.15	2392.30

Compiled by MIRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VALUE TERMS BROKEN DOWN BY INDIVIDUAL PHARAMCEUTICAL

FOR YEARS (81/81 - 85/86)

UNIT : IN L.E. 1000

PAGE NO : 15

SUBGROUP : VACCINES

CSP CODE	COMMERCIAL CODE	TRADE NAME	PACK	IN VALUE TERMS VALUE 81/82	VALUE 82/83	VALUE 83/84	VALUE 84/85	VALUE 85/86
2701	513006	B.C.G. VACCINE	1 DOSE	42.30	0.00	92.00	93.00	175.00
2701	513007	DIPHTHERIA TOXOID	1 AMP	3.00	3.00	3.40	5.00	25.00
2701	513009	DIPHTHERIA AND TETANUS VACCINE	1 VIAL	22.96	260.68	278.88	190.68	339.94
2701	513010	TRIPLE VACCINE	3 AMP	639.00	938.40	647.20	1040.20	1179.60
2701	513011	MEASLES VACCINE	1 AMP	160.00	200.00	253.80	400.00	700.00
2701	513013	TETANUS TOXOID	1 VIAL	16.50	24.00	22.50	59.25	45.00
2701	513014	POLIOMYELITIS VACCINE	1 DOSE	291.88	1148.40	968.64	989.96	836.55
TOTALS				1175.64	2574.48	2266.42	2778.09	3300.09

Compiled by IRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VALUE TERMS BROKEN DOWN BY INDIVIDUAL PHARAMCEUTICAL

FOR YEARS (81/81 - 85/86)

UNIT : IN L.E. 1000

PAGE NO : 16

SUBGROUP : SERA

CSP CODE	COMMERCIAL CODE	TRADE NAME	PACK	IN VALUE TERMS VALUE 81/82	VALUE 82/83	VALUE 83/84	VALUE 84/85	VALUE 85/86
2702	513002	DIPHTHERIA ANTITOXIN 20,000 U	1 AMP	100.00	100.00	125.00	150.00	200.00
2702	513004	TETANUS ANTITOXIN 1.500 U	5 AMP	749.65	1354.65	1115.95	589.60	379.50
2702	513005	TETANUS ANTITOXIN 30,000 U	5 AMP	217.80	217.80	242.00	217.80	290.40
TOTALS				1067.45	1672.45	1482.95	957.40	869.90

Compiled by MIRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VALUE TERMS BROKEN
DOWN BY INDIVIDUAL PHARANCEUTICAL

FOR YEARS (81/81 - 85/86)

UNIT : IN L.E. 1000

PAGE NO : 17

SUBGROUP : GAMMA GLOBULINS

IN VALUE TERMS

CSP CODE	COMMERCIAL CODE	TRADE NAME	PACK	VALUE 81/82	VALUE 82/83	VALUE 83/84	VALUE 84/85	VALUE 85/86
2703	465002	GAMMA GLOBULIN 16.5 %	VL 2 ML.	52.00	52.00	52.00	78.00	78.00
2703	513003	GAMMA GLOBULIN 16%	1 AMP	39.00	7.80	44.20	83.20	91.00
TOTALS				91.00	59.80	96.20	161.20	169.00

Compiled by MIRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VALUE TERMS BROKEN DOWN BY INDIVIDUAL PHARAMCEUTICAL

FOR YEARS (81/81 - 85/86)

UNIT : IN L.E. 1000

PAGE NO : 18

SUBGROUP : MESCILLINEOUS

IN VALUE TERMS

CSP CODE	COMMERCIAL CODE	TRADE NAME	PACK	VALUE 81/82	VALUE 82/83	VALUE 83/84	VALUE 84/85	VALUE 85/86
2B00	509329	ETHAMIVAN DROPS	DROPS 10 ML.	18.20	14.70	13.65	13.30	14.35
TOTALS				18.20	14.70	13.65	13.30	14.35

Compiled by MIRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VALUE TERMS BROKEN DOWN BY INDIVIDUAL PHARAMCEUTICAL

FOR YEARS (81/81 - 85/86)

UNIT : IN L.E. 1000

PAGE NO : 19

SUBGROUP : EXPECTORANTS / MYCOLYTICS

IN VALUE TERMS

CSP CODE	COMMERCIAL CODE	TRADE NAME	PACK	VALUE 81/82	VALUE 82/83	VALUE 83/84	VALUE 84/85	VALUE 85/86
3301	501191	EXPECTYL SYP	SYP 120 ML	672.10	1571.90	608.30	1076.70	657.90
3301	501430	SOLVIN SYP	SYP 60 CC	56.70	479.25	812.70	260.80	90.45
3301	501453	SOLVIN DROPS	DROPS 15 ML	0.00	0.00	0.00	47.00	126.00
3301	503078	BISOLVON SOLUTION 4 MG / 2 ML	SOL 40 ML	0.00	0.00	125.05	270.60	340.30
3301	503079	BISOLVON ELIXIR 4 MG/ 5ML	ELIX. 115 ML	0.00	165.30	912.00	1314.80	2046.70
3301	503147	COLDAL SYP	SYP 120 ML	676.50	651.75	809.60	588.50	725.45
3301	503421	NEOCOLDAL SYP	SYP 120 ML	896.40	780.00	776.40	744.00	991.20
3301	505468	ISILIN SYRUP	SYP 120 ML	1339.00	1229.50	921.50	1030.00	869.00
3301	506013	AVIPECT SYP 100 ML	SYP 100 ML	1744.60	2531.10	3089.30	3976.50	3687.20
3301	507512	BRONCHISTAL SYP	SYP 120 ML	1904.65	2283.60	2144.45	2133.45	2057.00
3301	507524	SEDALINE SYP	SYP 125 ML	533.00	646.50	597.50	598.50	459.00
3301	508609	BRONCHOLASE SYP	SYP 120 ML	2945.00	2418.50	2560.50	2454.50	3035.50
TOTALS				10767.95	12757.40	13357.90	14515.55	15124.20

Compiled by MIRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VALUE TERMS BROKEN
DOWN BY INDIVIDUAL PHARAMCEUTICAL

FOR YEARS (81/81 - 85/86)

UNIT : IN L.E. 1000

PAGE NO : 21

SUBGROUP : BRONCHODILATORS

CSP CODE	COMMERCIAL CODE	TRADE NAME	PACK	IN VALUE TERMS VALUE 81/82	VALUE 82/83	VALUE 83/84	VALUE 84/85	VALUE 85/86
3303	12501	BABY-RHINOL	BT 120 ML	0.00	210.00	210.00	252.00	252.00
3303	349502	RHINOPRONT SYRUP	BT 90 ML	0.00	0.00	220.00	242.00	220.00
3303	502308	SALBOVENT SYP	SYP 120 ML	0.00	82.80	175.50	284.40	382.50
3303	503008	ALUPENT 1 ML IM AMP	AMP 6	3.20	4.00	5.60	4.00	4.80
3303	503085	BRICANYL SYP	SYP 120 ML	0.00	0.00	145.70	240.25	398.35
3303	505686	ASMASONE DROPS	DROPS 10 ML	23.60	24.00	35.20	64.40	69.20
3303	508007	EFANOL 2 ML IM AMP	AMP 6	102.20	150.50	127.05	141.40	100.45
3303	508619	POLARAMINE EXPECT SYR.	SYP 120 ML	0.00	0.00	0.00	0.00	0.00
3303	511671	TRIAMINIC SYRUP	BT 100 ML	0.00	0.00	1050.00	1200.00	1260.00
3303	511673	TRIAMINIC DROPS	BT 15 ML	0.00	0.00	300.00	330.00	420.00
3303	511763	ZADITEN PEDIATRIC SYP	SYP 100 ML	0.00	159.00	302.10	376.30	439.90
TOTALS				129.00	630.30	2571.15	3134.75	3547.20

Compiled by MIRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VALUE TERMS BROKEN DOWN BY INDIVIDUAL PHARAMCEUTICAL

FOR YEARS (81/81 - 85/86)

UNIT : IN L.E. 1000

PAGE NO : 22

SUBGROUP : MULTIVITAMINS

IN VALUE TERMS

CSP CODE	COMMERCIAL CODE	TRADE NAME	PACK	VALUE 81/82	VALUE 82/83	VALUE 83/84	VALUE 84/85	VALUE 85/86
3500	501285	MEDIVIT SYP	SYP 100 ML	1987.20	1276.80	1261.20	1202.40	1139.40
3500	502381	VICIBEX SYP	SYP 120 ML	447.15	489.50	377.30	215.05	170.50
3500	503262	FRUITAL SYP	SYP 120 ML	15.60	1166.10	1089.40	1375.40	1576.90
3500	505302	ECAPLEX C SYRUP	SYP 120 ML	326.70	318.45	355.85	367.40	301.55
3500	507566	VI-DAYLIN SYR.	SYP 90 ML	0.00	0.00	75.00	373.50	714.00
3500	507591	NEOTOTAVINE DROPS	DROPS 15 ML	139.50	260.10	154.35	104.40	102.60
3500	508641	VAROLEX SYP	SYP 120 ML	3772.20	4308.60	5576.40	5989.80	5496.00
3500	508697	MULTIVAROL DROPS	DROPS 15 ML	1372.00	1735.00	1359.00	987.50	365.50
3500	509334	POLYVIT DROPS	DROPS 10 ML	60.60	115.20	132.00	139.80	144.00
3500	509805	BECO C SYRUP	SYP 125 ML	405.60	415.35	407.55	499.85	519.35
3500	512101	THERAGRAN LIQ	LIQ 90 ML	0.00	577.50	695.00	725.00	1152.50
3500	515056	BECOZYM SYP	SYP 125 ML	0.00	0.00	0.00	0.00	540.00
TOTALS				8526.55	10662.60	11483.05	11980.10	12222.70

Compiled by MIRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VALUE TERMS BROKEN DOWN BY INDIVIDUAL PHARAMCEUTICAL

FOR YEARS (81/81 - 85/86)

UNIT : IN L.E. 1000

PAGE NO : 23

SUBGROUP : RESTORATIVES / PARENTRAL

IN VALUE TERMS

CSP CODE	COMMERCIAL CODE	TRADE NAME	PACK	VALUE 81/82	VALUE 82/83	VALUE 83/84	VALUE 84/85	VALUE 85/86
4100	50289	SODIUM-BICARBONATE 8.4 %	B X 1 VL 50 CC	0.00	6.00	10.00	16.00	16.00
4100	455009	HUMAN ALBUMIN 20 % 50 ML.	B X 1 VIAL	75.00	100.00	225.00	300.00	350.00
4100	504036	DEXTROSE 5% 500 ML AMP	PACK 1	505.80	1342.80	819.00	1005.30	1302.30
4100	504038	DEXTROSE 10 % SOLUTION	PACK 1	0.00	0.00	21.00	24.00	23.00
4100	504041	DEXTROSE IN NORMAL SALINE	SOL 500 ML	107.10	108.00	108.00	134.00	160.20
4100	504096	RINGERS LACTATED SOLUTION	SOL. 500 ML	0.00	0.00	95.00	95.00	125.40
4100	504100	NORMAL SALINE 500 ML AMP	AMP 1	263.70	304.20	528.30	514.80	851.40
4100	504141	SEPACK DEXTROSE 5% BAG	BAG 1	0.00	0.00	0.00	403.20	259.20
4100	504143	SEPACK DEXTROSE IN NORMAL SALINE	BAG 1	0.00	0.00	0.00	0.00	64.00
4100	504146	SEPACK N. SALINE 500 ML BAG	BAG 1	0.00	0.00	0.00	115.20	813.60
4100	505212	DEXTROSE 5% SOLUTION	SOL 500 ML	1131.00	890.30	1651.55	1445.65	1692.00
4100	505236	DEXTROSE 5% IN NORM SALINE SOL	SOL 500 ML	366.85	339.30	355.25	414.70	121.80
4100	505640	NORMAL SALINE SOLUTION	SOL 500 ML	809.10	651.05	1032.40	752.55	693.10
4100	505812	RINGER LACTATED SOLUTION	SOL 500 ML	120.40	184.80	239.40	179.20	151.20
4100	505837	SODIUM BICARBONATE 5 %	SOL 500 ML	0.00	0.00	0.00	34.80	46.40
4100	508087	DEXTROSE 25 % 20 ML IM AMP	AMP 5 X 5	43.00	29.00	36.00	49.00	55.00
4100	509835	K CHLOR SOLUTION	SOL 100 ML	80.70	65.10	45.60	55.20	54.00
TOTALS				3502.65	4020.55	5166.50	5548.60	6768.60

Compiled by MIRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VALUE TERMS BROKEN DOWN BY INDIVIDUAL PHARAMCEUTICAL

FOR YEARS (81/81 - 85/86)

UNIT : IN L.E. 1000

PAGE NO : 24

SUBGROUP : RESTORATIVES / ORAL

IN VALUE TERMS

CSP CODE	COMMERCIAL CODE	TRADE NAME	PACK	VALUE 81/82	VALUE 82/83	VALUE 83/84	VALUE 84/85	VALUE 85/86
4106	503995	MOALGAT EL GAFAF 5.5 GM.	1 PACK	229.00	174.78	399.64	1201.09	810.76
4106	503996	MOALGAT EL GAFAF M.D.H. 5.5 MG.	1 PACK	0.00	0.00	0.00	0.00	0.00
4106	503997	REHYDRAN	10 PACKS	231.75	197.10	437.85	37.35	0.00
TOTALS				460.75	371.88	837.49	1238.44	810.76

Compiled by MIRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VALUE TERMS BROKEN DOWN BY INDIVIDUAL PHARAMCEUTICAL

FOR YEARS (81/81 - 85/86)

UNIT : IN L.E. 1000

PAGE NO : 25

SUBGROUP : SEDATIVES / HYPNOTICS

IN VALUE TERMS

CSP CODE	COMMERCIAL CODE	TRADE NAME	PACK	VALUE 81/82	VALUE 82/83	VALUE 83/84	VALUE 84/85	VALUE 85/86
4200	503101	CID WATER	SYP 100 ML	264.90	230.70	228.30	325.50	96.00
4200	505148	CHLORAL SYRUP	SYP 120 ML	28.35	24.30	20.25	13.05	11.25
4200	507568	WALIRINE SYP	SYP 125 ML	448.70	531.65	716.80	641.55	652.05
4200	516145	AQUA BABY SYRUP	SYP 125 ML	0.00	0.00	0.00	0.00	400.00
TOTALS				741.95	786.65	965.35	980.10	1159.30

Compiled by MIRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VALUE TERMS BROKEN DOWN BY INDIVIDUAL PHARAMCEUTICAL

FOR YEARS (81/81 - 85/86)

UNIT : IN L.E. 1000

PAGE NO : 26

SUBGROUP : SPASMOLYTICS

IN VALUE TERMS

CSF CODE	COMMERCIAL CODE	TRADE NAME	PACK	VALUE 81/82	VALUE 82/83	VALUE 83/84	VALUE 84/85	VALUE 85/86
4400	506011	BARALGIN INFANT SUPP	SUPP 5	90.75	79.20	48.40	55.00	44.55
4400	507460	SPASMOPYRALGIN M INF SUPP	SUPP 5	110.40	78.40	94.00	116.00	123.20
4400	507586	PIPTAL PED DROPS	DROPS 15 ML	55.20	117.00	297.00	72.60	177.00
4400	509337	SPASMOTAL DROPS	DROPS 10 ML	171.50	130.50	167.50	289.50	461.50
4400	511391	SPASMO CIBALGIN CH	SUPP 5 ST	897.65	900.25	1519.05	1819.35	1595.75
TOTALS				1325.50	1305.35	2125.95	2352.45	2402.00

Compiled by MIRCOTECH, M. Gamaledin

CONSUMPTION FIGURES IN VALUE TERMS BROKEN DOWN BY INDIVIDUAL PHARAMCEUTICAL

FOR YEARS (81/81 - 85/86)

UNIT : IN L.E. 1000

PAGE NO : 27

SUBGROUP : LACTOSE - FREE MILK

CSP CODE	COMMERCIAL CODE	TRADE NAME	PACK	IN VALUE TERMS VALUE 81/82	VALUE 82/83	VALUE 83/84	VALUE 84/85	VALUE 85/86
4700	338003	SIMILAC ISOMEL	TN 4554 GM.	240.00	420.00	1000.00	1000.00	1000.00
4700	344019	BEBELAC FREE LACTOSE	TN 400 GM.	0.00	0.00	0.00	0.00	175.00
4700	376006	PROSEBEE	TN 400 GM.	60.00	75.00	125.00	375.00	750.00
TOTALS				300.00	495.00	1125.00	1375.00	1925.00

Compiled by MIRCOTECH, M. Gamaledin

TABLE (VI) - 5

TOTAL CONSUMPTION FIGURES IN
VALUE TERMS BROKEN DOWN BY SUBGROUP

FOR YEARS (81/82 - 85-86)

TOTAL CONSUMPTION FIGURES IN VALUE
TERMS BROKEN DOWN BY SUBGROUP

FOR YEARS (81/81 - 85/86)

UNIT : IN 1000 L.E.

AGE NO : 1

IN VALUE TERMS

CSF CODE	SUBGROUP NAME	VALUE 81/82	VALUE 82/83	VALUE 83/84	VALUE 84/85	VALUE 85/86
200	ANALGESICS / ANTIPYRETICS	1066.95	1494.75	1854.15	2491.05	2629.65
502	ANTIMOTILITY DRUGS	193.60	181.60	251.20	537.20	341.80
505	ANTIAMOEBICS	256.65	381.35	662.65	830.85	1484.80
508	ANTIEMETICS	720.00	997.20	1140.60	1443.00	1914.40
509	ANTIDIARRHEALS	1773.50	2713.65	3725.35	5408.15	7480.05
600	ANTIBIOTICS	20086.70	23184.35	27929.75	31119.45	43504.25
700	ANTIMALARIALS	161.10	161.40	276.10	181.15	153.60
1000	ANTIHISTAMINICS	1678.70	1665.15	2505.95	2896.45	2782.00
1300	CHEMOBIOTICS	559.40	396.70	711.80	1324.60	1223.00
1400	ANTITUBERCULOUS	13.85	14.25	44.80	437.45	628.30
1600	SULPHA + TRIMETHOPRIM	1003.60	1157.10	1552.40	2061.50	2625.95
2310	CORTICOSTEROIDS	1867.40	2131.65	3187.26	3812.70	4973.50
2320	CONTRACEPTIVES	1153.45	1296.70	1820.50	1815.15	2372.70
2701	VACCINES	1175.64	2574.48	2266.43	2778.10	3300.09
2702	SERA	1067.45	1672.45	1482.95	957.40	869.90
2703	GAMMA GLOBULINS	91.00	59.80	96.20	161.20	169.00
2800	MESCILLINEOUS	18.20	14.70	13.65	13.30	14.35
3301	EXPECTORANTS / MYCOLYTICS	10767.95	12757.40	13357.90	14515.55	15124.20
3302	COUGH SEDATIVES	1678.65	1356.85	2808.30	2996.00	2975.00
3303	BRONCHODILATORS	129.00	630.30	2571.15	3134.75	3547.20
3500	MULTIVITAMINS	8526.55	10662.60	11483.05	11980.10	12222.70
4100	RESTORATIVES / PARENTRAL	3502.65	4020.55	5166.50	5548.60	6768.60
4106	RESTORATIVES / ORAL	460.75	371.88	837.50	1238.44	810.76
4200	SEDATIVES / HYPNOTICS	741.95	786.65	965.35	980.10	1159.30
4400	SPASMOLYTICS	1325.50	1305.35	2125.95	2352.45	2402.00
4700	LACTOSE - FREE MILK	300.00	495.00	1125.00	1375.00	1925.00
TOTAL :		60320.19	72483.86	89962.43	102377.70	123421.00

Compiled by MICROTECH, M. Gamaledin

TABLE (VI) - A

CONSUMPTION PATTERN OF C.S.P. IN
VOLUME TERMS BROKEN DOWN BY SUBGROUP

FOR YEARS (81/82 - 85-86)

CONSUMPTION PATTERN OF C.S.P. IN VOLUME
TERMS BROKEN DOWN BY SUBGROUP

FOR YEARS (81/82 - 85/86)

UNIT : IN 1000 PACKS

PAGE NO : 1

IN % QUANTITY TERMS

CSP CODE	SUBGROUP NAME	QUANTITY % 81/82	QUANTITY % 82/83	QUANTITY % 83/84	QUANTITY % 84/85	QUANTITY % 85/86
200	ANALGESICS / ANTIPYRETICS	1.75	1.86	2.33	2.58	2.68
502	ANTIMOTILITY DRUGS	0.18	0.13	0.17	0.24	0.16
505	ANTIAMOEBICS	0.13	0.15	0.25	0.27	0.47
508	ANTIEMETICS	0.91	0.93	1.05	1.13	1.04
509	ANTIDIARRHEALS	2.36	2.26	2.88	3.52	3.99
600	ANTIBIOTICS	33.86	28.36	25.00	21.08	22.93
700	ANTIMALARIALS	0.09	0.05	0.07	0.04	0.05
1000	ANTIHISTAMINICS	1.66	1.21	1.64	1.45	1.33
1300	CHEMOBIOTICS	0.70	0.37	0.66	1.06	0.97
1400	ANTITUBERCULOUS	0.07	0.05	0.12	0.13	0.14
1600	SULPHA + TRIMETHOPRIM	0.72	0.62	0.80	0.90	1.12
2310	CORTICOSTEROIDS	1.19	1.02	1.25	1.29	1.39
2320	CONTRACEPTIVES	6.11	4.90	5.27	3.88	5.70
2701	VACCINES	11.32	24.76	21.65	20.85	20.33
2702	SERA	1.06	1.41	1.14	0.53	0.35
2703	GAMMA GLOBULINS	0.03	0.01	0.02	0.03	0.03
2800	MESCILLINEOUS	0.04	0.02	0.02	0.02	0.02
3301	EXPECTORANTS / MYCOLYTICS	14.09	11.71	10.96	9.85	9.90
3302	COUGH SEDATIVES	2.25	1.35	1.97	1.72	1.41
3303	BRONCHODILATORS	0.27	0.40	1.05	1.11	1.18
3500	MULTIVITAMINS	11.16	9.44	9.82	8.37	7.56
4100	RESTORATIVES / PARENTRAL	2.24	2.04	2.32	2.23	2.81
4106	RESTORATIVES / ORAL	4.23	2.43	5.43	13.49	10.60
4200	SEDATIVES / HYPNOTICS	1.68	1.32	1.57	1.38	1.20
4400	SPASMOLYTICS	1.70	1.23	1.92	1.82	1.87
4700	LACTOSE - FREE MILK	0.22	0.27	0.61	0.61	0.78
TOTAL :		100.00 %	100.00 %	100.00 %	100.00 %	100.00 %

Compiled by MICROTECH, M. Gamaledin

CHR(15)

SET PRINT OFF

ANNEX (VI - 1) CONSUMPTION PATTERN GRAPHS.

* Observed = Actual Consumption
* Predicted = Forecasted Consumption.

ν_2 = analogous to rotational ν_1 = band

The rotation band of ν_2 on ν_1

ν_2 = 4235.4 x 10^{-3} ± 3.27 $\pm$ x 10^{-3} ν_1



V_3 = antimotility V_1 = No. of children

The regression line of V_3 on V_1

$$V_3 = -1301.7383 \times 10^3 + 181.8823 \times 10^3 V_1$$



V_4 – [illegible] V – [illegible]

The regression line of V_4 on V_1

$V_4 = 4.98.8 \times 10^3 + 200.4 \times 10^3 V_1$



V_5 = [illegible] V_1 = [illegible]

The equation line of V_5 on V_1

$V_5 = 1886.2 \times 10^3 + 188.5 \times 10^3 V_1$



V_7 = antibiotics V_1 = Ns of children

The regression line of V_7 on V_1

$$V_7 = 30410.8623 \times 10^3 + 1860.8803 \times 10^3 V_1$$



V_8 = antimalarials — V_1 = No of children

The regression line of V_8 on V_1

$$V_8 = 219.8202 \times 10^3 - 12.7280 \times 10^3 V_1$$



V_g = antihistaminic V_1 = No of children

The regression line of V_g on V_1

$$V_g = 5966.9938 \times 10^3 - 302.2475 \times 10^3 \, V_1$$



Y_{10} = Change in Time Y_1 = Time

The regression line of Y_{10} on Y_1

$Y_{10} = 1.30 \times 10^{3} + 2.56 \times 10^{3} Y_1$



V_{II} = antituberculous V_I = Tiers

The regression line of V_{II} on V_I

$V_{II} = 53.8 \times 10^3 + 60.4 \times 10^3 V_I$



V_{12} = Sulphonamide V_1 = Tuna

The regression line of V_{12} on V_1

$V_{12} = 1575.6 \times 10^{-5} + 373.0 \times 10^{-5} V_1$



V_{13} = Cattlehead V_1 = Tank

The regression line of V_{13} on V_1

$V_{13} = 22.85 + 3.82 \times 10^{3} V_1$



V_{14} = Contraceptive V_1 = No. of children

The regression line of V_{14} on V_1

$$V_{14} = -19639.017 \times 10^3 + 3242.2069 \times 10^3 \, V_1$$



V_{15} = Vacin V_1 = No of children

The regression line of V_{15} on V_1

$V_{15} = -159663.2164 \times 10^3 + 21994.1381 \times 10^3 V_1$



V_{16} = Serum V_1 = No. of children

The regression line of V_{16} on V_1

$V_{16} = 11155.4946 \times 10^3 - 1070.0246 \times 10^3 V_1$



V_{18} = Miscellaneous V_1 = No. of children

The regression line of V_{18} on V_1

$$V_{18} = 128.0254 \times 10^3 - 9.5583 \times 10^3 V_1$$



V_{19} = Expectorant $\qquad$ V_1 = No. of children

The regression line of V_{19} on V_1

$$V_{19} = 307.5045 \times 10^3 + 2240.3938 \times 10^3 \, V_1$$



V_{20} = Cough sedative V_1 = No. of children

The regression line of V_{20} on V_1

$$V_{20} = -1453.1582 \times 10^3 + 512.4644 \times 10^3 \, V_1$$



V_{21} = Branch velocity V_1 = Time

The regression line of V_{21} on V_1

$V_{21} = 1581.8 \times 10^{-3} + 60.7 \times 10^{-3} V_1$



V_{22} = Multivitamins V_1 = No. of children

The regression line of V_{22} on V_1

$$V_{22} = 3014.8566 \times 10^3 + 1531.3058 \times 10^3 V_1$$



V_{23} – Calibration Period $\qquad V_1$ – Time

The regressed line of $V_{23} - V_1$

$V_{23} = 4335.4 \times 10^3 \rightarrow 7335.4 \times 10^3 V$



V_{24} = Restoration oral V_1 = No. of children

The regression line of V_{24} on V_1

$$V_{24} = -188392.2615 \times 10^3 + 22628.0348 \times 10^3 \, V_1$$



V_{25} = Scabbrives $\qquad$ V_1 = No. of children

The regression line of V_{25} on V_1

$$V_{25} = -1859.1021 \times 10^3 + 497.2903 \times 10^3 \, V_1$$



V_{26} = Spusoma eglise $\qquad$ V_1 = Tuna

The regression line of V_{26} on V_1

$$V_{26} = 3125.8 \times 10^3 + 631.8 \times 10^3 V_1$$



V_2Y = Labour for milk V_1 = Time

The regression line of V_2Y on V_1

$V_2Y = 972.6 \times 10^3 + 364.4 \times 10^3 V_1$



(VI) - B LOCAL PRODUCTION / IMPORTS OF C.S.P.

* Almost all C.S.P.'s needs are satisfied by local production. Only 24 pharmaceutical products (out of 245 products) are imported as finished products and 8 products (vaccines & sera) as bulk pharmaceuticals to be repacked locally.

* Local production covers 100 % of the needs of 18 subgroups of C.S.P.'s (out of 26 subgroups).

* Table (VI-7) shows the annual local production and importation of C.S.P.'s in value and volume terms, broken down by subgroup in 1985/1986.

TABLE (VI-7): LOCAL PRODUCTION, IMPORTATION OF C.S.P. IN VALUE AND VOLUME TERMS (1985/1986).

GROUP	KIND	VALUE TERMS IN 1000 L.E.			VOLUME TERMS IN 1000 PACKS		
		TOTAL	PROD.	IMPORT.	TOTAL	PROD.	IMPORT.
0200	UNIT	2630	2630	0	5823	5823	0
	%	--	100	0	--	100	0
0502	UNIT	342	197	145	346	246	100
	%	--	58	42	--	71	29
0505	UNIT	1485	1485	0	1024	1024	0
	%	--	100	0	--	100	0
0508	UNIT	1914	114	0	2263	2263	0
	%	--	100	0	--	100	0
0509	UNIT	7480	7480	0	8662	8662	0
	%		100	0	--	100	0
0600	UNIT	43504	42988	516	49811	49751	60
	%	--	98.8	1.2	--	99.8	0.2
0700	UNIT	154	154	0	98	98	0
	%	--	100	0	2882	2882	0
1000	UNIT	2782	2782	0	2882	2882	0
	%		100	0	--	100	0
1300	UNIT	1223	1223	0	2110	2110	0
	%		100	0	--	100	0
1400	UNIT	628	628	0	298	298	0
	%		100	0	--	100	0
1600	UNIT	2626	2626	0	2436	2436	0
	%	--	100	0	--	100	0
2310	UNIT	4973	3271	1702	3025	2443	582
	%	--	56	34	--	81	19
2320	UNIT	2392	2392	N.A.	12389	11600	789
	%	--	--	--	--	93.6	6.4
2701	UNIT	3300	3300	0	44169	44169	0
	%		100	0	--	100	0
2702	UNIT	870	870	0	754	754	0
	%		100	0	--	100	0
2703	UNIT	169	91	78	65	35	30
	%		54	46	--	54	46
2800	UNIT	14	14	0	41	41	0
	%	--	100	0	--	100	0
3301	UNIT	15124	15124	0	21500	21500	0
	%		100	0	--	100	0

TABLE (VI-5) : LOCAL PRODUCTION, IMPORTATION OF C.S.P. IN VALUE AND VOLUME TERMS (1985/1986). (Cont.) ...

GROUP	KIND	VALUE TERMS IN 1000 L.E.			VOLUME TERMS IN 1000 PACKS		
		TOTAL	PROD.	IMPORT.	TOTAL	PROD.	IMPORT.
3302	UNIT %	2975	2975 100	0 0	3060 --	3060 100	0 0
3303	UNIT %	3547	3075 87	472 13	2571 --	2351 91.4	220 8.6
3500	UNIT %	12223	12223 100	0 0	16426 --	16426 100	0 0
4100	UNIT %	6769 --	6403 95	366 5	6101 --	6079 99.6	22 0.4
4106	UNIT %	811	811 100	0 0	23017 --	23107 100	0 0
4200	UNIT %	1159	1159 100	0 0	2608 --	2608 100	0 0
4400	UNIT %	2402	2402 100	0 0	4062 --	4062 100	0 0
4700	UNIT %	1925	0 0	1925 100	1700 --	0 0	1700 100
TOTAL	UNIT %	123421	118217 95.8	5204 4.2	217241 --	213738 98.3	3503 1.7

* N.B. Vaccines and Sera are imported in bulk and repacked locally by VACSERA.

(VI) - C PRICES / COSTS

* C.S.P.'s, like other pharmaceuticals in Egypt are tarrified centerally by the Ministry of Health. Tarrification takes place after registration grants are given.

  Tarrification is performed by a committee headed by the Chairman of Board of the Egyptian Drug Organization. Its decisions are valid only after the final approval and signature of the Health Minister.

* Documents, which include cost sheets, original invoices, registeration grants, price comparisons, suggested price and samples are forewarded to this committee for analysis and price setting.

  There are not any appeals for the committee's decisions.

* Although there is no recognition of C.S.P.'s as such, in price manipulations, nevertheless, most of them are included in a wider group known as (masses-pharmaceuticals). This group is handled in a special way in price-increase programs old drugs and in price setting of new ones.

* This special way does not stem from well-stated social goals or norms but it is rather dependent on some economic/costing factors.

* Lately, an Essential Drug List of Egypt has been compiled and its primary version was issued in June 1987. It is expected to be published by the beginning of 1988 after being appraised by different medical/pharmaceutical institutions.

  One of the main functions, the list is to serve, is its use in price policies. Pharmaceuticals on this list should not endure any annual public price increases but their prices are to be kept fixed and subsidised by the government pharmaceutical support programs.

  Public prices of C.S.P.'s include the following margins :

	Local Product	Imported Product
Public Price	100	100
Retailer Margin	20	10-12
Wholesaler Margin	7	8-7

* Public prices of C.S.P.'s ranges from 10 p.t. (Penicillin vial) to 25 L.E. (Human Albumen).
  Price groups are as follows :
  Less than 1 L.E. : 112 products
  From 1 to 3 L.E. : 114 products
  More than 3 L.E. : 19 products.

(VI) - C PRICES / COSTS (Cont.) ...

* From the 245 items of C.S.P.'s, 64 have negative margins (i.e.) products incurring losses.
  Loss/pack ranges from 1 p.t. to 87 p.t.
  Total annual losses amounts to 9.978 L.E. in 1986/87.
  The highest losses are endured by the following items :

Enteroquine syrup	(1.62 million L.E.)
Streptomycin vials	(1.525 million L.E.)
Penicillin G sodium	(0.85 million L.E.)
Penicillin Procain vial	(0.42 million L.E.)
Streptomycin/chloramphenicol syrup	(0.28 million L.E.)

(VI - D M.O.H. ALLOCATIONS AND EXPENDITURE

* M.O.H. allocations and expenditure on C.S.P. are very difficult, if not impossible to identify by analysis of official budgets, balances and expenditure statements.

* Nevertheless, we can identify, the following expenditures in 1985/86.
    1. Annual tenders of M.O.H. for basic needs of its service units in different governorates, for C.S.P.

    2. Annual supply agreement with the Egyptian Organizaion for Biological Products within the C.S.P.

Both segments give us a fair but not exhaustive estimate of M.O.H. expenditure on C.S.P.
This estimate amounted to 11.95 million L.E. in 1985/1986.
Table (VI- 8) shows this expenditure broken down by subgroup.

TABLE (VI -8 : M.O.H. EXPENDITURE ON C.S.P. IN 1985/1986.
(IN MILLION L.E.)

SUBGROUP CODE	SUBGROUP NAME	EXPENDITURE
509	ANTIDIARRHEALS	0.765
600	ANTIBIOTICS	3.484
1400	ANTITUBERCULOUS	0.022
2701	VACCINES	2.900
2702	SERA	0.700
3302	COUGH SEDATIVES	0.330
3500	MULTIVITAMINS	0.222
4101	RESTORATIVES / PARENTRAL	3.525
4106	RESTORATIVES / ORAL	FREE
T O T A L		11.948

(VI) - E Projected Needs of C.S.P.'S for the Next Five Years (86/87 - 90/91)

Projected needs were estimated by using one of the following methods :

1. **Method One : (Single Regression Analysis)**
   Single linear regression of the annual consumption volumes of the 26 subgroups* of C.S.P.'s during the last five years (81/82 - 85/86), using each of the following one at a time :
   a) time
   b) number of children under six years of age
   as the independent variable.

2. **Method Two : (Multiple Regression Analysis)**
   Multiple linear regression of the annual consumption volumes of the 26* subgroups of C.S.P.'s during the last five years (81/82 - 85/86), using time and number of children together as the independent variables.

3. **Method Three : (Direct Method)**
   This method was used for diseases of known and reliable morbidity figures and standard formal therapies using the following formula :
   standard therapy regime X annual number of cases X constant
   where :
   annual no. of cases = morbidity rate X population size
   constant = planned percentage coverage

4. **Method Four : (Annual Rate Method)**
   Actual annual growth rate of total consumption of different pharmaceutical groups in Egypt, calculated for the period (81/82 - 85/86), was used as an expected growth rate for the next five years.

* 25 regressions were made and 2 subgroups were combined as their products are highly interchangable, namely, cough sedatives and expectorants.

RESULTS AND INTERPRETATIONS :

- By applying regression methods, we found the following :

  a. 15 subgroups have a significant regression with time.

  b. 16 subgroups have a significant regression with number of children under the age of six years.

  c. 13 subgroups have a significant regression with time and number of children under the age of six years.

- By choosing the most significant regression results of different methods, we found that there are 18 subgroups having significant regression results.
  Table (VI-9) shows the level of significance of the regression equations of all subgroups for the different methods.

  For the rest of the subgroups (9 subgroups) which have an insignificant regression, we used the following methods for predicting their consumption :-

  a. For subgroups : vaccines, sera and contraceptives, we applied the direct method (i.e) morbidity rate and standard therapy formulea as follows :

     1. Vaccines :

     2. Sera :

     3. Contraceptives :

  b. For subgroups : antimotility, antibiotics, antimalarials, antihistaminics, Mescillaneous and sedatives, we applied annual rate of growth of total consumption of relevent groups, as shown in table (VI-I0)-

     Table (VI-II) shows the predicted volumes of C.S.P.'s by subgroup during the next five years (86/87 - 90/91) with; confidence intervals when tahe prediction is done by a regression method.

     Table (VI-I2) shows the predicted values of C.S.P.'s by subgroup for the next five years (86/87 - 90/91).

     Annex (VI-1) shows the graphs of the significant regression equations (17 subgroups) and the insignificant equations (9 subgroups).

TABLE (VI-9) LEVEL OF SIGNIFICANCE OF THE REGRESSION EQUATIONS BY THE THREE METHODS.

SUBGROUPS	METHOD 1	METHOD 2	METHOD 3
	Regression on Time, V1	Regression on No. of children V2	Regression on both Time and No. of Children
V2. ANALGYSICS & ANTIPYRETICS	P = 0.0014	P = 0.0031	P = 0.0082
V3. ANTIMOTILITY.	Insignificant	Insignificant	Insignificant
V4. ANTIAMEBIC.	P = 0.0122	P = 0.0072	P = 0.0099
V5 ANTIEMETIC.	P = 0.0177	P = 0.0258	P = 0.0285
V6 ANTIDIARRHEALS.	P = 0.0015	P = 0.0013	P = 0.0214
V7 ANTIBIOTICS.	Insignificant	Insignificant	Insignificant
V8 ANTIMALARIALS.	Insignificant	Insignificant	Insignificant
V9 ANTIHISTAMINICS.	Insignificant	Insignificant	Insignificant
V10 CHEMOBIOTICS.	P = 0.0523	P = 0.0540	Insignificant
V11 ANTITUBERCULOUS.	P = 0.0139	P = 0.0171	Insignificant
V12 SULPHONAMIDS.	P = 0.0028	P = 0.0014	P = 0.0114
V13 CORTICOSTEROIDS.	P = 0.0005	P = 0.0009	P = 0.0119
V14 CONTRACEPTIVES.	Insignificant	Insignificant	Insignificant
V15 VACCINES.	Insignificant	Insignificant	Insignificant
V16 SERA.	Insignificant	Insignificant	Insignificant

TABLE (VI-9) LEVEL OF SIGNIFICANCE OF THE REGRESSION EQUATIONS BY THE THREE METHODS.

(Cont.) ...

SUBGROUPS	METHOD 1	METHOD 2	METHOD 3
	Regression on Time, V1	Regression on No. of children V2	Regression on both Time and No. of Childre
V17. GAMMA GLOBULINS.	Insignificant	P = 0.0598	Insignificant
V18. MESCILLENEOUS.	Insignificant	Insignificant	Insignificant
V19. EXPECTORANTS.	P = 0.0185	P = 0.0285	P = 0.0213
V20. COUGH SEDATIVES.	P = 0.0185	P = 0.0285	P = 0.0213
V21. BRONCHODILATORS.	P = 0.0069	P = 0.0109	P = 0.0288
V22. MULTIVITAMINS.	Insignificant	Insignificant	P = 0.054
V23. RESTORATIVES / PARENTRAL.	P = 0.0031	P = 0.00013	P = 0.0044
V24. RESTORATIVES / ORAL.	P = 0.064 Slightly	Insignificant	Insignificant
V25 . SEDATIVES.	Insignificant	Insignificant	Insignificant
V26. SPASMOLYTICS.	P = 0.0191	P = 0.0235	Insignificant
V27. LACTOSE-FREE MILK.	P = 0.0018	P = 0.0023	P = 0.0261

TABLE (VI-10)

GROUP	MEAN ANNUAL RATE OF CHANGE OF VOLUME CONSUMPTION (81/82 - 85/86)
ANTIMOTILITY.	7.35 %
ANTIBIOTICS.	11.77 %
ANTIMALARIALS.	5.26 %
ANTIHISTAMINICS.	12.74 %
MISCELLANIOUS.	10.66 %
SEDATIVES.	10.23 %

TABLE (VI-II) PREDICTED VOLUMES AND CONFIDENCE INTERVALS OF C.S.P.'S BROKEN DOWN BY SUBGROUP FOR YEARS (86/87 - 90/91). (IN 1000 PACKS)

SUBGROUPS	86/87	87/88	88/89	89/90	90/91
0200 - V2. ANALGYSICS & ANTIPYRETICS.	6999 6191-7808	7921 7113-8730	8843 8034-9651	9765 8956-10573	10686 9878-1149
0502 - V3. ANTIMOTILITY.	372	400	430	462	497
0505 - V4. ANTIAMOEBIC.	1100 729-1470	1300 930-1670	1501 1130-1871	1701 1331-2071	1902 1531-2272
0508 - V5 ANTIEMETIC.	2746 2139-3354	3033 2426-3641	3321 2713-3928	3608 3000-4215	3895 3287-4502
0509 - V6 ANTIDIARRHEALS.	18001 8761-11401	11539 10219-12859	12996 11676-14316	14453 13133-15773	15911 14590-172
0600 - V7 ANTIBIOTICS.	55673	62225	66892	71909	77302
0700 - V8 ANTIMALARIALS.	103	108	114	120	126
1000 - V9 ANTIHISTAMINICS	3220	3595	4013	4480	5000
1300 - V10 CHEMOBIOTICS.	2620 1342-3898	3017 1740-4295	3414 2136-4191	3810 2533-5088	4207 2930-5484
1400 - V11 ANTITUBERCULOUS	375 260-492	435 318-552	496 379-613	556 439-673	616 500-734
1600 - V12 SULPHONAMIDS.	2713 2289-3136	3092 2668-3515	3471 3047-3894	3850 3426-4273	4229 3808-4650
2310 - V13 CORTICOSTEROIDS	3040 3190-3685	3819 3572-4067	4202 3954-4450	4584 4337-4832	4967 4915-675
2320 - V14 CONTRACEPTIVES.	1 590	1 643	1 794	1 907	2009
2701 - V15 VACCINES.	27000	31 000	35000	39000	41 100
2702 - V16 SERA.	840	840	840	1 000	1 000
2703 - V17 GAMMA GLOBULINS	77 43-111	88 54-121	98 64-132	108 75-142	119 85-153

TABLE (VI-III) PREDICTED VOLUMES AND CONFIDENCE INTERVALS OF C.S.P.'S BROKEN DOWN BY SUBGROUP FOR THE YEARS (86/87 - 90/91). (IN 1000 PACKS)

(Cont.) ...

SUBGROUPS	86/87	87/88	88/89	89/90	90/91
2800 - V18 MESCILLANEOUS.	45	50	55	61	68
3301 - V19 3302 - V20 EXPECTORANTS/ COUGH SEDATIVES	25697 24131-27262	26424 24858-27989	27150 25585-28716	27877 26312-29443	28605 27039-30170
3303 - V21 BRONCHODILATORS	3405 2485-4325	4013 3092-4933	4620 3400-5540	5228 4308-6148	5836 4915-6756
3500 - V22 MULTIVITAMINS.	14630 13323-15936	14622 13316-15928	14659 13353-15966	14198 12892-15504	13781 12476-15088
4100 - V23 RESTORATIVES/ PARENTRAL.	6550 5701-7400	7290 6441-8139	8029 7180-8878	6769 7919-9617	9508 8659-10357
4106 - V24 RESTORATIVES/ ORAL.	32098 --------	38025 --------	43953 --------	49881 --------	55809 --------
4200 - V25 SEDATIVES.	2874	3168	3492	3864	4259
4300 - V26 SPASMOLYTICS.	4771 3611-5930	5303 4143-6462	5835 4675-6994	6366 5207-7526	6898 5739-8058
4700 - V27 LACTOSE FREE MILK.	2067 1718-2415	2431 2083-2780	2796 2447-3144	3160 2812-3509	3524 3176-3873
TOTAL	21 9006	235431	25801 4	28071 3	301 854

N.B.

1. Vi = 0 for 1983/1984
2. Yi = ai + biVi
3. Confidence intervals td(f) = 3.182 standard error of estimate.
4. Oral restoratives subgroup V24 is slightly insignificant as it has confidence limits of 93.5% and not 95.0%.

TABLE (VI-12) : PREDICTED VALUES OF C.S.P.'S IN THE NEXT FIVE YEARS 86/87 - 90-91, BROKEN DOWN BY SUBGROUP.

(IN 1000 L.E.)

SUBGROUP		86/87	87/88	88/89	89/90	90/91
0200-V2 ANALEGESICS	0.45	3150	3565	3979	4394	4809
0502-V3 ANTIMOTILITY	1.0	372	400	430	462	497
0505-V4 ANTIAMEBICS	1.0	1595	1885	2177	2677	2758
0508-V5 ANTIEMETICS	1.45	2334	2578	2823	3067	3311
0509-V6 ANTIDIARRHEALS	0.85	15301	9808	11047	12285	13524
0600-V7 ANTIBIOTICS	0.88	48992	54758	58865	63280	68026
0700-V8 ANTIMALARIALS	1.55	160	167	177	186	195
1000-V9 ANTIHISTAMINICS	0.96	3091	3451	3853	4501	4800
1300-V10 CHEMOBIOTICS	0.58	1520	1750	1980	2210	2440
1400-V11 ANTITUBERCULOUS	2.1	788	914	1042	1168	1294
1600-V12 SULPHONAMIDES	1.08	2930	3339	3749	4158	4567
2310-V13 CORTICOSTEROIDS	1.64	5642	6263	6891	7518	8146
2320-V14 CONTRACEPTIVES	0.2	318	339	359	382	402
2710-V15 VACCINES	0.07	1890	2170	2450	2730	2873
2720-V16 SERA	1.15	970	970	970	1150	1150
2730-V17 GAMMA GLOBULINS	2.6	200	229	255	281	309
2800-V18 MESCILLENEOUS	0.35	16	18	19	21	24

TABLE (VI-12) : PREDICTED VALUES OF C.S.P.'S IN THE NEXT FIVE YEARS 86/87 - 90-91, BROKEN DOWN BY SUBGROUP.

(Cont.) ...

(IN 1000 L.E.)

SUBGROUP		86/87	87/88	88/89	89/90	90/91
3301,3302-V19,V20 EXPECTORANTS	0.74	19016	19554	20091	20629	21168
3303-V21 BROCHODILATORS	1.38	4699	5538	6376	7215	8054
3500-V22 MULTIVITAMINS	0.74	16826	10820	10848	10507	10198
4100-V23 RESTORATIVES/PARENTRAL	1.10	7205	8019	8832	9646	10459
4106-V24 RESTORATIVES/ORAL	0.04	1284	1521	1758	1995	2232
4200-V25 SEDATIVES	0.92	2644	2915	3213	3555	3918
4300-V26 SPASMOLYTICS	0.60	2863	3182	3501	3820	4139
4700-V27 LACTOSE-FREE MILK	1.13	2336	2747	3160	3571	3982
T O T A L		1 461 42	1 46900	1 58845	1 71 408	1 83279

(VII) DISTRIBUTION

A. DISTRIBUTION NETWORKS, PRIVATE AND PUBLIC

B. RESOURCES DISTRIBUTION / ANNUAL COSTS

(VII) - A DISTRIBTUTION NETWORKS, PRIVATE AND PUBLIC

* By distribtution, we mean the movement of pharmaceuticals from depot stores of the provision units (manufacturers and importers) till they reach the patients.

* We can identify two main networks in the Egyptian distribution system, together with a third specialized one. These networks are as follows :-

    1. Private Network : where pharmaceuticals reach the patient through private outlets (pharmacies and private hospitals). Pharmaceuticals dispensed through theis network are either paid-for or reimbursed by the health insurance system.

    2. Public Network : where pharmaceuticals reach the patients through public outlets (different Health Servic Units). Pharmaceuticals dispensed through this network are free of charge.

    3. Family Planning / Birth Control Network : where birth control means reach the users through public and private outlets. These means are either free of charge or paid-for completely.

1. PRIVATE NETWORKS

It is composed of three levels :

a. First wholesaler level
b. Second wholesaler level
c. Retailer level

a. First Wholesaler Level

This level comprises the depot stores of manufacturers (8 public + 7 private) and importers (1 public + 11 private).

Sales departments supervising those stores can distribute pharmaceuticals directly to the retailer level or to distribution firms which constitute the second wholesaler level.

All manufacturers have finished goods stores located in Cairo, and some of the public sector manufacturers have branch stores located in Alexandria, Asuit, the Canal Zone and mid Delta regions.

Misria company which is the only public sector importer, (85 % of importation) has four main stores in Cairo, Alexandria, Asuit and Mansoura.

Private importers have stores of limited capacities and they usually move their merchandise directly to distribution firms.

b. Second Wholesaler Level

This level comprises the distribution firms. We have one public sector distribution firm (Misria Company) which is considered the main distributor of pharmaceuticals in Egypt together with seven main private distribution firms.

Misria which is responsible for distributing nearly 80-85 % of imported pharmaceuticals plus 30-35 % of locally produced pharmaceuticals, has 39 branches in all parts of Egypt :

- 7 in Northern Cairo region
- 3 in Suez Canal region
- 9 in Southern Cairo region
- 6 in Alexandria region
- 9 in the Delta region
- 5 in Upper Egypt.

Private distribution stores are located mostly in Cairo. They distribute privately imported pharmaceuticals and very minor share of privately locally produced pharmaceuticals, (eg), 80 % of Squibb-Egypt production.

c. Retailer Level

This level is composed of pharmacies and private hospitals. They can get pharmaceuticals either from the first or second wholesaler levels.

There are 7632 private pharmacies located in all parts of Egypt, together with 45 co-operative pharmacies. 24 public pharmacies are owned by Misria company.

We also have 12 private hospitals, getting their pharmaceuticals either from first or second wholesaler levels. The remaining private hospitals are fed directly from pharmacies.



- PAID FOR
- REIMBURSED
PHARMACEUTICALS

Fig. (VII-1) : Private Distribution Network

2. PUBLIC NETWORK

It comprises three levels :

a. Depot stores of manufacturers and importers and VACSERA depot stores.

b. Main stores for rural and hospital supply (Misria company).

c. Governments Health Department stores and Health Unit stores (public hospitals, child and materinty centers, rural units .....) and university hospital stores.

Fig. (VII-2) depicts the public network.

a. Depot Stores of Manufacturers and Importers

It is similar to that of the private network, together with the main depot store of VACSERA at Agouza, Cairo.

b. Main Stores for Rural and Hospital Supply.

We have two main stores subordinated to Misria, one located in Cairo and the other in Alexandria. These are responsible for supplying all governorates stores of the Ministry of Public Health with their needs of pharmaceuticals.

c. Governerate Health Department Stores (different public health units stores) and University Hospitals Stores.

All except university hospitals are supplied by Misria's rural and hospital stores, and VACSERA depot stores (for vaccines and sera).
University hospitals get their needs directly from the first level.



Fig. (VII-2) : Public Distribution Network

3. BIRTRH CONTROL NETWORK.

It consists of four levels :

a. Depot stores of manufacturers and importers.

b. Misria depot stores and branches and Family of the Future depot stores.

c. Governerate Health Department stores and governerate General Society for family planning stores.

d. Family Planning units of the Ministry of Health, general society for family planning units of the Ministry of Social Welfare, pharamicies and other private societies.

Fig. (VII-3) depicts the birth control network.



Fig. (VII-3) : Birth Control Networks

(VII) - B RESOURCES DISTRIBUTION / ANNUAL COSTS

1. Resources Distribution comprises the following :

a. Storing capacity
b. Vehicles

a. Storing Capacity

In distribution networks, depot stores of manufacturers and importers constitute the main part of the storing capacity. Modern stores, cold rooms and refridgerated rooms are found by all manufacturers and at Misria company. For example :,

- CID firm which is the biggest public sector firm has 10,000 m² stores of finished goods.
- Adco firm which is the smallest public sector firm has 6,000 m² stores.
- Hoechst, a private sector firm, has 4,000 m² stores.
- A.B.I., a new private sector firm, has 5,000 m² stores.
- Misria, the main importer, (public sector), has 4 depot stores.
  1. Shoubra principle depot 12,200 m² with 2 cold refridgerator rooms.
  2. Alexandria depot 4,500 m² for infant milk formula.
  3. Mansoura depot 700 m² with one cold refridgerator room.
  4. Asuit depot 200 m² for infant milk formula.

b. Vehicles

Each store of a pharmaceutical manufacturer, on the average, has two vans and three trucks, each branch has at least one van.

Each governerate has two vans and two trucks on the average. /sometimes these vehicles are rented.

2. ANNUAL COSTS

* Annual costs of distribution, at the wholesaler level, were identified by studing two examples.

    a. The main public sector manufacturers, who are performing massive distribution activities which covered from 65 % to 80 % of their production in 1985/1986.

    b. A main wholesaler of imported / local products, (Misria company).

* Total annual distribution costs of Misria amounted to 24.87 million L.E. in 1985/1986, constituting 8.7 % of total sales, while these costs ranged between 8.7 % (ADCO) to 11.8% (Kahira) of total sales.

* Wages and salaries, costs to total sales ranged between 2.78 % (Misria) to 4.9 % (C.I.D.).

* Commodities, costs to total sales ranged between 0.11 % (Misria) to 0.85 % (Nile).

* Services costs to total sales ranged between 0.53 % (Misria) to 5.7 % (Kahira).

* Other current expenses to total sales ranged between 0.22 % (ADCO) to 5.2 % (Misria).

* Table (VII-1) shows the detailed annual distribution costs in 1985/1986 for selected public sector manufacturers and Misria, broken down in cost categories.

TABLE (VII-1) : ANNUAL DISTRIBUTION COSTS AS A PERCENTAGE OF SALES FOR SELECTED PUBLIC SECTOR MANUFACTURERS AND MISRIA IN THE YEAR 1985/1986.

FIRM	DISTRIBUTION COST CATEGORIES AS A PERCENTAGE OF TOTAL SALES				
	SALARIES & WAGES (Including Fringe Benefits)	COMMODITIES	SERVICES	OTHER CURRENT EXPENSES	TOTAL
1. MISRIA	2.78 %	0.11 %	0.53 %	5.29 %	8.71 %
2. C.I.D.	4.90 %	0.57 %	4.12 %	0.44 %	10.03 %
3. NILE	4.70 %	0.85 %	4.17 %	0.43 %	10.15 %
4. MISR	4.00 %	0.54 %	3.15 %	2.25 %	9.94 %
5. KAHIRA	4.67 %	0.45 %	5.7 %	1.04 %	11.86 %
6. ADCO	4.70 %	0.56 %	3.20 %	0.22 %	8.68 %

N.B.

1. Commidities comprise : energy, spare parts, packing materials, stationary, water and electricity.

2. Services comprise : maintenance, advertising, publishing, transportation and other services.

3. Other current expenses comprise : taxes, depriciation and rents.

4. Misria's large costs other expenses is due to the incurring of taxes on imports which amounted to 4.83 %.

SOURCE :

Firms balance sheet statement reports 1985/1986.

(VIII) PRESCRIPTION BEHAVIOUR

A. METHODOLOGY
B. PRESCRIPTION BEHAVIOUR IN PUBLIC AND PRIVATE INSTITUTIONS, RESULTS.
C. MISUSE-ABUSE PATTERNS.

(VIII) - A METHODOLOGY :

* A field study was designed to identify and document prescription behaviour in different public and private institutions for forty diagnosis.

  These forty diagnosis encompass the 17 illnesses relevant to the study for the age group 0-6 years old.

  Annex no. (VIII-1) shows the protocol of the study giving the details of its objectives and methodology.

* The gathered prescriptions of the field study were coded and processed to describe the prescription behaviuor. This behaviour was then compared against standard therapies for each diagnosis to identify deviations and potential misuse and abuse.

(VIII) - B PRESCRIPTION BEHAVIOUR OF PUBLIC/PRIVATE INSTITUTIONS, RESULTS :

The results are summarized in the following table (VIII-1) showing both public and private behaviour together with total behaviour patterns. Standard therapy patterns, (ideal) are also included in the tables.

It can be seen that :

1. There is a tendency to over prescribe in almost all diseases, except Tetanus and Pertusis.

2. Prescription behaviour of both, private and public institutions, are almost the same.

3. O.R.S. is not used as a treatment in its own, but as a supplementary treatment.

4. Antidiarrheals, either plain or with antibiotics and antibiotic preparations, are still used extensively in diarrhea.

5. There is no selective use of pulmonic preparations as cough sedatives, expectorants and brochodilators, however, they are used interchangably.

6. The use of gamma globulins is a limited practice in infectious diseases like Diphtheria, Tetanus and Pertusis.

TABLE (VIII-1) : PRESCRIPTION BEHAVIOUR IN PUBLIC & PRIVATE INSTITUT VS. IDEAL PRESCRIPITION BEHAVIOUR.

11.	MECONIUM ASPIRATION SYNDROM AND HYALINE MEMBRANE SYNDROM (NEW B

AVERAGE TOTAL NUMBER OF :	IDEAL	TOTAL	PUBLIC	PRIVATE
Drugs/presc.	2	2.20	2.20	2.20
Corticosteroids/presc.	1	0.07	0.07	0.07
Antiobiotics/presc.	1	1.43	1.45	1.39
Pulmonics/presc.	0	0.24	0.29	0.20
Others/presc.	0	0.46	0.39	0.54

(Others include mainly Fluids and Analgesics).

12.	ACUTE BRONCHITIS (NEWBORN - INFANT - CHILD)

AVERAGE TOTAL NUMBER OF :	IDEAL	TOTAL	PUBLIC	PRIVATE
Drugs/presc.	2	2.87	2.85	2.90
Pulmonics.	1	1.02	1.03	1.01
Antihistaminics/presc.	1	0.03	0.03	0.03
Antiobiotics/presc.	0	1.20	1.20	1.20
Others/presc.	0	0.62	0.59	0.66

(Others include mainly Vitamins and Analgesics).

13.	ACUTE LARYNGOTRACHEOBRONCHITIS (INFANT-CHILD)

AVERAGE TOTAL NUMBER OF :	IDEAL	TOTAL	PUBLIC	PRIVATE
Drugs/presc.	2	3.16	3.02	3.30
Antiobiotics/presc.	1	1.03	1.07	1.00
Pulmonics/presc.	1	0.78	0.71	0.85
Corticosteroids/presc.	0	0.58	0.42	0.73
Analgesics/presc.	0	0.27	0.33	0.21
Others/presc.	0	0.49	0.47	0.51

(Others include mainly Analgesics, Antihistaminics and Vitamins).

TABLE (VIII-1) : PRESCRIPTION BEHAVIOUR IN PUBLIC & PRIVATE INSTITUTIO' VS. IDEAL PRESCRIPITION BEHAVIOUR.

14.	ACUTE BRONCIOLITIS (NEW BORN - INFANT - CHILD)

AVERAGE TOTAL NUMBER OF :	IDEAL	TOTAL	PUBLIC	PRIVATE
Drugs/presc.	2.35	2.70	2.70	2.71
Antiobiotics/presc.	0.35	0.97	1.00	0.94
Pulmonics/presc.	1.00	0.68	0.64	0.71
Sedatives.	1.00	0.00	0.00	0.00
Corticosteroids/presc.	0.00	0.28	0.31	0.26
Others/presc.	0.00	0.77	0.75	0.80

(Others include mainly Analgesics and Fluids).

15.	ACUTE BRONCHITIS (NEWBORN - INFANT - CHILD)

AVERAGE TOTAL NUMBER OF :	IDEAL	TOTAL	PUBLIC	PRIVATE
Drugs/presc.	3.00	3.20	3.22	3.18
Antiobiotics/presc.	1.00	1.65	1.68	1.58
Bronchodilators/presc.	1.00	0.37	0.37	0.35
Antipyretics/presc.	1.00	0.40	0.39	0.43
Cough mix/presc.	0.00	0.49	0.49	0.50
Others/presc.	0.00	0.30	0.30	0.33

(Others include mainly Vitamins).

TABLE (VIII-1) : PRESCRIPTION BEHAVIOUR IN PUBLIC & PRIVATE INSTITU
VS. IDEAL PRESCRIPITION BEHAVIOUR.

16.	NASOPHARYNGITIS (Common Cold) (NEWBORN - INFANT - CHILD)

AVERAGE TOTAL NUMBER OF :	IDEAL	TOTAL	PUBLIC	PRIVATE
Drugs/presc.	1	2.45	2.35	2.55
Oral Nasal Decoughestant/presc	1	0.33	0.28	0.37
Pulmonics/presc.	0	0.10	0.10	0.11
Antiobiotics/presc.	0	0.39	0.33	0.45
Local Nasal Decough./presc.	0	0.21	0.21	0.21
Analgesics/presc.	0	0.62	0.58	0.66
Others/presc.	0	0.83	0.85	0.75

(Others include mainly, Vitamin C and Antihistaminics)

17.	SINUSITIS, PHARYNGITIS, TONSILITIS (INFANT - CHILD)

AVERAGE TOTAL NUMBER OF :	IDEAL	TOTAL	PUBLIC	PRIVATE
Drugs/presc.	1	2.70	2.62	2.78
Antibiotics/presc	1	1.33	1.26	1.40
Analgesics/presc.	0	0.61	0.62	0.60
Pulmonics/presc.	0	0.13	0.10	0.16
Others/presc.	0	0.63	0.64	0.62

(Others include mainly Antihistaminics, Vitamins and Nasal Decoghesta

21.	ACUTE INFECTIOUS DIARRHEA (NEWBORN - INFANT - CHILD)

AVERAGE TOTAL NUMBER OF :	IDEAL	TOTAL	PUBLIC	PRIVATE
Drugs/presc.	1.1	2.76	2.75	2.76
Antiobiotics/presc.	0.1	1.06	1.08	1.04
Rehydration prep./presc.	1.0	0.96	0.97	0.96
Antidiarrheals/presc.	0.0	0.46	0.48	0.44
Others/presc.	0.0	0.28	0.22	0.32

(Others include mainly Sulphonamides and Analgesics).
N.B- 74% of the rehydration prep. is O.R.S, the rest is parentral flu

TABLE (VIII-1) : PRESCRIPTION BEHAVIOUR IN PUBLIC & PRIVATE INSTITUTION VS. IDEAL PRESCRIPITION BEHAVIOUR.

22.	ACUTE TOXIC DIARRHEA (INFANT - CHILD)

AVERAGE TOTAL NUMBER OF :	IDEAL	TOTAL	PUBLIC	PRIVATE
Drugs/presc.	1	2.35	2.30	2.40
Rehydration/presc.	1	0.92	0.93	0.90
Antiobiotics/presc.	0	0.68	0.68	0.68
Antidiarrheals/presc.	0	0.51	0.50	0.52
Others/presc.	0	0.24	0.19	0.30

(Others include mainly, Sulphonamides).

23.	LACTOSE INTOLERANCE DIARRHEA (INFANT - CHILD)

AVERAGE TOTAL NUMBER OF :	IDEAL	TOTAL	PUBLIC	PRIVATE
Drugs/presc.	1	1.52	1.50	1.54
Lactose-free Milk/presc.	1	0.94	0.90	0.96
Rehydration prep./presc.	0	0.26	0.28	0.24
Antidiarrheals/presc.	0	0.17	0.18	0.17
Antibiotics/presc.	0	0.00	0.00	0.00
Others/presc.	0	0.15	0.14	0.17

(Others include mainly Medical Milks).

30.	MALARIA (NEWBORN - INFANT - CHILD)

AVERAGE TOTAL NUMBER OF :	IDEAL	TOTAL	PUBLIC	PRIVATE
Drugs/presc.	1	1.33	1.40	1.27
Antimalarials/presc.	1	1.00	1.00	1.00
Others/presc.	0	0.33	0.40	0.27

(Others include mainly Analgesics).

TABLE (VIII-1) : PRESCRIPTION BEHAVIOUR IN PUBLIC & PRIVATE INSTITUT VS. IDEAL PRESCRIPITION BEHAVIOUR.

40.	MEASLES (INFANT - CHILD)

AVERAGE TOTAL NUMBER OF :	IDEAL	TOTAL	PUBLIC	PRIVATE
Drugs/presc.	3	3.19	3.14	3.24
Antibiotcis/presc.	1	0.86	0.90	0.84
Amm. Chloride/presc.	1	0.14	0.11	0.17
Other Pulmonics/presc.	0	0.40	0.41	0.40
Gamma Globulins/presc.	1	0.04	0.04	0.05
Others/presc.	0	1.75	1.68	1.78

(Others include mainly, Analgesics, Ophthalmics and oral local antihistaminics).

50.	TUBERCULOSIS (INFANT - CHILD)

AVERAGE TOTAL NUMBER OF :	IDEAL	TOTAL	PUBLIC	PRIVATE
Drugs/presc.	2.0	3.40	2.70	4.10
I.N.H./presc	0.9	0.86	0.71	1.00
Antibiotics/presc.	1.0	1.92	1.63	2.22
Ethambutol/presc.	0.1	0.00	0.01	0.00
PAS/presc.	0.00	0.03	0.04	0.03
Others/presc.	0.00	0.59	0.31	0.85

(Others include mainly Corticosteroids).

60.	POLIOMYELITIS (INFANT - CHILD)

AVERAGE TOTAL NUMBER OF :	IDEAL	TOTAL	PUBLIC	PRIVATE
Drugs/presc.	1	1.73	1.55	1.91
Rehydration prep./presc.	1	0.02	0.00	0.04
Analgesics/presc.	0	0.80	0.82	0.78
Neostigmin/presc.	0	0.20	0.20	0.20
Others/presc.	0	0.71	0.53	0.89

(Others include mainly Vaccine and Vitamins).

TABLE (VIII-1) : PRESCRIPTION BEHAVIOUR IN PUBLIC & PRIVATE INSTITUTIONS VS. IDEAL PRESCRIPTION BEHAVIOUR.

70.	PERTUSIS (INFANT - CHILD)

AVERAGE TOTAL NUMBER OF :	IDEAL	TOTAL	PUBLIC	PRIVATE
Drugs/presc.	3	2.84	2.88	2.80
Antibiotics/presc.	1	1.02	1.05	0.97
Codein Cough Mix/presc.	1	0.19	0.19	0.19
Other Pulmonics/presc.	0	0.83	0.90	0.76
Gamma Globulin/presc.	1	0.19	0.20	0.18
Others/presc.	0	0.62	0.54	0.70

(Others include mainly, Antispasmodics).

80.	DIPHTHERIA (INFANT - CHILD)

AVERAGE TOTAL NUMBER OF :	IDEAL	TOTAL	PUBLIC	PRIVATE
Drugs/presc.	2	2.32	2.31	2.33
Antitoxin/presc.	1	0.95	0.95	0.96
Antibiotics/presc.	1	0.95	0.99	0.92
Others/presc.	0	0.42	0.37	0.45

(Others include mainly Corticosteroids and Analgesics).

90.	TETANUS (INFANT - CHILD)

AVERAGE TOTAL NUMBER OF :	IDEAL	TOTAL	PUBLIC	PRIVATE
Drugs/presc.	4	2.47	2.47	2.47
Antitoxin/presc.	1	1.05	0.97	1.13
Sedatives/presc.	1	0.48	0.47	0.50
Antibiotics/presc.	1	0.68	0.74	0.62
Muscle Relaxant/presc.	1	0.10	0.12	0.07
Others/presc.	0	0.16	0.17	0.15

(Others include mainly Analgesics and Vitamins).

(VIII) - C MISUSE -ABUSE PATTERNS :

1. Antibiotics are highly misused, specially in Diarrhea and Common Cold.

2. Vitamins and analgesics use is not justified in most cases.

3. Dangerous abuse of corticosteriods in some acute respiratory infections.

4. PAS, a deleted medication, appeared in some tuberculosis prescriptions.

ANNEX (VIII - 1)

EGYPT DRUG STUDY

FIELD STUDY PROTOCOL

JUNE 1987

EGYPT DRUG STUDY

FIELD STUDY OBJECTIVES

I. OBJECTIVES :-

1. To investigate and document prescription behaviour of Egyptian doctors, in both private and public institutions, concerning following diseases in age group (0-6) years of age :-

   1- Acute Respiratory infections.
   2- Diarrhea.
   3- Malaria.
   4- Measles.
   5- T.B.
   6- Polio.
   7- Pertussis.
   8- Diphteria.
   9- Tetanus.

2. To identify misuse of prescribed pharmaceuticals for the above mentioned diseases.

II. METHODOLOGY

1. Sample Selection :-

(A) * Four governorates were chosen namely :-

- Cairo governorate, representing "Big City environment".
- Alexandria governorate, representing "Sea-Shore Region".
- Gharbia governorate, representing "Delta Region".
- Minia goverorate, representing "Upper Egypt Region".

* Total population of the selected governorates amounts to 15.7 millions representing almost 30% of the total Egyptian population.*(a)

---

*(a) Estimated population report of 1987, Central Authority for Statistics.

* Total number of children under 6 years of age in the selected governorates amounts to 1.95 millions, representing 29.98% of the total number of Egyptian children under 6 years of age.*(a)

* Total number of doctors working in the selected governorates amounts to 24,192 doctors representing 35.6% of the total number of Egyptian doctors. Table no.(1) shows the details of these population facts for each governorate.

(B) * All relevant health institutions in the selected governorates were enumerated, to identify those delivering child care services. It was found out that the following institutions qualify as institutions delivering child care services :-

1. Public Institutions
   - 1.1 Hospitals, including university, educational, M.E.E.*(c) specialized & general hospitals.
   - 1.2 Maternal & child care centers.
   - 1.3 Rural Institutions, including rural hospitals, collective centers, rural centers & others.
   - 1.4 Health Offices.

2. Private Institutions
   - 2.1 Private Hospitals, including general & specialized hospitals.
   - 2.2 Private Clinics including G.P. clinics and pediatrician clinics.

It was found that doctors in all of these institutions prescribe for their patients except doctors working in health offices, they merely deliver vaccination services i.e., no prescription writing activity, so health offices were excluded from the study.

* Total number of identified health institutions in the selected governorates amounted to 1103 institutions, namely :-

1.1	Public hospitals	: 84	Hosp.
1.2	Maternal & child-care centers	: 85	Center
1.3	Rural Institutions	: 388	Center
2.1	Private Hospitals	: 190	Hosp.
2.2	Private Clinics	: 356	Clinic

Table no.(2a) represents the details for each governorate.

---

*(b) M.E.E. Moassasat El Elagia.

* Total number of doctors (pediatricians and G.Ps delivering child care services) working in the identified institutions amounted to 1877 doctors. Table no.(2b) represents the details for each governorate.

(C) * A sample size of 150 doctors were chosen representing :-

0.6% of the total number of doctors working in selected governorates.
8.0% of the total number of (pediatricians & G.Ps delivering child care services) working in the identified institutions in the selected governorate.

* The sample was drawn as follows :-

1- Distributed among the governorate according to their relative total number of doctors.
2- Each governorate share was distributed among health institutions using the same % representation of the total sample, i.e., (8%).
3- For each health institution we draw the sample size randomly using random tables.

Table no.(3) shows details of the sample composition.

2. Procedure

* The enclosed form was designed to be filled by each chosen doctor to document his/her prescription behaviour concerning the study's targeted diseases which are broken down into 17 diagnosis.
Also, the targeted age group was broken down into three age sub-groups namely :-

- New born (0 - 1) months.
- Infant (1 - 24) months.
- Child (2 - 6) years.

* By combining the 17 diagnosis with the 3 age sub-groups, we got 40 cases to be investigated, as some of the diagnosis is not encountered in some age sub-groups, (e.g) Measles is not encountered in the new born age sub-groups ...etc.
Table no.(4) shows the details of the 40 cases.

* Filling of the form is going to be done either by doctors alone or in the presence of the investigator. Study objectives will be explained before handing out the form to the doctor.

TABLE NO. (1)

POPULATION DATA

Governorate	Tot. pop.	Age Group 1-6 Years	Tot. no. of Doctors	% Total Doctors
Cairo	7,051,687	828,576	11,119	16.36%
Alexandria	3,116,299	359,872	6,782	10.00%
Gharbia	2,933,267	383,293	3,951	5.80%
Minia	2,584,928	379,929	2,340	3.44%
TOTAL	15,686,181	1,951,670	24,192	35.6%

TABLE NO. (2a)

HEALTH INSTITUTIONS " NUMBER OF UNITS "

GOVERNORATE	PUBLIC INSTITUTIONS				PRIVATE INSTITUTIONS			TOTAL
	HOSPITALS	M.&CHILD CARE CENTERS	RURAL INSTIT.	OTHER CENTERS	HOSP.	G.P CLINIC	PEDIATRIC CLINICS	
CAIRO	28	49	-	20	161	61	118	437
ALEXANDRIA	14	12	5	-	24	40	60	155
GHARBIA	23	14	165	3	4	18	18	245
MINIA	19	10	189	6	1	24	17	266
TOTAL	84	85	359	29	190	143	213	1103

TABLE NO. 124

HEALTH INSTITUTIONS " NUMBER OF DOCTORS " *(a)

GOVERNORATE	PUBLIC INSTITUTIONS				PRIVATE INSTITUTIONS			TOTAL
	HOSPITALS	M.&CHILD CARE CENTERS	RURAL INSTIT.	OTHER CENTERS	HOSP.	G.P CLINIC	PEDIATRIC CLINICS	
CAIRO	399	98	-	20	161	61	118	857
ALEXANDRIA	225	24	5	-	24	40	60	378
GHARBIA	102	28	165	3	4	16	18	338
MINIA	47	20	189	6	1	24	17	304
TOTAL	773	170	359	29	190	143	213	1877

*(a) By doctors we mean, pediatricians & G.PS delivering child care services.

TABLE NO. (3)

SAMPLE COMPOSITION

GOVERNORATE	TOT. NO. of DOCTORS *a	TOT. SAMPLE SIZE = 8%	SAMPLE SIZE				
			Public hosp.	M&C Ctrs	Rural Instit.	Private hosp.	clin
CAIRO	857	68	32	9	-	13	14
ALEXANDRIA	378	31	18	2	1	2	8
GHARBIA	338	27	8	2	13	1	3
MINIA	304	24	4	2	14	1	3
TOTAL	1877	150	62	15	28	17	28

*(a) By doctors we mean pediatricians & G.Ps delivering child-care services

TABLE NO. (4)

DIAGNOSIS / CASES TO BE ENCOUNTERED

CODE	AGE GROUP	A	B	C
	DIAGNOSIS	NEW BORN	INFANT	CHILD
11	ARI, Meconium Aspiration Syndrome & Hyaline membrane syndrome.	A11	N.A	N.A
12	ARI, Acute Bronchitis (Viral-Bacterial)	A12	B12	C12
13	ARI, Acute Laryngotracheo-bronchitis.	N.A	B13	C13
14	ARI, Acute Bronchiolitis.	A14	B14	C14
15	ARI, Bronchopneumonia.	A15	B15	C15
16	ARI, Nasopharyngitis (Common Cold).	A16	B16	C16
17	ARI, Sinusitis, Pharyngitis, Tonsilitis.	N.A	B17	C17
21	Diarrhea, Acute infectious diarrhea.	A21	B21	C21
22	Diarrhea, Acute toxic diarrhea (Food Poisoning).	N.A	B22	C22
23	Diarrhea, Lactose Intolerance.	N.A	B23	C23
30	Malaria.	A30	B30	C30
40	Measles.	N.A	B40	C40
50	Tuberculosis, Pulmonary, Meningeal.	N.A	B50	C50
60	Poliomyelitis.	N.A	B60	C60
70	Pertusis.	N.A	B70	C70
80	Diphteria.	N.A	B80	C80
90	Tetanus.	N.A	B90	C90

Ser

E.D.S

FROM (1)

Governorate : Cairo,Alex,Gharb,Minia

Sector Health Institution

Name :

(Pub.Hosp, M&ch.Center, Rural Inst., Priv.Hosp.,Clinic g.p, Clinic Ped.)

1	1

Diagnosis :- Acute Respiratory Infection, Meconium aspiration syndrome, hyaline membrane syndrome

New Born (0-1 Month)				Infant (1-24 Month)				Child (2-5 Years)			
S.Code	Tr Name	Form	Dru.	S.Code	Tr.Name	Form	Dru.	S.Code	Tr.Name	Form	Dru.
					N.A				N.A		

(IX) CONSUMPTION PATTERNS OF ANTIDIARRHEALS IN THE LAST SIX YEARS.

- IN PHYSICAL TERMS
- IN VALUE TERMS

(IX) CONSUMPTION PATTERNS OF ANTIDIARRHEALS IN THE LAST SIX YEARS IN PHYSICAL TERMS AND VALUE TERMS.

* 90 products were identified as the most commonly prescribed pharmaceuticals by Egyptian doctors in case of diarrhea in children.

* Consumption figures in both volume and value terms for these products, (which were classified into six subgroups) were compiled during the last six years (1980/1981 - 1985/1986). The six subgroups were classified as follows :
    1. Antibiotics.
    2. Antidiarrheals.
    3. Antiemetics.
    4. Antimotility.
    5. O.R.S.
    6. Others, (mostly, Restoratives/Parentral).

  Table (IX-1) and table (IX-2) show the results.

* The Antidiarrheal subgroup scored the largest increase (233 %) during the last six years.

* O.R.S showed remarkable increase but indured a minor decrease in the last year. This was said to be due to storage routines, mothers'practice now using O.R.S as an emergency household item.
  The increase in the use of O.R.S is accompanied with increase in the other subgroups. This stressed the findings of the previous chapter, indicating that doctors tend to use O.R.S as a supplementary treatment.

* Annex (IX-1) shows the detailed consumption data broken down by individual drug both in volume and value terms.

TABLE (IX-1)

TOTAL CONSUMPTION OF ANTIDIARRHEALS

IN VOLUME TERMS

UNIT : (IN 1000 PACKS)

GROUP NAME	80/81	81/82	82/83	83/84	84/85	85/86
ANTIBIOTICS	10800	9952	10939	13414	15091	17964
ANTIDIARRHEALS	4073	3240	4191	5595	8007	9496
ANTIEMETICS	1647	1200	1662	1901	2405	1654
ANTIMOTILITY / ANTISPASMODICS	3098	2842	2971	3953	4127	4264
O.R.S.	3970	5604	4322	9854	28774	23017
OTHERS	2254	2565	3247	4713	4227	5549
T O T A L	25842	25403	25182	39430	62631	61944

TABLE (Ix-2)

IN VALUE TERMS

UNIT : (IN 1000 L.E.

GROUP NAME	80/81	81/82	82/83	83/84	84/85	85/86
ANTIBIOTICS	14016	12650	14493	18497	22136	27580
ANTIDIARRHEALS	2664	2021	3081	4374	6227	8651
ANTIEMETICS	988	720	997	1140	1443	991
ANTIMOTILITY / ANTISPASMODICS	1252	1133	1191	1660	1866	2555
O.R.S.	252	461	372	838	1238	81[illegible]
OTHERS	2564	2988	3245	4171	4425	572[illegible]
T O T A L	21736	19973	23379	30680	37385	4631[illegible]

ANNEX (IX - 1)

CONSUMPTION FIGURES OF ANTIDIARRHEALS
BY INDIVIDUAL DRUG

IN PHYSICAL TERMS (1000 PACKS)
IN VALUE TERMS (1000 L.E.)

TOTAL CONSUMPTION
OF ANTIDIARRHEALS

80/81 - 85/86

UNIT : IN 1000 PACKS

PAGE NO : 1 ANTIBIOTICS — IN VOLUME TERMS

CODE	TRADE NAME	PACK	FIRM	80/81	81/82	82/83	83/84	84/85	85/86
50002	ERTHROCIN GRANULES IMPORT	SUSP 60 ML	ABBOTT	0	0	0	0	0	0
59119	PENTREXYL SYRUP .125 MG IMPORT	BOT 60 ML	BRISTOL	0	0	0	0	94	0
502329	SUPRISTOL SUSP	SYP 60 ML	ALEX	0	0	0	0	0	103
502336	SEPTAZOLE SUSP	SUSP 100 ML	ALEX	465	395	365	621	743	891
503123	CIDOCETINE SUSP	SUSP 60 ML	CID	657	620	782	820	851	825
503125	CIDOCETINE S SUSP	SUSP 60 ML	CID	0	0	0	394	359	295
503195	ERYTHROCID SUSP	SUSP 60 ML	CID	0	0	0	0	0	65
503471	PALITREX 250 MG SYRUP	SYP 60 ML	CID	0	0	0	0	83	146
503472	PALITREX 125 MG SYRUP	SYP 60 ML	CID	70	82	120	103	259	129
503474	PALITREX DROPS	BOTT 10 ML	CID	32	25	21	60	25	32
503515	PENTREXYL 125 MG SUSP	SUSP 60 ML	CID	476	527	531	593	460	1463
503530	PENTREXYL 250 MG SUSP	SUSP 60 ML	CID	548	518	513	713	803	899
503662	STREPTOCETINE SUSP	SUSP 60 GM	CID	456	408	543	673	886	813
504152	SULPHAGUANIDINE 500 MG TAB	TAB 10 ST	WASR	0	0	0	0	0	100
505053	AMPICILLIN 125 MG SUSP	SUSP 60 ML	NILE	0	296	39	265	244	341
505054	AMPICILLIN FORT 250 MG DRY SUSP	SUSP 60 ML	NILE	208	72	347	564	789	844
505343	ENTRIM SUSP	SUSP 100 ML	NILE	0	0	22	126	170	196
505890	SULFAGUANIDINE STRIPS	BX 10 TAB	NILE	70	60	90	90	80	90
505952	VERACETIN SUSP	SUSP 60 ML	NILE	0	0	0	0	0	348
507502	ERYTHROCIN GRAN 200 MG / 5 ML	SUSP 60 ML	KAHIRA	375	338	365	823	1023	1385
507542	CHEMOTRIN SUSP	SUSP 100 ML	KAHIRA	225	189	205	274	266	165
507561	KEFLEX SYRUP 250 MG	SUSP 60 ML	KAHIRA	0	0	0	0	0	270
507562	KEFLEX SYRUP 125 MG	SUSP 60 ML	KAHIRA	60	154	244	298	640	552
507564	KEFLEX DRY DROPS	BOTT 19 ML	KAHIRA	40	52	141	154	34	40
508072	GARAMYCIN 20 MG AMP	AMP 6	MEMPHIS	85	46	141	294	532	835
508559	NEOMYCIN DRY SUSP	SUSP 60 ML	MEMPHIS	56	48	60	70	64	94
508637	SUTRIM SUSP	SUSP 100 ML	MEMPHIS	535	371	509	436	750	997
508664	MEMCOCETIN SUSP	SUSP 60 ML	MEMPHIS	0	0	71	186	149	110
509331	ERYTHRIN DROP	DROPS 30 ML	MISR	0	0	0	0	0	2
509929	MICYCLINE 125 MG SUSP	SUSP 60 ML	MISR	277	497	171	81	150	73
509934	LIDAPRIM SUSP	SUSP 60 ML	MISR	0	0	0	0	0	84
509935	MIPHENICOL 125 MG SUSP	SUSP 60 ML	MISR	846	761	833	536	656	776
509936	STREPTOPHENICOL SUSP	SUSP 60 ML	MISR	745	642	788	1067	1095	917
509937	AMPICILLIN 125 MG SYP	SYP 60 ML	MISR	1391	1213	1237	675	566	589
509938	AMPIPEN 125 MG SYP	SYP 60 ML	MISR	555	532	598	606	448	415
509939	AMPIPEN 250 MG SYP	SYP 60 ML	MISR	1012	795	894	769	852	729
509940	AMPICILLIN 250 MG SYP	SYP 60 ML	MISR	0	0	0	426	525	1074
509942	ERYTHRINE 200 MG SUSP	SUSP 60 ML	MISR	0	0	0	0	103	348
510107	SIGMAMYCIN SYRUP	SUSP 60 ML	PHIZER	694	627	597	878	661	468
510131	TERRAMYCIN 125 MG	SYP 90 ML	PHIZER	612	402	420	528	316	295
510173	VIBRAMYCIN SYRUP	SUSP 60 ML	PHIZER	310	282	292	291	205	116
515244	EPICOCILLIN 250 MG DRY MIX	SYP 60 ML	IPECO	0	0	0	0	0	0
515246	EPICOCILLIN 125 MG DRY MIX	SYP 60 ML	IPECO	0	0	0	0	0	0
516103	AMPICYN 125 MG DRY SYRUP	SYP 60 ML	A.B.I.	0	0	0	0	0	0
516104	AMPICYN 250 MG DRY SYRUP	SYP 60 ML	A.B.I.	0	0	0	0	0	0
TOTALS				10800	9952	10939	13414	15091	17964

led b ...OTECH, ... naledi

TOTAL CONSUMPTION
OF ANTIDIARRHEALS

80/81 - 85/86

UNIT : IN 1000 PACKS

PAGE NO : 1 ANTIDIARRHEALS

IN VOLUME TERMS

CODE	TRADE NAME	PACK	FIRM	80/81	81/82	82/83	83/84	84/85	85/86
501181	ENTROQUINE COMP SUSP	SUSP 100 ML	ADCO	1861	1093	1449	1260	2280	1626
502117	FLAGYL SUSP	SUSP 120 ML	ALEX	202	177	263	457	573	1024
502269	PECKTOKAL SUSP	SUSP 100 ML	ALEX	283	264	246	218	180	159
502274	PECKTOKAL N SUSP	SUSP 100 ML	ALEX	381	423	376	463	536	406
503205	ENTOCID COMPOUND POWDER	POWD 15 BAG	CID	322	128	478	859	990	881
505323	ENTEROGUANIL SUSP	SUSP 60 ML	NILE	206	392	238	479	537	357
505383	PERCURAL N SUSP	SUSP 60	NILE	44	93	27	228	430	376
507522	GABIDZOL SUSP	SUSP 120 ML	KAHIRA	189	173	201	163	284	259
508299	PEKTAL SYR	BT 60 ML	MEMPHIS	0	0	0	0	0	0
508300	PEKTAMYCIN SYR	BT 60 ML	MEMPHIS	0	0	0	0	0	0
508541	DIAMYCIN DRY SUSP	SUSP 100 ML	MEMPHIS	188	186	164	346	351	440
509817	FUDIZOL SUSP	SUSP 100 ML	MISR	108	198	92	171	240	499
509947	DIAKAN SUSP	SUSP 60 ML	MISR	176	113	206	231	438	798
510033	DIAPEC S SUSP	SUSP 90 ML	PHIZER	113	0	451	720	1168	1395
511379	NIMAROL SUSPN	BT 100 ML	SWISS PH	0	0	0	0	0	0
515390	KAPECT SUSP	SUSP 120 ML	IPECO	0	0	0	0	0	450
515392	KAPECT CD SUSP	SUSP 120 ML	IPECO	0	0	0	0	0	826
TOTALS				4073	3240	4191	5595	8007	9496

Compiled by MICROTECH, M. Gamaledin

TOTAL CONSUMPTION
OF ANTIDIARRHEALS

80/81 - 85/86

UNIT : IN 1000 PACKS

PAGE NO : 1 ANTIEMETICS

IN VOLUME TERMS

CODE	TRADE NAME	PACK	FIRM	80/81	81/82	82/83	83/84	84/85	85/86
502168	LARGACTIL DROPS	DROP 30 ML	ALEX	0	0	0	0	0	7
503587	PROMACID DROPS	DROPS 15 ML	CID	424	377	411	287	213	104
505168	CORTIGEN B6 PEDIATRIC AMP	AMP 3	NILE	916	538	930	1286	1909	1325
509327	NEURAZINE DROPS	DROPS 10 ML	MISR	307	185	321	328	283	218
TOTALS				1647	1200	1662	1901	2405	1654

Compiled by MICROTECH, M. Gamaledin

TOTAL CONSUMPTION
OF ANTIDIARRHEALS

80/81 - 85/86

UNIT : IN 1000 PACKS

PAGE NO : I ANTIMOTILITY / ANTISPASMODICS

IN VOLUME TERMS

CODE	TRADE NAME	PACK	FIRM	80/81	81/82	82/83	83/84	84/85	85/86
80000	PIPTAL DROPS IMPORT	BOT 15 ML	LAKESIDE	0	0	0	0	0	0
152503	PRIMPERAN SYRUP IMPORT	BOT 200 ML	DELAGRANGE	0	0	0	0	0	0
152504	PRIMPERAN SYRUP IMPORT	BOT 60 ML	DELAGRANGE	0	0	0	0	0	0
417501	IMODIUM DROPS IMPORT	BOT 10 ML	JANSEEN	0	0	0	0	0	0
417520	IMODIUM SYRUP IMPORT	BOT 30 ML	JANSEEN	0	0	0	0	200	100
503101	CID WATER	SYP 100 ML	CID	811	853	769	761	1085	320
507549	LOMOTIL SYP	SYP 60 ML	KAHIRA	257	242	227	314	309	246
507568	WALIRINE SYP	SYP 125 ML	KAHIRA	1562	1282	1519	2048	1833	1863
507586	PIPTAL PED DROPS	DROPS 15 ML	KAHIRA	228	92	195	495	121	295
508618	PRIMPERAN SYP	SYP 120 ML	MEMPHIS	0	0	0	0	0	517
508704	PRIMPERAN DROPS	DROPS 30 ML	MEMPHIS	0	0	0	0	0	0
509337	SPASMOTAL DROPS	DROPS 10 ML	MISR	240	343	261	335	579	923
TOTALS				3098	2842	2971	3953	4127	4264

Compiled by MICROTECH, M. Gamaledin

TOTAL CONSUMPTION
OF ANTIDIARRHEALS

80/81 - 85/86

PAGE NO : 1 OTHERS

UNIT : IN 1000 PACKS

IN VOLUME TERMS

CODE	TRADE NAME	PACK	FIRM	80/81	81/82	82/83	83/84	84/85	85/86
504036	DEXTROSE 5% 500 ML AMP	PACK 1	NASR	584	562	1492	910	1117	1447
504041	DEXTROSE IN NORMAL SALINE	SOL 500 ML	NASR	90	119	120	120	160	178
504100	NORMAL SALINE 500 ML AMP	AMP 1	NASR	264	293	338	587	572	946
504141	SEPACK DEXTROSE 5% BAG	BAG 1	NASR	0	0	0	0	448	288
504143	SEPACK DEXTROSE IN NORMAL SALINE	BAG 1	NASR	0	0	0	0	0	64
504146	SEPACK N. SALINE 500 ML BAG	BAG 1	NASR	0	0	0	0	128	904
505212	DEXTROSE 5% SOLUTION	SOL 500 ML	NILE	579	780	614	1139	997	1160
505213	DEXTROSE 5 PC IN WATER	VL 1000 ML	NILE	0	0	0	0	0	0
505236	DEXTROSE 5% IN NORM SALINE SOL	SOL 500 ML	NILE	255	253	234	245	286	84
505237	DEXTROSE 5 PC INSAL	1000 ML	NILE	0	0	0	0	0	0
505640	NORMAL SALINE SOLUTION	SOL 500 ML	NILE	482	558	449	712	519	478
505641	NORMAL SALINE	1000 ML	NILE	0	0	0	0	0	0
TOTALS				2254	2565	3247	3713	4227	2549

Compiled by MICROTECH, M. Gasaledin

TOTAL CONSUMPTION
OF ANTIDIARRHEALS

80/81 - 85/86

UNIT : IN 1000 L.E.

PAGE NO : 1 ANTIBIOTICS

IN VALUE TERMS

CODE	TRADE NAME	PACK	FIRM	80/81	81/82	82/83	83/84	84/85	85/86
50002	ERTHROCIN GRANULES IMPORT	SUSP 60 ML	ABBOTT	0	0	0	0	0	0
59119	PENTREXYL SYRUP .125 MG IMPORT	BOT 60 ML	BRISTOL	0	0	0	0	92	0
502329	SUPRISTOL SUSP	SYP 60 ML	ALEX	0	0	0	0	0	92
502336	SEPTAZOLE SUSP	SUSP 100 ML	ALEX	511	434	401	683	817	980
503123	CIDOCETINE SUSP	SUSP 60 ML	CID	657	620	782	820	851	825
503125	CIDOCETINE S SUSP	SUSP 60 ML	CID	0	0	0	394	359	295
503195	ERYTHROCID SUSP	SUSP 60 ML	CID	0	0	0	0	0	130
503471	PALITREX 250 MG SYRUP	SYP 60 ML	CID	0	0	0	0	319	562
503472	PALITREX 125 MG SYRUP	SYP 60 ML	CID	157	184	270	231	582	290
503474	PALITREX DROPS	BOTT 10 ML	CID	56	43	36	105	43	143
503515	PENTREXYL 125 MG SUSP	SUSP 60 ML	CID	571	632	637	711	552	1755
503530	PENTREXYL 250 MG SUSP	SUSP 60 ML	CID	1233	1165	1154	1694	1806	2022
503662	STREPTOCETINE SUSP	SUSP 60 GM	CID	547	489	651	607	1063	975
504152	SULPHAGUANIDINE 500 MG TAB	TAB 10 ST	NASR	0	0	0	0	0	180
505053	AMPICILLIN 125 MG SUSP	SUSP 60 ML	NILE	0	355	46	318	292	409
505054	AMPICILLIN FORT 250 MG DRY SUSP	SUSP 60 ML	NILE	384	133	641	1043	1459	1561
505343	ENTRIM SUSP	SUSP 100 ML	NILE	0	0	26	151	204	235
505890	SULFAGUANIDINE STRIPS	BX 10 TAB	NILE	10	9	13	13	12	13
505952	VERACETIN SUSP	SUSP 60 ML	NILE	0	0	0	0	0	348
507502	ERYTHROCIN GRAN 200 MG / 5 ML	SUSP 60 ML	KAHIRA	750	676	730	1646	2046	2770
507542	CHEMOTRIM SUSP	SUSP 100 ML	KAHIRA	213	179	194	260	252	156
507561	KEFLEX SYRUP 250 MG	SUSP 60 ML	KAHIRA	0	0	0	0	0	1039
507562	KEFLEX SYRUP 125 MG	SUSP 60 ML	KAHIRA	120	308	488	596	1720	1104
507564	KEFLEX DRY DROPS	BOTT 19 ML	KAHIRA	70	91	246	269	59	70
508072	GARAMYCIN 20 MG AMP	AMP 6	MEMPHIS	204	110	338	705	1276	2004
508559	NEOMYCIN DRY SUSP	SUSP 60 ML	MEMPHIS	36	31	39	45	41	61
508637	SUTRIM SUSP	SUSP 100 ML	MEMPHIS	561	389	534	457	787	1046
508664	MEMCOCETIN SUSP	SUSP 60 ML	MEMPHIS	0	0	71	186	149	110
509331	ERYTHRIN DROP	DROPS 30 ML	MISR	0	0	0	0	0	4
509929	MICYCLINE 125 MG SUSP	SUSP 60 ML	MISR	152	273	94	44	82	40
509934	LIDAPRIM SUSP	SUSP 60 ML	MISR	0	0	0	0	0	109
509935	MIPHENICOL 125 MG SUSP	SUSP 60 ML	MISR	846	761	833	536	656	776
509936	STREPTOPHENICOL SUSP	SUSP 60 ML	MISR	894	770	945	1280	1314	1100
509937	AMPICILLIN 125 MG SYP	SYP 60 ML	MISR	1669	1455	1484	810	679	706
509938	AMFIPEN 125 MG SYP	SYP 60 ML	MISR	666	638	717	727	537	498
509939	AMFIPEN 250 MG SYP	SYP 60 ML	MISR	2024	1590	1788	1538	1704	1458
509940	AMPICILLIN 250 MG SYP	SYP 60 ML	MISR	0	0	0	852	1050	2148
509942	ERYTHRINE 200 MG SUSP	SUSP 60 ML	MISR	0	0	0	0	206	696
510107	SIGMAMYCIN SYRUP	SUSP 60 ML	PHIZER	451	407	388	570	429	304
510131	TERRAMYCIN 125 MG	SYP 90 ML	PHIZER	856	562	588	739	442	413
510173	VIBRAMYCIN SYRUP	SUSP 60 ML	PHIZER	372	338	350	349	246	139
515244	EPICOCILLIN 250 MG DRY MIX	SYP 60 ML	IPECO	0	0	0	0	0	0
515246	EPICOCILLIN 125 MG DRY MIX	SYP 60 ML	IPECO	0	0	0	0	0	0
516103	AMPICYN 125 MG DRY SYRUP	SYP 60 ML	A.B.I.	0	0	0	0	0	0
516104	AMPICYN 250 MG DRY SYRUP	SYP 60 ML	A.B.I.	0	0	0	0	0	0
TOTALS				14016	12650	14493	18497	22136	27580

. 11.

TOTAL CONSUMPTION
OF ANTIDIARRHEALS

80/81 - 85/86

UNIT : IN 1000 L.E.

PAGE NO : 1 ANTIDIARRHEALS

IN VOLUE TERMS

CODE	TRADE NAME	PACK	FIRM	80/81	81/82	82/83	83/84	84/85	85/86
501181	ENTROQUINE COMP SUSP	SUSP 100 ML	ADCO	930	546	724	630	1140	813
502112	FLAGYL SUSP	SUSP 120 ML	ALEX	292	256	381	662	830	1484
502269	PECKTOKAL SUSP	SUSP 100 ML	ALEX	127	118	110	98	81	71
502274	PECKTOKAL N SUSP	SUSP 100 ML	ALEX	247	274	244	300	348	263
503205	ENTOCID COMPOUND POWDER	POWD 15 BAG	CID	257	102	382	687	792	704
505323	ENTEROGUANIL SUSP	SUSP 60 ML	NILE	61	117	71	143	161	107
505383	PERCURAL N SUSP	SUSP 60	NILE	22	46	13	114	215	188
507522	GABIDZOL SUSP	SUSP 120 ML	KAHIRA	113	103	120	97	170	155
508299	PEKTAL SYR	BT 60 ML	MEMPHIS	0	0	0	0	0	0
508300	PEKTAMYCIN SYR	BT 60 ML	MEMPHIS	0	0	0	0	0	0
508541	DIAMYCIN DRY SUSP	SUSP 100 ML	MEMPHIS	197	195	172	363	368	462
509817	FUDIZOL SUSP	SUSP 100 ML	MISR	70	128	59	111	156	324
509947	DIAKAN SUSP	SUSP 60 ML	MISR	202	129	236	265	503	917
510033	DIAPEC S SUSP	SUSP 90 ML	PHIZER	141	0	563	900	1460	1743
511379	NIMAROL SUSPN	BT 100 ML	SWISS PH	0	0	0	0	0	0
515390	KAPECT SUSP	SUSP 120 ML	IPECO	0	0	0	0	0	392
515392	KAPECT CO SUSP	SUSP 120 ML	IPECO	0	0	0	0	0	1032
TOTALS				2664	2021	3081	4374	6227	8651

Compiled by MICROTECH, M. Gamaledin

12.

TOTAL CONSUMPTION
OF ANTIDIARRHEALS

80/81 - 85/86

UNIT : IN 1000 L.E.

PAGE NO : 1 ANTIEMETICS

IN VOLUE TERMS

CODE	TRADE NAME	PACK	FIRM	80/81	81/82	82/83	83/84	84/85	85/86
502168	LARGACTIL DROPS	DROP 30 ML	ALEX	0	0	0	0	0	2
503587	PROMACID DROPS	DROPS 15 ML	CID	254	226	246	172	127	62
505168	CORTIGEN B6 PEDIATRIC AMP	AMP 3	NILE	549	382	558	771	1145	795
509327	NEURAZINE DROPS	DROPS 10 ML	MISR	184	111	192	196	169	130
TOTALS				988	720	997	1140	1443	991

Compiled by MICROTECH, M. Gamaledin

TOTAL CONSUMPTION
OF ANTIDIARRHEALS

80/81 - 85/86

UNIT : IN 1000 L.E.

PAGE NO : 1 ANTIMOTILITY / ANTISPASMODICS IN VOLUME TERMS

CODE	TRADE NAME	PACK	FIRM	80/81	81/82	82/83	83/84	84/85	85/86
80000	PIPTAL DROPS IMPORT	BOT 15 ML	LAKESIDE	0	0	0	0	0	0
152503	PRIMPERAN SYRUP IMPORT	BOT 200 ML	DELAGRANGE	0	0	0	0	0	0
152504	PRIMPERAN SYRUP IMPORT	BOT 60 ML	DELAGRANGE	0	0	0	0	0	0
417501	IMODIUM DROPS IMPORT	BOT 10 ML	JANSEEN	0	0	0	0	0	0
417520	IMODIUM SYRUP IMPORT	BOT 30 ML	JANSEEN	0	0	0	0	290	145
503101	CID WATER	SYP 100 ML	CID	243	264	230	228	325	96
507549	LOMOTIL SYP	SYP 60 ML	KAHIRA	205	193	181	251	247	196
507568	WALIRINE SYP	SYP 125 ML	KAHIRA	546	448	531	716	641	652
507586	PIPTAL PED DROPS	DROPS 15 ML	KAHIRA	136	55	117	297	72	177
508618	PRIMPERAN SYP	SYP 120 ML	MEMPHIS	0	0	0	0	0	827
508704	PRIMPERAN DROPS	DROPS 30 ML	MEMPHIS	0	0	0	0	0	0
509337	SPASMOTAL DROPS	DROPS 10 ML	MISR	120	171	130	167	289	461
TOTALS				1252	1133	1191	1660	1866	2555

Compiled by MICROTECH, M. Gamaledin

TOTAL CONSUMPTION
OF ANTIDIARRHEALS

80/81 - 85/86

UNIT : IN 1000 L.E.

PAGE NO : 1 OTHERS

IN VALUE TERMS

CODE	TRADE NAME	PACK	FIRM	80/81	81/82	82/83	83/84	84/85	85/86
504036	DEXTROSE 5% 500 ML AMP	PACK 1	NASR	408	393	1044	637	781	1012
504041	DEXTROSE IN NORMAL SALINE	SOL 500 ML	NASR	63	83	84	84	112	124
504100	NORMAL SALINE 500 ML AMP	AMP 1	NASR	184	205	236	410	400	662
504141	SEPACK DEXTROSE 5% BAG	BAG 1	NASR	0	0	0	0	403	859
504143	SEPACK DEXTROSE IN NORMAL SALINE	BAG 1	NASR	0	0	0	0	0	57
504146	SEPACK N. SALINE 500 ML BAG	BAG 1	NASR	0	0	0	0	115	513
505212	DEXTROSE 5% SOLUTION	SOL 500 ML	NILE	839	1131	890	1651	1445	1682
505213	DEXTROSE 5 PC IN WATER	VL 1000 ML	NILE	0	0	0	0	0	0
505236	DEXTROSE 5% IN NORM SALINE SOL	SOL 500 ML	NILE	369	366	339	355	414	121
505237	DEXTROSE 5 PC INSAL	1000 ML	NILE	0	0	0	0	0	0
505640	NORMAL SALINE SOLUTION	SOL 500 ML	NILE	698	809	651	1032	752	693
505641	NORMAL SALINE	1000 ML	NILE	0	0	0	0	0	0
TOTALS				2564	2988	3245	4171	4425	5 1727

Compiled by MICROTECH, M. Gamaledin

(X) RECOMMENDATIONS.

- PROPOSED POLICY CONSIDERAITONS.

(X) RECOMMENDATIONS.

1. An integrated, well-planned vaccination program is needed. It will have a good impact on children health conditions. The program will need heavy training activities at all levels, starting from health planners to field workers. The program should build its information and documentation system.

2. Formulation of health insurance programs directed to children before age of schooling and to be implemented in phases is recommended.

3. An epidemiologic analytical study of acute respiratory infections in children under age of six years is highly needed.

4. Child survival pharmaceuticals (CSPs) should be recognized as a high priority group of pharmaceuticals in different health and pharmaceutical programs.

5. Standard therapy regimes should be worked out for the most common diseases of childhood. The medical profession should be made aware of them. They should be included in medical education courses as early as possible.

6. Antidiarrheal projects should aim at changing physicians' prescription habits in its next phase.

7. Organizational reform of the licensing authority is strongly advised to give it a higher degree of integrity and purify it from industry infleunces.